


# KPBMA MEMBERSHIP DIRECTORY



**2022**

# Table of Contents



**Greetings 4**

**Overview of Korea's Biopharmaceutical Industry 5**

**Information of Korean Pharmaceutical Companies 11**

**KPBMA Member Company List 204**

Comapny	Page	Comapny	Page	Comapny	Page	Comapny	Page
Ahngook Pharmaceutical Co., Ltd.	12	Dong-A Pharmaceutical.	60	Huons Co., Ltd.	108	PROTOX Inc.	156
AJU Pham Co., Ltd.	14	Dong-A ST Co., Ltd.	62	IKSU PHARMACEUTICAL CO., LTD.	110	QL Pharma Co., Ltd.	158
ANYGEN CO., LTD.	16	Dongkoo Bio & Pharma Co., Ltd.	64	ILDONG Pharmaceutical Co., Ltd.	112	Richwood Pharmaceutical Co., Ltd.	160
BCWorld Pharm. Co., Ltd.	18	Dongkook Pharmaceutical Co., Ltd.	66	IL-YANG PHARM. CO., LTD	114	RP Bio	162
BINEX Co., Ltd.	20	Dongkwang	68	INIST ST Co., Ltd.	116	SAEHAN Pharm. Co., Ltd.	164
Biosolution Co., Ltd.	22	Dongwha	70	ISUABXIS Co., Ltd.	118	Samil Pharm. Co., Ltd.	166
BIXINK Therapeutics	24	Elyson Pharmaceuticals	72	Jeil Pharmaceutical Co., Ltd.	120	SAMSUNG PHARM Co., Ltd.	168
Boryung Co., Ltd.	26	Fresenius Kabi Korea Co., Ltd.	74	JINYANG PHARM. Co., Ltd.	122	SCM Lifescience, Inc.	170
C&R Research, Inc.	28	GC Biopharma	76	KMS Pharm Co., Ltd.	124	Sinil Pharmaceutical Co., Ltd	172
Central Medical Service Co., Ltd.	30	GC Cell Corp.	78	Kolon Life Science	126	SK bioscience, Ltd.	174
Genyx Biotech Inc.	32	Genuone Sciences INC.	80	Korea Arlico Pharm Co., Ltd.	128	SK Chemicals Co., Ltd.	176
CHO-A PHARM	34	Green Pharmaceutical Co., Ltd.	82	Korea Otsuka Pharmaceutical Co., Ltd.	130	Standigm Inc.	178
CHONG KUN DANG	36	GUJU Pharm Co., Ltd.	84	KOREA PHARMA Co., Ltd.	132	Taejoon Pharmaceutical Co., Ltd.	180
Corepharm Bio Co., Ltd.	38	HAN KOOK SHIN YAK Corp.	86	Korean Drug Co., Ltd	134	TAI GUK PHARM. Co., Ltd.	182
CORESTEM INC.	40	Han Wha Pharma Co., Ltd.	88	Koreavaccine Co., Ltd.	136	TDS Pharm Co., Ltd.	184
CrystalGenomics, Inc.	42	Hana Pharm. Co., Ltd.	90	KUKJE PHARM Co., Ltd.	138	Tionlab Therapeutics	186
CTCBIO INC.	44	HanAll Biopharma	92	Kwangdong Phama Co., Ltd.	140	UKchemipharm Co., Ltd.	188
Daehwa Pharmaceutical Co., Ltd.	46	HANDOK	94	Kyung Dong Pharmaceutical Co., Ltd.	142	Whan In Pharm. Co., Ltd.	190
Daewon Pharm. Co. Ltd.	48	HANLIM PHARM. CO., LTD.	96	Medytox	144	YooYoung Pharmaceutical Co., Ltd.	192
Daewoong Pharmaceutical Co., Ltd.	50	Hanmi Pharm. Co., Ltd.	98	Mitsubishi Tanabe Pharma Korea Co., Ltd.	146	Yuhan Corporation	194
Dai Han Pharm. Co., Ltd.	52	HapInScience	100	Osstem Pharma Co., Ltd.	148	Yungjin Pharm. Co., Ltd.	196
Daiichi Sankyo Korea	54	HITS Inc.	102	Pharmacell Co., Ltd.	150		
Dalim BioTech Co., Ltd.	56	HK inno.N Corp.	104	PHARVIS	152		
DEARGEN INC.	58	Humedix Co., Ltd.	106	PMG PHARM Co., Ltd.	154		

# Greetings

Greetings from Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBMA).

In compilation of the KPBMA Directory, I would like to express my sincere gratitude to all the relevant readers who are interested in Korean pharmaceutical industry.

In recent years, Korean pharmaceutical industry has unleashed more potential and has drawn more attention from the global partners. Along with six areas including future vehicle and system semi-conductor, the bio-health industry was formally picked as the country's potential growth engine by the Korean government. And now, Korean pharmaceutical industry(K-Pharm) is ready to take a quantum leap toward the global market.

As you are well aware, Korean pharmaceutical companies are manufacturing quality products and providing global consumers with safe and efficacious medicines in compliance with ICH guidelines. As a result, the Ministry of Food and Drug Safety in Korea was able to join PIC/S in 2014, and became a regular member of ICH in 2016.

Even with short history of 120 years, Korea has succeeded in developing 34 new drugs and as of the end of 2021, 118 incrementally modified drugs(IMD) was developed. As for clinical trials, Korea is one of the most attractive and growing markets in Asia. Bio-pharmaceuticals are other area that Korea is making a success story. Furthermore, our industry is making efforts to combine the advanced AI technology with new drug development, which is making unprecedented progress in drug discovery and vaccine development.

The purpose of KPBMA Directory is to provide overseas experts from government, international organization and pharmaceutical companies with precise and abundant information regarding Korean companies's strengths, pipelines and so on. I hope that this directory would be helpful to promote the cooperation between our member companies and relevant partners overseas.

KPBMA will continue to do our best so that Korean pharmaceutical industry could successfully enter the global ecosystem. We look forward to your support and encouragement.

Thank you



Hee-Mok Won, Chairman of KPBMA


# Overview of Korea's Biopharmaceutical Industry

## 01 Vision and Mission



## 02 Market Overview


\$ 20 billion Market size at 4% CAGR




### 03 R&D Investment

14.2% R&D spending over sales and growing investment in Bio-health sector by government and VC


#### R&D expenses of Korean companies



#### Government R&D investment in bio-health Sector




#### Korean VC investment status in bio-health sector





### 05 New Drug Development

34 new drugs developed by Korean companies




### 04 Drug Pipelines

1,477 Drug pipelines, over 550 clinical trial cases, and Oncology research




### 06 Bio-Pharma Industry Ecosystem


#### Korea's Major Bio-Healthcare Industry Clusters



#### Biologics production capacity (unit: 1000L)



#### CRO market growth (2013-2019)




## 07 Overseas Expansion

### Export volume over \$ 8 billion at 24% CAGR from 2016 to 2020

#### Korean Pharmaceuticals' Exports

- Exports to 214 countries in the world
- Export volumes (\$ billion)



#### - Technology Exports (\$ billion, Cases)

Year	2016	2017	2018	2019	2020
Value (\$ billion)	\$ 2.5bn	\$ 1.1bn	\$ 4.4bn	\$ 7.1bn	\$ 9.1bn
Cases	(12 cases)	(8 cases)	(12 cases)	(14 cases)	(13 cases)

#### Business Expansion (2020)

- 78 companies 254 overseas branches

Plant	Laboratory	Corporate	Branch Office
23	26	192	13



## 08 Overseas Expansion

### 25 FDA-approved and 21 EMA-approved medicines

#### FDA Approvals

Approved Date	Company	Trade Name	Therapeutic Area	Type
2003.4	LG Life Sciences	Factive	Antibiotic	NME
2007.4	LG Life Sciences	Valtropin	hGH	Biosimilar
2013.8	Hanmi Pharm.	Esomezol	GERD	non-NME
2014.6	Dong-A ST	Tedizolid (oral)	Antibiotic	NME
2014.6	Dong-A ST	Tedizolid (injection)	Autoimmune disease	NME
2015.12	Daewoong Pharm	Meropenem	Antibiotic	Generic
2016.4	Celltrion	Inflectra	Autoimmune disease	Biosimilar
2016.5	SK Chemicals	Afstyla	Antihemophilic	Biological
2017.4	Samsung Bioepis	Renflexis	Autoimmune disease	Biosimilar
2017.7	Huons	0.9% Sodium Chloride	Normal Saline	Generic
2018.11	Celltrion	Truxima	Antineoplastic	Biosimilar
2018.11	Celltrion	Temixis	Antiretroviral	non-NME
2018.12	Celltrion	Herzuma	Antineoplastic	Biosimilar
2018.4	Huons	Lidocaine	Local Anesthetic	Generic
2019.1	Samsung Bioepis	Ontruzant	Antineoplastic	Biosimilar
2019.2	Daewoong Pharm	Jeuveau	Botulinum Toxin	Biological
2019.3	SK Biopharm	Sunosi	Sleep Disorder	NME
2019.4	Celltrion	Linezolid	Antibiotic	Generic
2019.4	Samsung Bioepis	Eticovo	Autoimmune disease	Biosimilar
2019.7	Samsung Bioepis	Hadlima	Autoimmune disease	Biosimilar
2019.11	SK Biopharm	Xcopri	Anticonvulsant	NME
2019.11	SK Chemicals	SID710	Dementia	Generic
2020.1	Huons	Bupivacaine HCl	Local Anesthetic	Generic
2020.5	Huons	Lidocaine (vial)	Local Anesthetic	Generic
2021.9	Samsung Bioepis	Byooviz	Ophthalmic	Biosimilar

#### EMA Approvals

Approved Date	Company	Trade Name	Therapeutic Area	Type
2006.5	LG Chemicals	Valtropin	hGH	Biosimilar
2013.3	SK Chemicals	SID710	Dementia	Generic
2013.6	Celltrion	Remsima	Autoimmune diseases	Biosimilar
2015.3	Dong-A ST	Tedizolid (oral)	Antibiotic	NME
2015.3	Dong-A ST	Tedizolid (injection)	Antibiotic	NME
2015.11	Shin Poong Pharm	Pyramax	Antimalarial	NME
2016.1	Samsung Bioepis	Benepali	Autoimmune diseases	Biosimilar
2016.5	Samsung Bioepis	Flixabi	Autoimmune diseases	Biosimilar
2017.1	SK Chemicals	Afstyla	Antihemophilic	Biological
2017.1	Samsung Bioepis	Lusduna	Insulin glargine	Biosimilar
2017.2	Celltrion	Truxima	Antineoplastic	Biosimilar
2017.8	Samsung Bioepis	Imraldi	Autoimmune diseases	Biosimilar
2017.11	Samsung Bioepis	Ontruzant	Antineoplastic	Biosimilar
2018.2	Celltrion	Herzuma	Antineoplastic	Biosimilar
2019.10	Daewoong Pharm	Nuceiva	Botulinum Toxin	Biological
2019.11	Celltrion	Remsima	Antirheumatic	Biobetter
2020.1	SK Biopharm	Sunosi	Sleep Disorder	NME
2020.8	Samsung Bioepis	Aybintio	Antineoplastic	Biosimilar
2021.2	Celltrion	Yuflyma	Autoimmune diseases	Biosimilar
2021.8	Samsung Bioepis	Byooviz	Ophthalmic	Biosimilar
2021.11	Celltrion	Regkirona	COVID-19 treatment	Biological



Meropenem



Remsima



Lidocain Injection




Sunosi

## 09 Meet the Global Quality Standards

### Pharmaceutical Production and Quality Management Capacities

K-GMP provides FDA, CFDA, CE Registration Compliance Assistant for Companies in the field of Food, Medical Device, Drug and Cosmetics Industries




## 10 About KPBA

Korea Pharmaceutical and Bio-Pharma Manufacturers Association(KPBA) is the largest pharmaceutical industry association in Korea.

It was founded in October 1945, representing Korean pharma industry under the authorization of the Ministry of Health and Welfare (MOHW) with 250 member companies.

Under the goal of National health promotion through the sound development of the pharmaceutical industry, KPBA plays key roles for the industry advancement such as government relations and policy supporting, training and education for member companies, and global capacity building.

It consists of 10 committees, 11 subcommittees, and 5 special committees to discuss and make decisions on each issue in the pharmaceutical industry.



## 11 KPBMA Member Companies

### Member Companies



Regular members 182



Associated Members 68

Sales \$ 1B ▲	5
Sales \$ 500M ▲	9
Sales \$ 100M ▲	62
Sales \$ 10M ▲	95
Sales Under \$ 10M	54

### Executive Board Members (2022)

Huons Global	GUJU PHARM.
Boryung Pharmaceutical	Hanmi Pharm
Chong KunDang Pharmaceutical	Ildong Pharmaceutical
Daewon Pharmaceutical	Jeil Pharmaceutical
Daewoong Pharmaceutical	JW Holdings
Dong-A ST	LG Chem
Dongkook Pharmaceutical	SK bioscience
GC Pharma	Yuhan

## 12 KPBMA Activities

Leading development & innovation and representing industry leadership with the member of 245 companies



01 Policy proposals to the Korean government representing the industry



02 Training and education for member companies



03 International exchange and cooperation




04 Establishment of ethical management



05 Fulfillment of social contribution and social responsibility

# Information of Korean Pharmaceutical Companies

## 2022 KPBMA MEMBERSHIP DIRECTORY



# Ahngook Pharmaceutical Co., Ltd.



www.ahn-gook.com



## Category

- Finished Pharmaceutical Products
- Biopharmaceuticals - Biosimilar
- Herbal Medicinal Product
- Others
  - Medical Device
  - Digital Therapeutics
  - Cosmetics
  - functional food

## CEO

Won Duk Kwon

## Established Date

1959.09.03

## Employee No.

400

## Contact point

### 1. Overseas Business

Global BD&MKT  
82-2-3289-4359  
agoverseas@ahn-gook.com

### 2. Licensing In/Out

Project Planning  
82-2-3289-4253  
agplan@ahn-gook.com

### 3. Overseas Branch

N/A

## Company Profile

Ahngook Pharmaceutical Co., Ltd is fully integrated pharmaceutical company dedication to manufacture, distribute, development, marketing and sales of good medicines in Korea since 1959.

We have a strong presence in Respiratory, GI and CV. For the future growth, we are concentrating its R&D efforts on those therapeutic areas.

## Strengths

1. Total Healthcare Products & Service
2. Open Innovation
3. Ethical management

## Collaboration Opportunities

1. Export
2. Licensing In/Out
3. R&D Collaboration



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Ivy Leaf + Coptis Rhizome	Synatura Syrup	expectorant, antitussive	more than 10 countries including Vietnam, Peru, Kuwait	PIC/s GMP	New herbal medicine with patent
2	Tadalafil	Valkyie ODIFS	Erectile Dysfunction, Benign Prostate Hyperplasia	Mexico, Mongolia	PIC/s GMP	New formulation (microgranule)
3	Ivy Leaf	Icopang Syrup	expectorant, antitussive	Malaysia, Singapore, Philippines	PIC/s GMP	
4	Montelukast sodium	Curost granule	Asthma, Allergic rhinitis	Vietnam, Peru	PIC/s GMP	
5	Alfuzosin HCl	Xaltrin XL Tab.	Benign Prostate Hyperplasia	Guatemala, Hong Kong	PIC/s GMP	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Circulatory system	AG 1705	Hypertension	Clinical trials Phase III	New combination Drug
2	Circulatory system	AG 1901	Hyperlipidemia	Clinical trials Phase III	New combination Drug
3	Respiratory system	AG 2002	Asthma, Allergic rhinitis	Clinical trials Phase I	Improved bioavailability

# AJU Pharm Co., Ltd.



[www.ajupharm.co.kr](http://www.ajupharm.co.kr)



## Category

Finished Pharmaceutical Products

## Company Profile

We, Aju Pharm Co., Ltd is Korean Pharmaceutical company dedicating on manufacturing a variety of pharmaceutical products since 1953.

We have been endeavoring are well-known company specializing in developing value added products like combination products and patient compliance improved medicine.

## Strengths

1. Combination product of Rosuvastatin + Ezetimibe Tablet
2. Combination product of Eperisone + Aceclofenac Tablet
3. Patient compliance improved product of Eperisone SR Tablet

## Collaboration Opportunities

1. Exporting Finished Pharmaceutical Products
2. Introducing new drugs

### CEO

Tae Hoon, Kim

### Established Date

1953-05-04

### Employee No.

400

### Contact point

#### 1. Overseas Business

Export/82-2-2630-0729  
export@ajupharm.co.kr

#### 2. Licensing In/Out

BD/82-2-2630-0694  
ajudevelop@ajupharm.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Rosuvastatin + Ezetimibe 5/10, 10/10, 20/10mg	Cretrol Tab.	Primary (heterozygous familial and non-familial) hypercholesterolaemia	Taiwan, Peru, Chile, South East Asian countries	
2	Eperisone 75mg	Exon SR Tab.	Painful muscular spasm, rigid paralysis by nervous system disease	Russia, Malaysia, South East Asian countries	EAEU GMP Approved
3	Eperisone + Aceclofenac 75/100mg	Apexon Tab.	Painful muscular spasm, rigid paralysis by nervous system disease	Will be exported to Russia	



# ANYGEN CO., LTD.



[www.anygen.com](http://www.anygen.com)



## Category

API  
Biopharmaceuticals  
Cosmetics



## Company Profile

ANYGEN supplies various types of high-quality peptides promptly by applying our optimal synthesis technology and extensive experiences in the peptide synthesis. We manufacture high-quality custom-made peptides by applying our thorough product managing system(ISO 9001, 14001, GMP Certificated) in the synthesis and purification of peptides, and we supply the peptides demanded by customers by applying custom-made synthesis and purifications according to the level of difficulty in the synthesis and types of modification.

## Strengths

1. Network & partners
2. R&D capabilities
3. Raw material development technology : APsoluT(ANYGEN Peptide Soluble & Targeting), Long chain technology, Rich disulfide bonding peptide, Ag-Tag(High-volume purification technology)
4. Production and supply technology : GMP plant #1(Jangseong), GMP plant #2 (Osong)

## Collaboration Opportunities

1. CDMO
2. API
3. Research

### CEO

Jaeil Kim

### Established Date

May. 03. 2000

### Employee No.

119 persons

### Contact point

#### 1. Overseas Business

Sales & Management  
82-62-714-1166  
techsupport@anygen.com

#### 2. Licensing In/Out

R&D Center  
82-62-715-2552  
jhryu@anygen.com

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Peptide	GMP(API,CDMO)	Research, Commercial	Japan, Mexico, Taiwan	ISO 9001, 14001 GMP Certificated
2	Peptide	Custom Peptide	Research, Commercial	Japan, USA, Canada, UK	ISO 9001, 14001 GMP Certificated
3	Peptide	Cosmetic Peptide	Research, Commercial		ISO 9001, 14001 GMP Certificated
4	Peptide	Catalog Peptide	Research, Commercial	Japan	ISO 9001, 14001 GMP Certificated

## Generic Peptide APIs

No.	Product name	Code	Application	Stage of Development	Remarks
1	Leuprorelin	API	Prostate cancer, Precocious puberty For IVF	Commercialization	DMF, Ph Eur, USP
2	Desmopressin	API	Nocturnal enuresis	Commercialization	DMF, Ph Eur, USP
3	Ganirelix	API	Sterility	Under Developing	
4	Liraglutide	API	Diabetes, Obesity	Under Developing	
5	Vasopressin	API	Antidiuretic hormone	Under Developing	
6	Ziconotide	API	Pain killer	Under Developing	

# BCWorld Pharm. Co., Ltd.



www.bcwp.co.kr



## Category

Finished Pharmaceutical Products  
Drug Delivery System

## Company Profile

BCWP is expertized in the formulation and process development to provide quality generics. BCWP not only has been certified as Korea Innovative pharmaceutical company but also designated as Advanced Technology Center. BCWP is specialized in DDS technologies by way of proactive investments. In facilities complied with EU/cGMP standards, liquid and powder injection, lyophilized injection, and oral solid forms are manufactured. In 2019, the manufacturing site dedicated to Carbapenem injections completed its construction in Wonju city.



## Strengths

1. Incrementally Modified Drugs
2. Drug Delivery System(DDS)
3. Generic

## Collaboration Opportunities

1. Global market expansion
2. Searching new business
3. Codevelopment opprotunities



### CEO

Sung Han Hong

### Established Date

June 1,2006

### Employee No.

290 persons

### Contact point

#### 1. Overseas Business

Global Business team  
031-5178-3361  
gb@bcwp.co.kr

#### 2. Licensing In/Out

Global Business team  
031-5178-3361  
gb@bcwp.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Meropenem 500mg, 1g, 2g	Mepem Q Inj.	Antibiotics	Mexico, Yemen, Philippines and etc.
2	Imipenem/Cilastatin sodium	Ipem Q Inj.	Antibiotics	Vietnam, Philippines, and etc.
3	Ertapenem 1g	Erpem Q Inj.	Antibiotics	Mexico and etc.
4	Nicardipine HCl 10mg/10ml, 2mg/2ml	Binicarpin Inj.	Circulatory system	Thailand and etc.
5	Norepinephrine bitartrate 8mg/4ml, 20mg/10ml, 40mg/20ml	Qprin inj.	Cardiac stimulant	Philippines and Iran and etc.
6	Glutathione 600mg, 1200mg	Guthione inj.	Well-being product	Georgia and etc.
7	Vancomycin HCl 500mg, 1g	BC vancomycin Inj.	Antibiotics	Philippines and etc.
8	Fentanyl citrate	BC Fentanyl Citrate Inj.	Anesthetics and analgesics	confidential
9	Morphine sulfate	BC Morphine sulfate Inj.	Anesthetics and analgesics	confidential

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Microsphere	BCWP_D003	Prostate cancer	Pre-clinical
2		BCWP_D006	Prostate cancer	Pre-clinical
3		BCWP_D008	Osteoarthritis	Formulation
4	Nanosuspension	BCWP_D009	Schizophrenia	Pre-clinical
5		BCWP_D010	Schizophrenia	Clinical
6		BCWP_D011	Schizophrenia	Pre-clinical
7		BCWP_D012	Schizophrenia	Pre-clinical
8	FDT-SR (fast dissolving tablet sustained release)	BCWP_G1905	Pain	Pre-clinical
9		BCWP_G2011	Vasodilator	Pre-clinical
10	Orally Disintegrating Tablet (ODT)	BCWP_G1906	High blood pressure	Clinical
11		BCWP_G1908	High cholesterol	Launched
12		BCWP_G2101	High blood pressure	Formulation
13	*Fixed-dose combination (FDC) drugs	BCWP_G2103	Ulcer	Formulation
14		BCWP_G1909	High blood pressure	Launched
15		BCWP_G2005	High blood pressure/hyperlipidemia	Formulation

# BINEX Co., Ltd.



<http://www.bi-nex.com/eng/index.asp>



## Category

- API
- Finished Pharmaceutical Products
- Biopharmaceuticals
- Vaccine
- Recombinant DNA
- Biosimilar

## Company Profile

BINEX is a biopharmaceutical company that provides biologics CDMO services in compliance with cGMP standards. Our CDMO services support clients to achieve successful development and commercialization of biologic pipelines by offering top quality one-stop service from cell-line development to GMP manufacturing.

## Strengths

1. Flexible manufacturing capacity of DS and DP with state-of-the-art facility
  - < Drug substance, DS >
  - Mammalian cultivation : 200/500/1,000/5,000(L)
  - Microbial fermentation : 180/500(L)
  - < Drug product, DP >
  - DP : Liquid vial/Lyophilized vial/Prefilled syringe
2. Robust manufacturing experience and know-how
  - Product : mAb, fusion protein, bispecific antibody, DNA therapeutic vaccine, etc.
  - Successful manufacturing records of 1,005 GMP batches(as of May 2022)  
(DS : 389/DP : 616 batches/more than 150 projects)
3. Validated quality system acknowledged by regulatory agencies in advanced countries(EMA, Japanese PMDA) and global pharmaceutical companies.

## Collaboration Opportunities

1. Biologics CDMO(contract service)
2. Business development
3. Investment(M&A, etc.)

### CEO

Hyukjong Lee

### Established Date

Dec 17, 1957

### Employee No.

561 (Jun 2022)

### Contact point

#### 1. Overseas Business

New Business Team  
+82-32-850-3255  
hclee@bi-nex.com

#### 2. Licensing In/Out

New Business Team  
+82-32-850-3255  
hclee@bi-nex.com

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use
1	Biologics pipelines (mAb, fusion protein, bispecific antibody, DNA therapeutic vaccine, etc.)	CDMO services	Cell line development, culture optimization, purification methods, analytical methods, tech transfer, clinical & commercial DS/DP manufacturing, etc.
2	Probiotics	Biscan N powder	Probiotics
3	Ophthalmic solution	Hylenplus eye drops and others	Ophthalmic solution

## Others

As a result of providing global quality CDMO services, BINEX' clients have out-licensed their biologics pipelines to global players which guarantee successful industrialization and commercialization.

# Biosolution Co., Ltd.



Bio Solution Co.,Ltd

<https://biosolutions.co.kr>



## Category

Biopharmaceuticals  
Cell/Gene Therapy  
Cosmetics

## Company Profile

A Leading Company of Cell-based Biotechnology Contributing to the Humanity's Health and Lifestyle, established in 2000.

1. Aiming at the rapidly growing global cell therapy market, skin and joint cartilage target cell treatments are being marketed with the approval of KFDA.
2. Human tissue model has been developed based on cell application technology in order to preoccupy the future market.

## Strengths

1. Extensive versatility after rapid commercialization
2. Selection/Application of optimal stem cell for each disease
3. Next generation cell application technologies

## Collaboration Opportunities

1. Global clinical trial collaboration
2. Licensing out



### CEO

Chang, Song Sun

### Established Date

2000. 1. 14

### Employee No.

96

### Contact point

#### 1. Overseas Business

Lian Kim(G. Manager)  
010-3676-8815  
kskim8815@biosolutions.co.kr

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Global Quality Certification /Market Authorization	Remarks
1	BaSol autologous chondrocytes	CartiLife	Cartilage defect (osteoarthritis, trauma)	Nov '17 NET certification Apr '19 Marketing authorization in Korea Nov '19 phase 2 IND approval in USA	autologous cartilagenous matrix contained pellet-type
2	BaSol autologous keratinocytes	KeraHeal	Burn(severe burn)	May '06 Marketing authorization in Korea Jan '09 Approved for coverage of industrial accident Insurance	spray-type cell suspension
3	BaSol allogenic keratinocytes	KeraHeal-Allo	Burn(deep second degree burn)	Oct '15 Marketing authorization in Korea Nov 16 Approved for coverage of National Health Care insurance covered	thermosensitive hydrogel-type cell suspension
4	Human normal corneal epithelial cell	MCTT HCE	Cornea model	Apr '19 OECD TG registration (4th in the world, the only one in Korea)	
5	Human normal skin cell(Asian)	KeraSkin	Skin model	Jun '21 OECD TG registration (the only one in Korea)	
6	Human nasal epithelial cell	SoluOral	Mucosal Model		
7	Human normal oral mucosal cell	SoluAirway	Mucosal Model		
8	Human stem cell-conditioned medium	STEMSOO, STeMSoo-Exo	Skin Rejuvenation, Hair loss		
9	Peptide	BSP-11	Skin Rejuvenation, Hair loss		

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Cell therapy	CartiOiD	Cartilage defect (osteoarthritis, trauma)	Non-clinical trial in progress
2	Gene therapy	ExoCART	Solid tumor	Candidate discovery

## Others

4th Generation Autologous Chondrocyte Implantation product, "CartiLife"

- Derived from non-articular cartilage – Safety, No age limit
- Autologous chondrocytes + extracellular matrix – Fast restoration of hyaline cartilage
- Small bead-type products – Improve clinical convenience
- Demonstrate clinical efficacy & long term safety(5 years)

# BIXINK Therapeutics



<http://bixink.com>



## Category

Finished Pharmaceutical Products  
Digital Therapeutics

## Company Profile

'BIXINK' is a NEW Biopharmaceutical company dedicated towards establishing a new treatment paradigm via converging biotechnology and information technology.

Focused on the field of oncology and digital therapeutics, BIXINK has in-licensed competitive assets starting with Nerlynx®, FDA approved and globally marketed HER2 targeted therapy for breast cancer. Furthermore, portfolio includes cancer supportive care originating from Italy intended for various mucositis resulting from anti-cancer therapy. As one of the pioneers of digital therapeutics, BIXINK has its first own asset, OC Free®, under clinical development in the US and is rapidly building a series of customized digital therapeutics by disease and age through partnership with leading US companies. BIXINK is a young yet fast-growing company diligently seeking opportunities to enrich its portfolio in both arenas.

## Strengths

1. Competence in oncology from development to commercialization
2. Pioneers of DTx capable of development and validation
3. Proven track record in portfolio development

## Collaboration Opportunities

1. L/I of oncology/DTx assets
2. L/O of DTx asset
3. Commercial partnership in the region
4. Research/Development collaboration

### CEO

Mikyong Hahn

### Established Date

08/11/2016

### Employee No.

30

### Contact point

1. Overseas Business  
BD/827052232871  
ms.sung@bixink.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Neratinib maleate	Nerlynx®	HER2+ breast cancer	Imported	FDA, EMA approved	Approved in 15 over countries worldwide besides US and EU
2	Hyaluronic acid	Mucosamin®	1. Mucositis due to chemo/radiotherapy 2. Dry mouth	Japan, Taiwan, Hong Kong, Macau, Malaysia, Singapore, Indonesia, Philippines, Thailand, Vietnam (expected to start from 2023)	ISO 13485/CE Mark	Hold regional exclusivity in Asia

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Circulatory system	OC Free®	Contamination obsessive compulsive disorder	Clinical	Development ongoing in US
2		attune™	Mental distress of cancer patients	Clinical	Pivotal ongoing in US/ Pivotal under preparation in Korea
3		SparkRx™	Adolescent depression	Clinical	
4		DreAMLand™	Mental distress specific to AML patients	Clinical	Pivotal under preparation in US



# Boryung Co., Ltd.

BORYUNG

<https://boryung.co.kr/en/>



## Company Profile

When the domestic pharmaceutical industry was heavily dependent on imported products in the period before and after the Korean War, Boryung was a major contributor to the modernization of the Korean pharmaceutical industry by producing active pharmaceutical ingredients locally, developing pharmaceutical research, and establishing a production and quality management system through technical partnerships with advanced foreign pharmaceutical companies. Beginning with Boryung's Yonggaksan(1967), Gelfos(1975) has established itself as a medicine loved by everyone. In 2010, Boryung developed South Korea's first antihypertensive drug 'Kanarb'(fimasartan) and has made it a blockbuster drug with sales of 10 billion won. In addition, Boryung continues to be the No.1 domestic pharmaceutical company in anticancer drugs and has demonstrated its role as a pharmaceutical company responsible for the health, quality of life and well-being of people.

## Strengths

1. The nation's first and only new high blood pressure drug 'Kanarb(fimasartan)' was developed and exported overseas.
2. Lymphoma treatment BR2002 is in a South Korea-U.S.-Taiwan concurrent clinical trial(Phase 1b/2).
3. Possessing a GMP smart factory with world-class manufacturing competitiveness.

### CEO

Jay Kim, Daniel Chang

### Established Date

1963.11.11

### Employee No.

1,734(as of 2021.12)

### Contact point

#### 1. Overseas Business

Global business group  
+82-708-8474  
lsk9234@boryung.co.kr

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Fimasartan	Kanarb®	Hypertenion	Mexico, Ecuador, Peru, Thailand, Malaysia, Singapore, Philippine, Russia, etc	More than 20 countries	Original
2	Fimasartan+HCTZ	Kanarb Plus®	Hypertenion	Mexico, Euador, Peru	14 countries	Original
3	Fimasartan+Amlodipine	Dukarb®	Hypertenion	Mexico	Mexico, Honduras, El salvador, Guatemala, Dominica	Original
4	Fimasartan+Rosuvastatin	Tuvero®	Hypertenion+Statin administartion	Mexico	Mexico	Original
5	Fimasartan+Amlodipine+HCTZ	Dukarb Plus®	Hypertenion	New product	New product	Original
6	Fimasartan+Amlodipine+Rosuvastatin	Dukaro®	Hypertenion+Statin administartion	New product	New product	Original
7	Bortezomib	Velkin	Cancer	New product	New product	
8	Pemetrexed	Alimxid	Cancer	New product	New product	
9	Doxorubicin	AD mycin	Cancer	Thailand	Indonesia, Thailand	
10	Oxaliplatin	Oxalitin	Cancer	Germany	Germany(in 2023)	
11	5-Fluorouracil	Effcil	Cancer	Thailand	Indonesia, Thailand	
12	Epirubicin	EP mycin	Cancer		Indonesia, Thailand	
13	Carboplatin	Neoplatin	Cancer	Thailand	Indonesia, Thailand	
14	Colloidal Aluminium Phosphate	Gelfos M®	Hyperhastric acidity, Gastritis	China, Taiwan	China, Taiwan	Original
15	Pitavastatin Calcium	API	Cardiovascular	Japan	Japan	
16	Alacepril	API	Cardiovascular	Japan	Japan	
17	Dasatinib	API	Antineoplastics	Japan	Japan	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	IMD(Incrementally modified drug)	BR4002	dementia	phase 1
2		BR3003	diabete	phase 3
3		BR1015	hypertension	phase 1
4		BR1017	hypertension	phase 1
5		BR1018	hypertension	phase 1
6		BR2008	cancer	phase 1
7		BR2009	cancer	phase 1
8	Licensiing	Lubinectedin	cancer	phase 3
9		Plitidepsin	cancer	phase 3

## Others

Boryung is expanding its drug portfolio through the LBA(Legacy Brands Acquisition) strategy, which aims to acquire legacy brands from global pharmaceutical companies while strengthening sales stability and profitability. Boryung has succeeded in acquiring all rights, including domestic copyrights and licenses, for the anticancer drug Gemzar(gemcitabine) in 2020 and the schizophrenia treatment Zyprexa(olanzapine) in 2021. From April this year, Boryung will increase profitability by directly manufacturing Gemzar in a GMP manufacturing facility with world-class competitiveness in Yesan, Chungcheongnam-do.

# C&R Research, Inc.



[www.cnrres.com](http://www.cnrres.com)



## Category

Finished Pharmaceutical Products  
Biopharmaceuticals  
- Vaccine, Recombinant DNA, Cell/Gene Therapy, Biosimilar

## Company Profile

As a pioneering CRO in Korea, C&R Research was established in 1997 and became No.1 in terms of skilled manpower and sales revenue among domestic companies in 2020. Now, it is growing to be a global CRO from Korea. Over the past 25 years, C&R Research has performed more than 1,600 domestic studies and been a bridgehead in new drug development for more than 300 pharmaceutical companies with over 400 employees at home and abroad.

## Strengths

### 1. First & Best CRO of Korea

- The largest CRO by sales in Korea
- Listed on KOSDAQ in December 2021
- The highest score achieved in the assessment for CRO accreditation conducted by KoNECT (Korean National Enterprise for Clinical Trials)
- Introduction of M.D.-centered clinical development division 'Medical team' for the first time, having the highest capability among local CROs
- A well established network with hospitals in Korea, allowing convenient and efficient site selection and patient enrollment
- Conducted more than 1,600 clinical studies in 25 years
- >> 2010~2021 Study Experience: 1,255 Studies
  - Oncology : 176+ Studies
  - Phase 1 : 200+ Studies
  - Cell Therapy : 70+ Studies
  - CAR-T : 3 Studies

### 2. Global Capabilities

- Global RA team and Global clinical operation team specialized in global clinical trials
- Introduction of "eClinical solution", extensively used in global clinical practice

## CEO

Moon Tae Yoon

## Established Date

1st July, 1997

## Employee No.

450+

## Contact point

### 1. Overseas Business

- (1) David Kwon, BDA, Business Development Team  
Tel. (+82)010-6275-2676  
E-mail: david.kwon@cnrres.com
- (2) Minjung Cho, BDA, Business Development Team  
Tel. (+82)010-2342-2730  
E-mail: minjung.cho@cnrres.com

### 2. Licensing In/Out

N/A

### 3. Overseas Branch

C&R Healthcare Global (Singapore)  
cnrhg@cnrres.com

- A wide experience in multi-national and multi-racial clinical Trials
- Clinical data management based on CDISC (Clinical Data Interchange Standards Consortium)

## 3. Total Value Chain CRO

Comprehensive service scope in line with global standard and best practice—supported by integrated services

## [Partnership]

- GCCL: A sample analysis company for clinical trials (Bio analysis & central lab)
- Trial Informatics: A Imaging IT solution company for clinical trials, providing preclinical consulting related to anticancer drugs & TTP and CDP preparation
- Asan Imaging Center: A imaging lab service for clinical trials
- C&R Academy (ISO and MFDS designated education institution): A clinical trial-related education service institute
- C&R Healthcare Global (100% subsidiary): Singapore-based global market entry platform for healthcare companies

## Collaboration Opportunities

Global clinical trials cooperation in Asia

## Others


A Variety Digital Solutions For Clinical Trials

## [CsafeR]

CsafeR is a system that supports the ICH guideline E2B (R3) standard in line with the implementation of electronic transmission of individual case safety reports, making it easy and convenient for pharmaceutical companies to perform electronic reporting according to the regulations.

## [IMTRIAL]

Imtrial is an integrated management system of CDISC, a global format for clinical trial data, automating the life cycle of clinical trial data as follow.



# Central Medical Service Co., Ltd.



[www.cmscorea.co.kr](http://www.cmscorea.co.kr)



## Category

Finished Pharmaceutical Products  
Medical Device

## Company Profile

Central Medical Service is a domestic pharmaceutical company that exclusively sells Iohexol-based domestic manufactured X-ray/CT contrast media <Bonorex>. With the completion of the Osong plant in 2021, the production of various and high-quality finished drugs is contributing to the development of domestic pharmaceutical industry.

## Strengths

1. Specialized in medical imaging
2. Localization
3. New KGMP plant

## Collaboration Opportunities

1. Market size
2. Authorization regulation
3. Standard customs clearance



### CEO

Kim Boogeun

### Established Date

14th of November, 2006

### Employee No.

80 people

### Contact point

1. Overseas Business  
Sales Department  
010-3583-2961  
[pjs@cmscorea.co.kr](mailto:pjs@cmscorea.co.kr)
2. Licensing In/Out  
Not applicable
3. Overseas Branch  
Not applicable

## Main Products

X-ray/CT contrast media "BONOREX"

## R&D Pipeline

New X-ray/CT contrast media

New MRI contrast media



# Cenyx Biotech Inc.



<https://www.cenyxbiotech.com/en/>



## Category

API  
Finished Pharmaceutical Products  
Platform Technology

## Company Profile

Cenyx Biotech Inc. is a biotech company that develops diagnostic and therapeutic nanocompounds including nanozymes and nanoparticles. Founded in Nov. 21, 2016, by a clinical expert and a neurologist at Seoul National University Hospital, the company's R&D team consists of experienced scientists and specialists with relevant skills and achievements in nanomedicine, which is well evidenced by publications in world's top journals and awards.

The company is the world's first to develop nanozyme drug to treat acute and fatal diseases.

## Strengths

1. A biotech startup established and led by a clinical expert who is a neurologist at Seoul National University Hospital
2. A team of R&D experts with proven track records of publications in prestigious journals including Stroke, Angewandte Chemie and many more.
3. World's first ceria nanozyme drug candidate, the next breakthrough medicine to treat rare and fatal diseases with huge unmet medical needs

## Collaboration Opportunities

1. Out-licensing
2. Co-development



### CEO

Seung-Hoon Lee (MD. PhD. FAHA)

### Established Date

2016-11-21

### Employee No.

33

### Contact point

1. Overseas Business  
contact@cenyxbiotech.com
2. Licensing In/Out  
hj Kim/+82 2 741 6110  
hjkim@cenyxbiotech.com
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	CeNP	CX213	Primary indication: Subarachnoid hemorrhage	US, EU	preclinical stage

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Nanozyme-P	lead asset: CX213	Parenteral drug	Preclinical
2	Nanozyme-E		Enteral drug	Discovery
3	Nanozyme-D			Discovery
4	Nanozyme-Drug Conjugate (NDC)			Discovery

## Others

We welcome inquiries for collaboration or co-development. If you are interested in developing and commercializing the world's first ceria nanozyme drug worldwide, please contact us.

# CHO-A PHARM

**CHO-A PHARM.CO.,LTD.**

<http://www.choa.co.kr/en/>



## Category

Finished Pharmaceutical Products

## Company Profile

Since the first export to Vietnam in 1995, CHO-A has been expanding through global distribution across different regions, Middle East, Asia, and South Africa. We are currently working with over 30 overseas partners including those in Iran, Mongolia, Myanmar, Cambodia, Indonesia, China and so on. We are continuously developing new partners through participating in international exhibitions and the expansion of our international business organization. With extensive global business experience, CHO-A Pharm understands that the demand for drugs, supplements or foods in the country and the current overseas market conditions are different. Therefore, CHO-A Pharm provides overseas customers with customer-oriented product design and management services in response to their needs.

### CEO

Mr. Sung-Hwan Cho(CEO)

### Established Date

1988

### Employee No.

274

### Contact point

#### 1. Overseas Business

Overseas Business Dept  
(+82)-2-6670-9223  
choapharm@choa.co.kr

#### 2. Licensing In/Out

Overseas Business Dept  
(+82)-2-6670-9223  
choapharm@choa.co.kr

#### 3. Overseas Branch

Overseas Business Dept  
(+82)-2-6670-9223  
choapharm@choa.co.kr

## Strengths

1. development of high-quality products
2. specializing in OTC drugs
3. international person of talent



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Ferrous Gluconate Hydrate	Hb-Max 50 Syr.	Prevention and treatment of iron deficiency	Myanmar
2	Ferric Hydroxide Polymaltose complex	Hemopoly Sol.	Iron deficiency anemia	Vietnam
3	Ferrous Gluconate Hydrate	Newhem Syr.	Iron deficiency anemia related to pregnancy, after delivery, weak stamina	Vietnam
4	Thymomodulin	Thioserin Sol.	Adjuvant treatment of bacterial and viral infectious diseases such as hepatitis and respiratory diseases	Vietnam
5	L-Arginine-L-Aspartate Hydrate	Manpos Sol.	Treatment of physical & mental asthenia	Guatemala
6	L-Ornithine-L-Aspartate	Uratonyl Sol.	Adjuvant treatment for acute and chronic hepatic diseases	Vietnam
7	DL-Methionine, L-leucine, L-Valine	Cho-a Tonic Cap.	Tonic, fragile habitus, physical fatigue	Myanmar
8	Royal Jelly, Wheat Germ Oil, Pollen Extract	Biotone Sol.	It helps improve concentration, endurance, immunity and fatigue.	Iran
9	Red Ginseng Extract Solution	Red Ginseng	Improve mental and physical performance, promote detoxification, lower blood cholesterol.	Afghanistan, Yemen
10	Betaine, Inositol, L-lysine, L-arginine	Jalkton Step 1	Healthy drink containing plenty of amino acids and vitamin that promotes children's growth and development, helping appetite recovery.	Indonesia
11	Betaine, Inositol, L-lysine, L-arginine	Jalkton Step 2	Healthy drink containing plenty of amino acids and vitamin that promotes children's growth and development, helping appetite recovery.	Indonesia

## Others

In order to meet the diverse needs of the global market, promote close cooperation and good communication with overseas partners, CHO-A Pharm overseas marketing team has been divided into different teams by regional areas. Additionally we use international talents to provide more globalized services and establish a better communication network.

# CHONG KUN DANG



[www.ckdpharm.com/en/home](http://www.ckdpharm.com/en/home)



## Category

- Finished Pharmaceutical Products
- Biopharmaceuticals
  - Biosimilar
- Herbal Medicinal Product
- Platform Technology
  - Drug Delivery System



## Company Profile

CKD, a fully integrated pharmaceutical company with 81 years of history, is one of the industry leaders in Korean pharma market. Since CKD established its research center in 1972 to accelerate the development of novel technologies and therapeutics, it has been focusing on R&D by investing more than 10% of revenues over the last several years. As a result, CKD has successfully launched two new drugs, Camtobell® for anti-cancer and Duvie® for type 2 diabetes, and world's first NESP biosimilar under the brand name of Nesbell®.

### CEO

YOUNG JOO KIM

### Established Date

May 7, 1941

### Employee No.

2,363 person

### Contact point

#### 1. Overseas Business

Global Business Planning Team  
+82-2-2194-0423  
ihch@ckdpharm.com

#### 2. Licensing In/Out

BD & Licensing Team  
+82-2-6373-0759  
srjo@ckdpharm.com

#### 3. Overseas Branch

Local office in Vietnam  
busunji@ckdpharm.com  
CKD-OTTO in Indonesia  
inbaik@ckd-otto.com

## Strengths

1. Excellence in sales & marketing in domestic market
2. World-leading expertise in HDAC6 biology
3. Strong R&D capability in NCE, biologics/biosimilar and IMD

## Collaboration Opportunities

License-out/co-development of CKD pipeline for global territories

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Darbepoetin-alfa	Nesbell PFS	treatment of anemia due to chronic kidney disease(CKD), including patients on dialysis and patients not on dialysis	Japan, South-east Asia(SEA), Turkey, Middle-east
2	Tacrolimus	Tacrobell	Immunosuppressant	South-east Asia(SEA)
3	Cyclosporine	Cipol-N	Immunosuppressant	South-east Asia(SEA), S. America
4	Mycophenolate mofetil	Myrept	Immunosuppressant	South-east Asia(SEA), Middle-east
5	Amino-Acids 5%	Ruchiasol inj	Supply of parenteral amino acids during chronic liver failure	Mongolia
6	Ceftizoxime Sodium	CKD Ceftizoxime Inj	3rd Generation Cephalosporin	China
7	Oxaliplatin	Belloxa Inj.	Colorectal cancer, Gastric cancer	South-east Asia(SEA)
8	Gemcitabine	Gemtan Inj.	Non-small cell lung cancer, Pancreatic cancer, Bladder cancer, Breast cancer, Ovarian cancer	South-east Asia(SEA)
9	Imatinib	Leukivec	Chronic myeloid leukemia, Myelodysplastic	South-east Asia(SEA)

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Biosimilar	CKD-701	AMD	Biologics License Application
2	New chemical drugs	CKD-510	CMT, AF	Phase1
3	New chemical drugs	CKD-508	Dyslipidemia	Phase1
4	New chemical drugs	CKD-506	IPF	Phase1
5	New chemical drugs	CKD-516	CRC	Phase1
6	Antibody drug	CKD-702	NSCLC	Phase1
7	Herbal medicine	CKD-495	anti ulcerant	New Drug Application
8	IMD	CKD-841	Central Precocious Puberty(CPP)	Phase1
9	IMD	CKD-845	male hypogonadism	Phase1
10	IMD	CKD-843	BPH, Androgenetic alopecia	Phase1

## Others

CKD is developing histone deacetylase 6(HDAC6) inhibitors for non-oncology indications(CV, neuropathy, CNS, respiratory) and open to various types of collaborations to support the progress of its HDAC6 science and pipeline programs and new business opportunities for a global market as well as Korea.

# Corepharm Bio Co., Ltd.



[www.corepharm.com](http://www.corepharm.com)



## Category

Finished Pharmaceutical Products  
Platform Technology  
- Drug Delivery System

## Company Profile

Corepharm Bio has been dedicating to development of new dosage forms, which mainly aim at enhancing patient adherence.

In microgranular form, our unique dosage form called OD!FS®(Oral Dissolving in a Few Seconds) successfully masks inherent bitter taste of drug substances and with its properties of being dissolved immediately, OD!FS® allows improved patient adherence for all age groups especially for elderly patients with dysphagia or xerostomia and patients lying in bed.

## Strengths

1. Novel formulations with OD!FS®
2. Versatile platform technology
3. Improved patient adherence

## Collaboration Opportunities

1. License-out
2. Co-development



### CEO

Baek Jin Ouk

### Established Date

Oct, 2006

### Employee No.

28

### Contact point

Overseas Business

Phone: +82-2-927-8220

jj@corepharm.com

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Desmopressin acetate	Desmopressin OD!FS®	Nocturnal enuresis	China(under contract)	-
2	Tadalafil	FACTIL OD!FS®	Erectyle dysfunction, Benign prostatic hyperplasia	Mexico(under registration), Mongolia	Mongolia
3	Oseltamivir phosphate	MeltO-flu OD!FS®	Influenza	-	-

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	OD!FS®	CPBP10	CNS	Phase I
2	OD!FS®	CPBP11	CNS	Formulation
3	OD!FS®	CPBP13	NSAIDs	Preclinical
4	OD!FS®	CPBP14	CNS	Formulation

# CORESTEM INC.



[www.corestem.com/en](http://www.corestem.com/en)



## Category

Biopharmaceuticals  
Cell/Gene Therapy

## Company Profile

CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease.

We developed the world's first stem cell therapeutic product for ALS(Amyotrophic Lateral Sclerosis), name of NEURONATA-R, received the permission of medicines by Korea's Ministry of Food and Drug Safety in July 2014 and commercialized to patients in February 2015.

## Strengths

1. More than 10 years research stem cell therapy and success it the market commercialization.
2. Excellent production facilities recognized by the Ministry of Food and Drug Safety in Korea.
3. There have been no adverse drug-induced cases while administering to more than 300 patients.

## Collaboration Opportunities

1. Licensing In/out
2. Joint R&D



### CEO

Kyung-Suk Kim

### Established Date

2014.07

### Employee No.

### Contact point

1. Overseas Business  
ymlee@corestem.com
2. Licensing In/Out  
ymlee@corestem.com
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Autologous Bone marrow-derived mesenchymal stem cells	Neuronata-R (Lenzumestrocel)	ALS (Amyotrophic Lateral Sclerosis)	none	South Korea

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Autoimmunity	CE211AT15	SLE(Systemic Lupus Erythematosus)	Finished Phase 1 Clinical stage
2	Nervous system	CE111BR16	MSA(Multiple System Atrophy)	Finished Phase 1 Clinical stage
3	Nervous system	CE211BR19	CA(Cerebellar Ataxia)	Finished preclinical stage(IIT)
4	Nervous system	CE211NS21	NMO(Neuromyelitis Optica)	Preclinical stage
5	Lung	EV231LU00	Fibrosis	Preclinical stage

# CrystalGenomics, Inc.



<http://www.crystalgenomics.com/en/>



## Category

Finished Pharmaceutical Products

## Company Profile

CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery, development and commercialization of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of oncology, pain and infectious disease. The Company is headquartered in Korea and has several subsidiary and affiliate companies including: CG Pharmaceuticals(CGP), CrystalGenomics' wholly owned US subsidiary company for managing global development of CrystalGenomics' therapeutic programs; Machaon Biotherapeutics, a start-up biotech focused in fibrotic diseases; Crystal Life Sciences(CLS), a fully integrated pharmaceutical company with GMP manufacturing facilities and sales & marketing teams; Crystal Biosciences(CBS), a new technology project financing company which has recently listed a special purpose acquisition company(SPAC) on the NASDAQ for the first time by a Korean company.

CrystalGenomics currently has one product on the market and is developing two additional novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation COX-2 inhibitor for osteoarthritis. The most advanced R&D program is ivaltinostat, an HDAC inhibitor being developed for various therapeutic areas including oncology and fibrosis. A phase 2 pancreatic cancer study was recently completed in Korea with positive outcome and recently, IND for another phase 1b/2 pancreatic cancer was approved by the US FDA. The second program is nilofabacin(formerly CG-549), a novel class antibiotic for MRSA infections where its phase 2a skin infection study in the US has been completed with a positive outcome of 100% clinical cure rate. Lastly, CrystalGenomics is preparing a bridging study IND for non small cell lung cancer(NSCLC) with the MFDS for camrelizumab, an anti-PD-1 antibody which was in-licensed from Hengrui Pharmaceuticals.

## Strengths

1. Published cover page on Nature(Sep. 2003), first time ever by any group from Korea, both industry and academia combined
2. First biotechnology company to IPO on the KOSDAQ exchange under the government's special policy, exempting certain financial criteria for companies with innovative technologies
3. First Korean biotech to independently accomplish successful development, approval, commercialization, and export of a novel drug in Korea(Acelex®)

## Collaboration Opportunities

1. Out-license or co-develop CrystalGenomics' R&D program(s) outside Korea
2. In-license novel, first-in-class or differentiated best-in-class therapeutic programs from partners overseas
3. Execute supply agreements for Acelex with overseas partners for unpartnered regions excluding Korea, Turkey, MENA region, Brazil, EAEU countries including Russia, and Thailand.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Polmacoxib	Acelex 2mg Capsule	To treat symptoms of osteoarthritis	Russia	Korea, Russia, Lebanon	Partners are currently working on NDA/ registration process in Brazil, Turkey, and MENA region
2	Polmacoxib	Acelex 2mg Tablet	To treat symptoms of osteoarthritis	None	None	Partner is currently working on NDA/ registration process in Thailand

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Anticancer	Ivaltinostat (CG-745)	Oncology(Pancreatic cancer, Myelodysplastic syndrome (MDS), AML, Hepatocellular carcinoma)	Phase 2 Completed	<ul style="list-style-type: none"> <li>Phase 2 study for pancreatic cancer is completed in Korea</li> <li>Recently received IND approval from FDA for a phase 1b/2 study for pancreatic cancer</li> </ul>
2	Anticancer	Camrelizumab (SHR-1210)	Oncology(Squamous and Non-squamous Non small cell lung cancer(NSCLC), esophageal cancer, classic hodgkin lymphoma, hepatocellular carcinoma, nasopharyngeal cancer)	Registrational bridging study in progress	<ul style="list-style-type: none"> <li>CrystalGenomics had in-licensed exclusive rights from Hengrui Pharmaceutical, for South Korea</li> <li>Approved in China for 6 indications</li> <li>Global hepatocellular phase 3 study was recently completed in 13 countries(US, Europe, China, &amp; Korea)</li> <li>CrystalGenomics plans to obtain first approval in Korea through a bridging study for a solid cancer indication, then expand to additional indications</li> </ul>
3	Antibacterial	Nilofabacin (CG-549)	Infectious Disease (Acute bacterial skin and skin structure infections (ABSSSI), osteomyelitis, other staphylococcus aureus infections)	Phase 2 Ready	<ul style="list-style-type: none"> <li>A novel, potentially first-in-class antibacterial drug candidate that inhibits enoyl-[acyl-carrier-protein] (ACP) reductase(fabI), an essential enzyme in fatty acid synthesis.</li> <li>In phase 2a proof-of-concept study, 100% of evaluable subjects were clinically cured by the TOC visit(Day 21~28)</li> </ul>
4	Anti-inflammatory/ Pain	CG-650	Various acute and chronic pain indications	Phase 3 Ready	<ul style="list-style-type: none"> <li>Fixed-dose combination drug product containing polmacoxib and tramadol</li> <li>Completed drug-drug interaction phase 1 study and ready for a phase 3 study</li> </ul>
5	Anti-inflammatory/ Neuropathic Pain	CG-651	Various neuropathic pain indications	Phase 2 Ready	<ul style="list-style-type: none"> <li>Fixed-dose combination drug product containing polmacoxib and pregabalin</li> <li>Completed drug-drug interaction phase 1 study and ready for a phase 2 study</li> </ul>

# CTCBIO INC.



www.ctcbio.com



## Category

Finished Pharmaceutical Products

## Company Profile

CTCBIO is a Korean pharmaceutical company which holds top 50 domestic pharmaceutical companies as solid clients and is involved in co-operative partnership with international pharmaceutical companies. Its pharmaceutical business covers development and production of super-generics with drug formulation and delivery technology. We are specialized in micro-encapsulation using fluid bed and OSF formulation. CTCBIO is capable of manufacturing various types of oral dosage forms and has business capabilities starting from formulation development and all the way to commercial production.

## Strengths

1. Development and production of Orodispersible film(ODF)
2. Consignment research
3. Technical transfer of drug formulation

## Collaboration Opportunities

1. Lisencc-out
2. Techical transfer
3. Export products

### CEO

Min Goo Lee

### Established Date

June, 1993

### Employee No.

266

### Contact point

#### 1. Overseas Business

Global Business Division  
+82 70 4033 0268  
jsmoon@ctcbio.com

#### 2. Licensing In/Out

Global Business Division  
+82 70 4033 0266  
n31@ctcbio.com

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Sildenafil free base	Please orally soluble film	Treatment of Erectile dysfunction	Lebanon, Paraguay, Cambodia, Macao, Taiwan, etc	Product manufacturer
2	Tadalafil	Godn orodispersible film	Treatment of Erectile dysfunction	Costa Rica, Turkey, Singapore, Macao, etc	Product manufacturer

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Sildenafil	CDF0311	Treatment of erectile dysfunction	Approved	Change of dosage form(OSF)
2	Tadalafil	CDF0213	Treatment of erectile dysfunction	Approved	Change of dosage form(ODF)
3	Donepezil free base	CDF0212	Treatment of Alzheimer's disease	Approved	Change of dosage form(ODF)
4	Desmopressin acetate	CDF0612	Treatment of primary enuresis, nocturnal enuresis	Approved	Change of dosage form(ODF)
5	Entecavir	CDF0511	Treatment of chronic hepatitis B virus	Approved	Change of dosage form(ODF)
6	Varaniline salicylate	CDF0318	Smoking cessation therapy	Approved	Change of dosage form(ODF)
7	Oseltamivir phosphate	CDF0716	Treatment of influenza A and B infection	Approved	Change of dosage form (powder)
8	Sodium picosulfate etc.	CDF0613	Eathartic for colonology and preoperative treatment	Approved	New dose and composition
9	Clomipramine/sildenafil	CDF0812	Treatment of premature ejaculation	Phase III	New combination drug

## Others

### CTC WAY

Our way of action on developing core competencies to practice our mission and to proceed towards accomplishing the vision shall be concentrated into three core values of Change, Try and Challenge, and such core values shall be expanded into the strengths of Fun, Creativity and Passion at the point where two core values meet. These 6 core values will lead us to the road to a great success.



# Daehwa Pharmaceutical Co., Ltd.



www.dhpharm.co.kr



## Category

API  
Finished Pharmaceutical Products  
Cosmetics

## Company Profile

DaeHwa Pharmceutical Co., Ltd. was established in the spirit of "providing society a more human-centered pharmceutical business" Sine 1984,DaeHwa seeks new Patch and developed the Korea Pharmaceutical industry through Globalization. With its own technologies, DaeHwa procudes APIs and finished products such as Cephametyl which is ranked third in the oral Cephalosporin market. DaeHwa currently exports more than 60 products to 20 countires. Moreover DaeHwa speed into the new area of cosmetic surgery market by taking over Ridoxbio Inc. as well as German cosmetics & Medical device manufacturing and distribution company.

## CEO

## Established Date

## Employee No.

## Contact point

- Overseas Business**  
Overseas Business Team  
+82 2 6716-1071  
shw0817@dhpharm.co.kr
- Licensing In/Out**  
BD Team  
+82-2-6716-1072  
crispaul@dhpharm.co.kr
- Overseas Branch**  
N/A

## Strengths

- ISO37001 & ISO37301
- Invest more than 10% to R&D
- High Quality Technolony on Pacht and Anticancer

## Collaboration Opportunities

- Product Exporting
- Tech Transfer



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Betamethasone etc	Posen Cream	Allergic dermatitis, alopecia areata, first gegree burn, dermatomycosis	Cambodia
2	Bromelain etc	Protase Tab	Fracture, Sprain, Internal, External amd increased hemorrhoid after proptosis and a hemorrhoidal surgery	Myanmar, Cambodia
3	Ibuprofen	UPRO Tab	Rheumatoid Arthritis, Oseteoarthritis, Ankylosing, Spondylitis	Thailand, Cambodia
4	Korean Ginseng etc	Top-Roll SC	Tonic, Nutritive supplement	Myanmar, Bolivia
5	BDD	Bidica Tab	Chronic hepatitis	Mongolia
6	Acyclovir	Acyclovir Cream	Virus Infections	Vietnam
7	Ketoprofen	Kebanon Plaster	Traumatic Inflammation of muscles, strains and sprains, Relief of symptoms of muscular pain	Mongolia, Bolivia, UZB, Malaysia
8	Rivastigmin	Rivamensa Patch	Symptomatic treatment of mild to moderate Alzheimer's type dementia or dementia associated with Parkinson's disease	
9	Trimebutine	Meritin Tab	Digestive dysfunction in esophageal reflux and hiatus hernia, gastroduodenitis, and gastroduodenal ulcer (abdominal pain, indigestion, nausea, vomiting)	
10	Terbinafine	Tenafine Cream	dermato-fungal infections(tinea pedis, tinea genitalia, tinea corpus callosum) and tinea warts and cutaneous candidiasis caused by Ptyrosporom olivulare.	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	DH-BIO/HELBAL Technology	DHP1404	Dementia	Phase 2
2	DH-BIO/HELBAL Technology	DH032005	Osteoarthritis	Non-Clinical
3	DH-BIO/HELBAL Technology	DHP32007	Colon Cancer	Non-Clinical
4	DH-BIO/HELBAL Technology	DHP32006A	Breast Cancer	Non-Clinical
5	DH-TDDS Technology	DHP26008	Bronchial Asthma	Global Launch
6	DH-TDDS Technology	DHP26005	Dementia	Domestic Launch
7	DH-TDDS Technology	DHP26007	Dementia	Optimization
8	DH-TDDS Technology	DHP27013	Inflammation	Domestic Launch
9	DH-TDDS Technology	DHP26003	Pain	Safety & Manufacture.



# Daewon Pharm. Co. Ltd.

**Daewon**  
Pharmaceutical

[www.daewonpharm.com](http://www.daewonpharm.com)



## Category

Finished Pharmaceutical Products  
Medical Device

## Company Profile

Daewon Pharm is a capable company that has developed new drugs using excellent technological basis and manufacturing facility. We are devoting ourselves to develop numerous new products to improve the quality of life, and trying our best to become the representative pharmaceutical company of the Republic of Korea.

## Strengths

1. Development of new drug(Pelubiprofen)
2. Best quality for stick sachet form drug
3. Diverse pipeline for innovative drugs

## Collaboration Opportunities

1. Export finished products
2. License-out
3. Food Supplement

### CEO

Seungryel Baek

### Established Date

1958

### Employee No.

1001

### Contact point

#### 1. Overseas Business

Overseas biz dept.  
02-2204-7086  
export@daewonpharm.com

#### 2. Licensing In/Out

Overseas biz dept.  
02-2204-7086  
bskim@daewonpharm.com

#### 3. Overseas Branch

Overseas biz dept.  
010-9204-4083  
nhyoo@daewonpharm.com

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Pelubiprofen 30mg/45mg	Pelubi Tab/ Pelubi CR Tab.	Reduce symptoms of Osteoarthritis, Rheumatoid arthritis, Back pain(Lumbago) and Fever	Myanamr, Mongolia, Russia	Approved in current exporting countries
2	Multivitamin+Minerals+Korean Ginseng	Oramin F Soft Cap.	Supplementation of vitamins and minerals	Iran, Cambodia, Peru, Ecuador, Syria, UAE and so on	Approved in current exporting countries
3	Megestrol Acetate 40mg	Megex-I Susp.	Anorexia, Cachexia of cancer or AIDS patients or predominant weight loss of unknown cause	Peru, Iran, Taiwan	Approved in current exporting countries
4	Propofol 1%, 2%	Freefol MCT Inj.	Anesthesia	Syria, Mexico, Ecuador, Mongolia	Approved in current exporting countries
5	Spherical adsorptive carbon 2g	Renamezin	Chronic renal failure	Taiwan	Approved in current exporting countries
6	Oxethazaine 20mg Dried Aluminum hydroxide gel 582mg Magnesium hydroxide 196mg	Trigel Susp.	Acute & Chronic pain, Gastritis, Duodenal ulcer, Esophagitis, Stomach pain by dyspepsia in radiotherapy	Vietnam, Cambodia, Peru, Mongolia	Approved in current exporting countries
7	Acetaminophen 325 mg Chlorpheniramine Maleate 2.5 mg Ephedrine HCl 18 mg Guaifenesin 42 mg	Coldwon Syr.	Temporarily relieves common cold/flu symptoms	Mongolia	Approved in current exporting countries
8	Diocahedral smectite 15g	Fotagel Susp.	Pain symptoms after esophageal, gastroduodenal and enteric disease. Acute or chronic diarrhea	Mongolia, Vietnam, Cambodia	Approved in current exporting countries

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	New Drug	DW-4301	Hyperlipidemia	Phase 2 in process	New substance drug
2	New Drug	DW-4902	Endometriosis	Phase 1 completed	New substance drug
3	Incrementally Modified/Combination	DW-1601	Respiratory system	Phase 3 in process	Combination
4	Incrementally Modified/Combination	DW-1704	Circulation system	Phase 3 in preparation	Formulation modified
5	Incrementally Modified/Combination	DW-1703	Endocrine system	Phase 1 completed	New salt
6	Incrementally Modified/Combination	DW-2701	Endocrine system	Phase 2 in process	New salt
7	Incrementally Modified/Combination	DW-1804	Endocrine system	Phase 2 in preparation	New salt, etc
8	Incrementally Modified/Combination	DW-1805	Endocrine system	Phase 1 in preparation	New salt, etc
9	Incrementally Modified/Combination	DW-1806	Endocrine system	Leading research	New salt, etc

# Daewoong Pharmaceutical Co., Ltd.



www.daewoong.com



## Category

API  
Finished Pharmaceutical Products  
Biopharmaceuticals - Cell/Gene Therapy - Biosimilar  
Others - Medical Device - Cosmetics

## Company Profile

Since its establishment in 1945, Daewoong Pharmaceutical has grown to become one of the top 5 pharmaceutical companies in Korea. With its strong and competent in-house R&D and qualified manufacturing facilities(cGMP), Daewoong provides a total healthcare solution to patients across the globe. We manufacture various products(ETC&OTC) including Biologic, Chemical, Medical Device, etc.

### CEO

Jeon Seng-Ho, Lee Chang-Jae

### Established Date

15th, Aug, 1945

### Employee No.

3,600+ (in 8 Countries)

### Contact point

#### 1. Overseas Business

+82-2-550-8112  
doyoung.kim@daewoong.co.kr

#### 2. Licensing In/Out

Global Strategy Team  
+82-2-550-8486  
hklee@daewoong.co.kr

#### 3. Overseas Branch

+82-2-550-8462  
yamyam2000@daewoong.co.kr

## Strengths

1. World 1st US approved Korean Neurotoxin
2. Top 5 Korean pharma sales revenue
3. 10+ Global on-going clinical trials

## Collaboration Opportunities

1. Open Collaboration
2. Licensing
3. Technology Transfer

## Others

1. Leading Korea Pharmaceuticals(Prescription drugs/OTC/CMO)
2. Fruition in R&D activities
  - Fexuprazan(P-CAB): NDA approved by Korea MFDS
  - Enavogliflozin(Best in class SGLT2 inhibitor, Diabetes): NDA filing(KOREA)
3. R&D in innovative new drug
  - Anti-FcRn mAb\*in US Phase 2, 3 in 5 indications across the world
  - HL036(dry eye syndrome) in the US phase 3
  - PRS(Anti Fibrosis) in Australia phase 2 ready(ODD, FDA)
  - Autoimmune(Dual inhibitors)
4. Neurotoxin
  - Aesthetics
    - US FDA approval+
    - EU EMA approval+
    - Health Canada approval+
  - Therapeutics
    - IND filing to FDA



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Botulinum toxin type A	Nabota	Glabellar lines, Post stroke, Upper limb spasticity	USA	100 U: 2019.02.01
				Brazil	100 U: 2020.02.17
				Canada	100 U: 2018.08.16
				Thailand	200 U: 2017.12.28(Nabota) 200 U: 2015.07.17(Clodew) 100 U: 2014.05.28(Nabota) 100 U: 2014.08.19(Clodew) 50 U: 2015.07.17(Nabota) 50 U: 2018.01.10(Clodew)
				UAE	100 U: 2019.12.31
				Taiwan	100 U: 2020.06.19
2	Ursodeoxycholic acid	URSA	Liver & bile disease including cholestasis, Gallstone, etc.	Philippines	300mg: Sep, 2009
				Cambodia	200mg: Jan, 2017
				Mongolia	200mg: May, 2014
				Myanmar	200mg: Jul, 2010
				Vietnam	100mg: Jan, 2012 200mg: Sep, 2014 300mg: Mar, 2014
				Jordan	100mg: Jul, 2019
3	Ursodeoxycholic acid	URSA Soft capsule	Liver & bile disease including cholestasis, Gallstone, etc.	Myanmar	50mg: May, 2007
4	Aluminium hydroxyde gel Magnesium hydroxide	Newlanta	Acid peptic ulcer disease, Erosive gastroduodenal lesions, Reflux esophagitis	China	10mL: Nov, 2010
				Philippines	10mL: Nov, 2014
				Cambodia	10mL: Jan, 2012
				Vietnam	10mL: Sep, 2017
5	Aluminium hydroxyde gel Magnesium hydroxide Simethicon	Trimafort	Hyperacidity(including gastritis, swelling, gastric ulcer & duodenal), Brash, Gastric inconvenience, Gastric swelling, Indigestion	Cambodia	10mL: Mar, 2016
6	Aluminium hydroxyde gel Magnesium hydroxide Simethicon	Loxmafort	Hyperacidity(including gastritis, swelling, gastric ulcer & duodenal), Brash, Gastric inconvenience, Gastric swelling, Indigestion		
7	rhEPO	Eposis	Anemia in end stage renal diseases	Philippines	- 2000IU: Apr.2012 - 4000IU, 10000IU : May.2012
				Tailand	- 3000, 4000, 5000, 8000, 10000IU: Jan. 2010
8	Fexuprazan	Fexuclue	Erosive Esophagitis	-	40mg: Jul 2022
9	Enavogliflozin	Envlo	Type 2 diabetes	-	40mg: Jul 2022

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	NCE	DWP14012(Fexuclue)	Prevention of NSAIDs-induced peptic ulcer	Phase III
2	NCE	DWP14012(Fexuclue)	Maintenance of healed erosive esophagitis	Phase III
3	Biologics	HL036	Dry eye syndrome	Phase III
4	NCE	DWP16001(Envlo)	Type 2 diabetes(CN)	Phase III
5	NCE	DWP305401	Ulcerative colitis(FDA)	Phase II
6	NCE	DWN12088	IPF(US)	Phase II
7	Biologics	DWP706	Corneal wound	Phase II
8	NCE	DWP213388	Autoimmune disease(US)	Phase I
9	NCE	DWP17061	Arthritis Pain(AU)	Phase I
10	NCE	DWP306001	Obesity	Phase I
11	Biologics	DWP710	Acute Respiratory Distress Syndrome	Phase I

# Dai Han Pharm. Co., Ltd.



www.daihan.com



## Category

Finished Pharmaceutical Products

## Company Profile

Dai Han Pharm. Co., Ltd. manufactured the first infusion as the basis of the national health, opening a new horizon for medical companies and grew as a representative infusion manufacturer of Korea

By procuring over 200 types of finished medicines for treatment, we are leading markets for therapeutic drugs, and keeping your health in diverse medical fields

### CEO

Yoon Woo Lee

### Established Date

Oct. 14, 1945.

### Employee No.

610 persons

### Contact point

- Overseas Business**  
Global Business Dept.  
+82-2-2620-8952  
hskim@daihan.com
- Licensing In/Out**  
Global Business Dept.  
+82-2-2620-8952  
hskim@daihan.com
- Overseas Branch**  
N/A

## Strengths

- Leading the advancement of diagnostic technology for Infusion products in Korea
- Innovating health solutions based on personalized nutrition products
- Numerous collaborations experience with many overseas partners

## Collaboration Opportunities

- Exporting finished dosage
- Tech Transfer



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Iohexol 300mg/50mL	Iohexol Inj. 300	Myelography, angiography, urography, Computerizedtomography(CT)-contrast enhancement	Vietnam, Costa Rica, Philippines
2	Acetaminophen 10mg/mL	Profa Infusion Inj.	Pain and high fever that needs a quick treatment (needs administration by IV)	Mongolia, Philippines
3	Metronidazole 5mg/mL	Metrynal Inj.	Use to following infectious diseases by anaerobic bacterium : Sepsis and bacteremia, encephalophyma etc. Prevention of infections by anaerobic bacterium after surgery.	Mongolia, Philippines
4	Levofloxacin 500mg	Levofloxacin Infusion	pneumonia, acute pyelonephritis, multiple urinary tract infection, acute sinusitis, infection of skin and tissue, etc.	Philippines, Vietnam, Azerbaijan
5	Lidocaine HCL 2%	Lidocaine HCL 2%	1. Anesthesia: epidural anesthesia, nerve block, infiltration anesthesia and surface anesthesia. 2. Internal medical use: ventricular arrhythmia.	Hong Kong, Philippines, Mongolia, Costa Rica
6	Vitamin B complex	Pan-B-Comp Inj.	Supply of vitamins and prophylaxis of deficiency of vitamin B series	Cambodia, Vietnam, Philippines
7	Phytonadione 10mg/ml	Vitamin K1 Inj.	1. Prophylaxis and treatment of hemorrhage disease for a newborn 2. Hypoprothrombinemia	Iran, Vietnam, Philippines, Ukraine, Turkey
8	L-Ornithin L-Aspartate 500mg/1ml	Orni Inj.	Hepatic coma, Treatment of precoma	Vietnam, Azerbaijan, Uzbekistan, Mongolia
9	L-Ornithin L-Aspartate 100mg/1ml	Heparogen Inj.	Detoxication of liver disease (hepatitis and sequela, tissue damage, hepatic cirrhosis)	Vietnam, Azerbaijan, Uzbekistan, Mongolia
10	Tranexamic acid 500mg/5ml	Tranexamin Inj. 500mg	Hemorrhage(by leukimia, aplastic anemia, purpura, cancer, pulmonary hemorrhage, renal hemorrhage, genital bleeding, etc.)	Vietnam, Philippines, Malaysia
11	Pyridoxine HCl 100mg/ml	Bidoxin inj.	Treatment and prophylaxis of vitamin B6 deficiency symptom	Costa Rica, Mongolia
12	Ketorolac tromethamine 30mg/mL	Ketorolac Inj.	Severe pain	Philippines, Panama, Malaysia
13	Sod. Bicarbonate 8.4%	Sod. Bicarbonate Inj.	Acidosis, Acute pruritus	Philippines, Costa Rica
14	Piroxicam 20mg/ml	Piroxicam Inj.	Rheumatic arthritis, osteoarthritis, ankylosing spondylitis etc.	Vietnam
15	Citicoline 500mg/2ml	Statirin Inj.	Disturbance of consciousness by head trauma and surgery of brain etc.	Vietnam, Azerbaijan
16	Ciprofloxacin 2mg/mL	Ciprofloxacin Inj.	Respiratory tract, ENT infections, renal or urinary tract infections, genital infection including gonorrhoea, GI infections, bone or joint infections, etc.	Philippines
17	Aminoacid Infusion	AminoheX Inj.	Supply of amino acids in following cases (Hypoproteinemia, hypoalbuminemia, and before/after surgery)	Vietnam, Mongolia
18	Aminoacid Infusion	Amicomplex Inj.	Supply of amino acids in following cases (Hypoproteinemia, hypoalbuminemia, and before/after surgery)	Mongolia
19	Aminoacid Infusion	Hepavia Inj.	Improvement of encephalopathy due to acute/chronic hepatic impairment, supply of amino acids to a patient with hepatic impairment	Vietnam, Mongolia
20	Epinephrine 1mg/ml	Epinephrine Inj.	Relief of bronchial asthmatic paroxysm, symptoms by serum disease, hives and angioneurotic edema.	Costa Rica, Philippines, Mongolia

# Daiichi Sankyo Korea



[www.daiichisankyo.co.kr](http://www.daiichisankyo.co.kr)



## Category

Finished Pharmaceutical Products

## Company Profile

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We are dedicated to creating new modalities and innovative medicines to help patients by leveraging our world-class science and technology with more than 100 years of scientific expertise.

### President

Dae-jung Kim

### Established Date

July 16, 1990.

### Employee No.

221 persons

### Contact point

1. Overseas Business  
N/A
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Strengths

1. Science & Technology
2. Global Organization & Talent
3. Sustainable Growth



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Edoxaban tosylate	Lixiana	Anticoagulant	Imported
2	Olmesartan medoxomil/ Amlodipine/Hydrochlorothiazide	Sevikar HCT	Antihypertensive drug	
3	Olmesartan medoxomil/Amlodipine	Sevikar	Antihypertensive drug	
4	Pravastatin	Mevalotin	Anti-hyperlipidemia drug	
5	Prasugrel HCl	Effient	Antiplatelet drug	
6	Ramosetron HCl	Nasea	Antiemetic drug	
7	Mirogabalin besylate	Taleaje	Miscellaneous central nervous system drug	
8	Nicardipine HCl	Perdipine	Antihypertensive drug	
9	Barnidipine HCl	Oldeca	Antihypertensive drug	
10	Pilsicainide HCl	Sunrythm	Antiarrhythmic drug	

# Dalim BioTech Co., Ltd.

**dalimbiotech**

[www.dalimpharm.co.kr](http://www.dalimpharm.co.kr)



## Category

Finished Pharmaceutical Products

## Company Profile

Dalim BioTech is the pharmaceutical company specialized in endocrine diseases such as Diabetes, Thyroid and Menopausal Disease.

As our Differentiation strategy, we always try to develop unique products such as modified drug or first generics in the world. Therefore we have various exclusive products which can be supplied only by Dalim BioTech.

In addition, we are the one of 3 companies in Korea that can produce sex hormonal product by themselves. We are able to supply various sex hormonal products at competitive cost and also to provide CMO production after establishment of our own dedicated sex hormonal premises.

## Strengths

1. Manufacturing facility in accordance with EU GMP level.
2. Various unique products to be exclusively supplied by us only in Korea.
3. Sex hormonal product & CMO production.

## Collaboration Opportunities

1. Products registration
2. Provide market trends
3. Government procurement guide

## Others

As a leading specialist in the field of Endocrine Diseases, Dalim BioTech always make an effort to accomplish social responsibilities with continuous challenge through developing and providing best quality to our customer.

### CEO

Jong-Sup Chung

### Established Date

1 July, 2001

### Employee No.

235 persons(as of 31 May, 2022)

### Contact point

#### 1. Overseas Business

Product Development Department  
82-2-3140-3873  
hwan@dalimpharm.co.kr

#### 2. Licensing In/Out

Product Development Department  
82-2-3140-3783  
plan783@dalimpharm.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Metformin HCl 500mg + Gliclazide 80mg	Glupa Combi Tab.	Oral hypo-glycemics	Azerbaijan, Uzbekistan	Bioequivalence	World 1st combination of Metformin HCl + Gliclazide
2	Estradiol hemihydrate 2.07mg	Preda Tab. 2mg	Postmenopausal syndrome	Peru, Georgia	-	1st generics, Estradiol hemihydrate 1.03mg is also available
3	Levothyroxine Na 25µg, 50µg, 100µg	Synthyroxine Tab. 25µg, 50µg, 100µg	Hypothyroidism (Thyroid Hormone T4)	Mongolia, registration is progress in Vietnam	Bioequivalence	Levothyroxine Na with 75, 88, 125, 150µg are also available
4	Tetracosactide 0.25mg/ml	Cynacten Inj.	Diagnosis of adrenocortical insufficiency	Hongkong, Malaysia, Singapore	-	-
5	Thioctic acid 200mg	Lipo-A Tab.	Diabetic multiple neuropathy	Mongolia	Bioequivalence	-
6	Heparin sodium 50 IU/g + Onion extract solution 100mg + Allantoin 10mg	Kelobex Gel	Treatment of keloid, surgery, cutting, burn, wound scar	Uzbekistan	-	20g/TUBE
7	Norepinephrine 4mg	Norpin Inj. 4ml	Acute hypotension or shock	Hongkong, Macau, Thailand	-	Norepinephrine 10mg and 20mg are also available
8	Tibolone 2.5mg	Tibiol Tab.	Postmenopausal syndrome	Chile, Vietnam (registration is in progress)	Bioequivalence	Easy to administer by divided dose(1/2)
9	Cabergoline 0.25mg	Dostinen Tab. 0.25mg	Prevention and suppression of Physiological lactation	Georgia	-	Cabergoline with 0.5mg, 1mg are also available
10	Carbimazole 5mg	Camen Tab. 5mg	Hyperthyroidism	Cambodia, registration is progress in Myanmar and Vietnam	-	Carbimazole 10mg is progress in Vietnam
11	Metformin HCl 500mg, 850mg, 1000mg	Glupa Tab. 500mg, 850mg, 1000mg	Non insulin dependent diabetes(Type 2)	Uzbekistan	Bioequivalence	Metformin HCl with 250mg is also available
12	Glimepiride 2mg, 3mg, 4mg	Diaryl Tab. 2mg, 3mg, 4mg	Non insulin dependent diabetes(Type 2)	Uzbekistan	Bioequivalence	-
13	Levonorgestrel 1.5mg	After 1 Tab.	Emergency contraceptive pill	Uzbekistan, registration is progress in Hongkong and Kuwait	-	-
14	Dienogest(micronized) 2mg	Diezan Tab.	Endometriosis	Hongkong, Jordan, Vietnam, Myanmar (registration is in progress)	Bioequivalence	First priority medicine of Endometriosis
15	Evening primrose oil 450mg (γ-linolenic acid 40mg)	Evoprim Soft Cap.	Diabetic neuropathy, Atopic eczem	-	Phase III	Developed 1st in the world (Add Indications)
16	Metformin HCl 500mg + Repaglinide 1mg/2mg	Repanorm M Tab. 1/500mg, 2/500mg	Oral hypo-glycemics	-	Phase I	World 1st generics
17	Conjugated equine estrogens 0.3mg, 0.625mg	Premina Tab. 0.3mg, 0.625mg	Postmenopausal syndrome	Hongkong (registration is in progress)	-	World 1st CEE generics, Natural estrogen component has low adverse effect

# DEARGEN INC.



<https://deargen.me>



## Category

Biopharmaceuticals  
Platform Technology  
- AI Drug Discovery

## Company Profile

Deargen is a sequence based AI-first drug discovery and development company located in South Korea. By integrating advanced AI technology and experts experience, our end-to-end solution is committed to discovering, designing and developing the best possible drugs in the fastest and most effective way.

### CEO

KilSoo Kang

### Established Date

2016 December 06

### Employee No.

60

### Contact point

1. Overseas Business  
bd@deargen.me
2. Licensing In/Out  
strategy@deargen.me
3. Overseas Branch  
bd@deargen.me

## Strengths

1. Bypassing the Need for 3D Structure
2. Applied patent for unstructured novel target candidate in 10 weeks by using an end-to-end solution of AI platform.
3. Establishment of R&D Center(iDearCenter) and US branch(DeargenUSA)

## Collaboration Opportunities

1. Co-development Agreement
2. SI

## Others

Deargen's advanced sequence-based end-to-end AI solution(DEARGEN iDears) supports the early drug discovery and development process. Our AI platforms applied newly recognized technology in the AI field, such as Cross-attention and Bayesian Deep Learning technology, to discover, design, and develop new drugs from target discovery to lead optimization



# Dong-A Pharmaceutical.

**DONG-A PHARM**

<http://en.dapharm.com/Main.da>



## Category

Finished Pharmaceutical Products

Others

- Medical Device
- Quasi Drug
- Cosmetics
- Functional health foods



## Company Profile

Dong-A Pharmaceutical began its business in 1932 and has been leveraged its outstanding expertise in R&D in order to improve its products, while helping customers to improve their quality of life. As such, it has continued to grow in a sustainable way, not only providing high-quality products, but also contributing to build a healthy society through customer-centric management.

The company focuses its research capabilities on preventative medicines and new functional products to enhance quality of life, rather than post-disease treatments, and thus boosts its product competitiveness.

Dong-A Pharmaceutaical is a leading healthcare company in Korea, and will continue to strengthen its ability to develop innovative medicine and services, with the ultimate goal of becoming a global healthcare company.

Dong-A Pharmaceutical's main business includes over-the-counter drugs, which can be bought without a prescription, as well as health functional foods and quasi-drugs such as Bacchus®, Garglin®, Morning Care®, and Tempo®.

### CEO

Choi Ho-Jin

### Established Date

December. 1932.

### Employee No.

956 persons

### Contact point

#### 1. Overseas Business

Derma Dept. Overseas Sales Team,  
Ji-Won Jung, jiwon@donga.co.kr

#### 2. Licensing In/Out

OTC Marketing Dept.  
New Product Development Team,  
Yeeun Choi, yeeunchoi@donga.co.kr



## Main Products

No.	Main Ingredient	Product name	Use
1	Taurine, Inositol, Nicotinamide, Thiamine Nitrate, Riboflavin Sodium Phosphate, Pyridoxine Hydrochloride, Anhydrous Caffeine	Bacchus-D Sol.	nutritional tonic, weakness, physical fatigue, post-disease physical strength, loss of appetite, and nutritional disorders
2	Taurine, Inositol, Nicotinamide, Thiamine Nitrate, Riboflavin Sodium Phosphate, Pyridoxine Hydrochloride, DL-Carnitine Hydrochloride, Anhydrous Caffeine	Bacchus-F Sol.	nutritional tonic, weakness, physical fatigue, post-disease physical strength, loss of appetite, and nutritional disorders
3	dl-Methylephedrine Hydrochloride, Guaifenesin, Acetaminophen, Anhydrous Caffeine, Chlorpheniramine Maleate, Titepidine Citrate	Panpyrin Q Sol.	relief of symptoms of a cold(runny nose, stuffy nose, sneezing, sore throat, cough, phlegm, chills, fever, headache, joint pain, muscle pain)
4	Dexpanthenol, Allantoin, Heparin Sodium	Noscarna Gel	After treatment of scar tissue(hypertrophic scars, keloid scars, acne scars, surgical scars)
5	Licorice, Ginger, Cinnamon Bark, Citrus Unshiu Peel, Atractylodes Rhizome, Corydalis Tuber, Fennel	Benachio-F Sol.	loss of appetite(lack of appetite), bloated stomach, overeating, indigestion, nausea, vomiting

# Dong-A ST Co., Ltd.



<http://en.donga-st.com/>



## Category

API  
 Finished Pharmaceutical Products  
 Biopharmaceuticals - Biosimilar  
 Herbal Medicinal Product - Drug Delivery System  
 Medical Device

## Company Profile

Founded in 1932, Dong-A Pharmaceuticals has been the No. 1 pharmaceutical company in Korea over 46 years with pharmaceutical sales and since the demerger in 2013, Dong-A reorganized its corporate structure by spinning off the ETC and export business into a new subsidiary, Dong-A ST. With nationwide sales branches, Dong-A ST is distributing prescription products in range of therapeutic areas including GI, CV/MD, Uro, Derma and Musculoskeletal

### CEO

Min-Young Kim

### Established Date

1932

### Employee No.

1640

### Contact point

#### 1. Overseas Business

International Business Division  
 +82-2-920-8364/dy\_lee@donga.co.kr

#### 2. Licensing In/Out

Business Development & Licensing  
 +82-2-920-8211/sunpark@donga.co.kr

#### 3. Overseas Branch

**U.S.A BRANCH**  
 International Business Division  
 +82-70-8636-1215/rsy@donga.co.kr

**BRAZIL BRANCH**  
 International Business Division  
 +55-119-4198-6013/smile@donga.co.kr

**INDIA BRANCH**  
 International Business Division  
 +91-099-6770-7111/  
 focusonsk@donga.co.kr

## Strengths

1. Innovative R&D pipeline
2. Expertise and Experiences in New Drug Development
3. Strong Sales/Marketing Capability in Domestic Market

## Collaboration Opportunities

1. L/O
2. L/I
3. R&D collaboration

## Others

Dong-A has been the largest pharmaceutical company in Korea since 1967. We have solidified our leading market position on the strength of in-house developed products such as Suganon tab. Evogliptin, the DPP-4 inhibitor for type 2 diabetes mellitus, Zyderna tab. Udenafil, the fourth PDE5 inhibitor in the world for erectile dysfunction, Stillen tab. Eupatilin for herbal treatment of gastritis and Motilitone tab. Corydaline for functional dyspepsia. Furthermore, we are offering branded generic drugs(anti-cancer, anti-TB, etc.), bio-pharmaceutical, APIs and OTC products ensuring full compliance to international quality standard. Currently Dong-A is exporting its products to more than 50 countries to leading pharmaceutical companies in Europe, Latin America, Asia and MENA.

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Cycloserine 250mg	CLOSERIN Cap.	Active pulmonary, Extra-pulmonary tuberculosis	WHO, China, India, The Democratic People's Republic of Korea, France, Botswana, Iran, Vietnam, Algeria	WHO Prequalification
2	Darbepoetin alfa	DA-3880	Intravenous or subcutaneous treatment for anaemia associated with chronic renal failure.	Japan	PMDA
3	Recombinant Erythropoietin 1000, 2000, 4000, 10000IU	EPORON Inj.	Anemia associated with chronic renal failure	Turkey, Philippine, Thailand, Chile, Indonesia, Iraq, Vietnam, Pakistan, Syria, Lebanon, Yemen, Morocco, Czech Republic, Georgia	
4	Recombinant Follitropin 75IU, 150IU, 300IU	GONADOPIN Inj.	Assisted reproduction (infertility in women patients)	Iraq, Iran, Czech Republic, Mongolia, Pakistan, Nigeria, Vietnam, Thailand, Syria	
5	Recombinant Somatropin 4IU, 12IU, 16IU, 30IU	GROWTROPINII for Inj.	Growth failure due to an inadequate secretion of growth hormone	Brazil, Ukraine, Iran, Syria, Lebanon, Algeria, Georgia, Czech Republic, Iraq, Nigeria, Thailand	
6	Recombinant Filgrastim 75µg, 150µg, 300µg, 480µg	LEUCOSTIM Inj.	Neutropenia in patients receiving myelosuppressive chemotherapy, etc.	Turkey, Philippine, Georgia, Vietnam, Syria, Lebanon, Chile, Iraq, Morocco, Columbia, Nigeria	
7	Corydalis tuber & Pharbitis seed Ext. 30mg	MOTILITONE Tab.	Functional dyspepsia	Turkey	
8	Artemisia Argyfolium 95% ethanol viscous ext. 60mg	STILLEN Tab.	Prevention of NSAIDs-induced gastritis, Acute & chronic gastritis	Lithuania, Republic of South Africa, Iran, Swiss, Kazakhstan, Ukraine, Estonia, Philippine	
9	Evogliptin 5mg, Evogliptin/Metformin 2.5mg/500mg, 2.5mg/850mg, 5mg/1000mg	SUGANON Tab.	Type 2 diabetes mellitus	Russia, Argentina, Brazil, Azerbaijan, India	
10	Udenafil 50mg, 100mg, 200mg	ZYDENA Tab.	Erectile dysfunction	Malaysia, Morocco, Russia, Ukraine, Jordan, Swiss, India, Czech Republic, Moldova, Brazil, Cambodia	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	DPP4 inhibitor	DA-1229	CAVD(Calcific aortic valve disease)	P2 (US) ongoing	Partner : REDNVIA(Global)
2	M3 antagonist	DA-8010	Overactive bladder	P3 (KR) ongoing	
3	GPR119 agonist	DA-1241	Type 2 diabetes/NASH	P1b (US) completed	
4	LpX inhibitor	DA-7310	MDR G(-) infection	IND (CN) preparation	Partner : Yangtze River(China)
5	Tau aggregation inhibitor	DA-7503	Alzheimer's disease	Pre-clinical study ongoing	
6	GCN2 inhibitor	DA-4507	Solid tumor	Pre-clinical study ongoing	
7	SARM	DA-4210	Sarcopenia	Pre-clinical study ongoing	
8	GLP1R & GCGR Dual agonist	DA-1726	Obesity	Pre-clinical study ongoing	
9	Nesp/Aranesp BS	DA-3880	Anemia	Marketed as Nes (JP) P1 (EU) completed as Aranesp	Partner : SKK(JP)
10	Stelara BS	DMB-3115	Psoriasis	P3 (global) ongoing	Partner : Intas(Global except for Korea, Greater China, Thailand, Indonesia, Vietnam)
11	Herceptin BS	DMB-3111	Breast cancer	P2 (JP) completed	
12	Keytruda BS	DMB-3116	Cancer	Pre-clinical study ongoing	
13	Donepezil Patch	DA-5207	Alzheimer's disease	Pilot BE (KR) ongoing P1a (IN) planned	



# Dongkoo Bio & Pharma Co., Ltd.



[www.dongkoo.com/eng](http://www.dongkoo.com/eng)



## Category

Finished Pharmaceutical Products  
Others - Medical Device - Cosmetics

## Company Profile

Dongkoo Bio&Pharma has been established in 1970 with the core business of production and selling ethical drugs. An industry leader specializing in Dermatology and Urology for many years, Dongkoo Bio&Pharma in 2021 recorded #1 in Dermatology and #6 in Urology in terms of numbers of prescriptions issued.

### CEO

Cho Yong Joon

### Established Date

01/05/1970

### Employee No.

+82-2-2684-5421(239)

### Contact point

#### 1. Overseas Business

Overseas Business Team  
+82-2-2684-5421(318)  
kyungho.kim@dongkoo.co.kr

#### 2. Licensing In/Out

BD Team  
+82-2-2684-5421(358)  
ysrah@dongkoo.co.kr

#### 3. Overseas Branch

N/A

## Strengths


- 2021 recorded #1 in Dermatology and #6 in Urology in terms of numbers of prescriptions issued.
- Soft Cab. Capa No.5(Pharma)
- Modified & Sustained Release Technology

## Collaboration Opportunities

- Tech-Transfer(In & Out) 2. CMO
- Co-Marketing(Local production & Sales & Marketing in ASEAN)

## Others

We are willing to cooperation with reliable partner, specially Co-Marketing in ASEAN Market.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Tacrolimus hydrate	Tacro ointment	Local treatment of plaque psoriasis	Mongolia, Hongkong, Azerbaijan, Macao	-
2	Adapalene, Hydrous Benzoyl Peroxide	AC Cure MLE Gel	Local treatment of acne with comedones, papules and pustules over 9 years old	Uzbekistan, Iran, Mongolia, Azerbaijan	-
3	Solifenacin Succinate	Urocare Tablet	Treatment of overactive bladder symptoms such as urge incontinence, frequent urination, and urgency	Hongkong, Peru, Uzbekistan	-
4	Lidocaine, Prilocaine	Licarlo Cream	1. Superficial anesthesia of the skin during needle insertion or superficial surgical treatment 2. Genital mucosal surface anesthesia(eg, before removal of condylome) 3. Superficial anesthesia of leg ulcers prior to irrigation or topical surgery(eg, removal of fibrin, pus, and subcutaneous sites)	Mongolia, Hongkong	-
5	Cabergoline	Caberlactin Tablet	Prevention and inhibition of milk secretion	Uzbekistan, Georgia	-
6	Betamethasone Dipropionate, Calcipotriol Monohydrate	Betatriol Ointment	Local treatment of plaque psoriasis	Philippines	Vietnam : Pharmaceutical composition with improved stability and skin permeability
7	Sildenafil Citrate	Zygra Tablet	Treatment of erectile dysfunction	Hongkong	-
8	Tadalafil	Zyris Tablet	Treatment of erectile dysfunction	Hongkong	-
9	Levodropropizine	Procough Tablet	Cough in the following diseases: acute and chronic bronchitis	Hongkong	-
10	Famciclovir	Famclovir Tablet	Herpes zoster virus infection	Macao	-
11	Acyclovir, Hydrocortisone	A-Clo Cream	Initial treatment of recurrent herpes labialis	-	-
12	Clobetasol Propionate	Domo-Horn Cream & Ointment	Eczema/dermatitis group(including progressive keratoderma jitosac, chronic lichen simplex, photodermatitis), eczema group(including urticaria papules), palmar/plantar pustules, psoriasis	-	-
13	Alitretinoin	Palmtoc Soft Capsule	Chronic severe hand eczema in adults who do not respond to at least 4 weeks of strong topical corticosteroids	-	-
14	Isotretinoin	Trenon Soft Capsule	Severe acne(nodular, cystic, and lumpy) that is not treated well with other treatments, especially cystic and agglomerate acne associated with trunk lesions	-	-
15	Zinc oxide	Bosomi Ointment	Relief and improvement of sweat spots and erosions	-	-
16	Tamsulosin Hydrochloride	Uropa SR Tablet	Dysuria due to benign prostatic hyperplasia	-	-
17	Epinastine Hydrochloride	Alestin Tablet	1. Bronchial asthma 2. Allergic rhinitis 3. Hives, eczema/dermatitis, itchy skin, itchy rash, normal psoriasis accompanied by itching	-	-
18	Edosteine	Elotin Capsule	Mucolysis and expectoration in acute and chronic respiratory diseases	-	-

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Differentiated Generic Drugs	DKB1801	Acne	NDA submission
2		DKB1902	Psoriasis	NDA submission
3		DKB19003	Dermatitis/Allergic rhinitis	NDA preparation
4		DKB21001	Hypertension	NDA preparation
5		DKB2103	Allergic rhinitis	NDA preparation
6		DKB22001	Hypertension/Hyperlipidemia	Formulation study
7		DKB211	Local anesthesia	Formulation study
8		DKB212	Skin disease	Formulation study
9	Incrementally Modified Drugs	DKB17001	Urinary disease	Phase I, III
10		DKB17002	Lumbago	NDA submission
11		DKB19001	Hypertension/Hyperlipidemia	On Market
12		DKB19002	Diabetes	MA Approval
13		DKB21002	Diabetes	Formulation study
14		DKB21003	Diabetes	Formulation study
15		DKB21004	Diabetes	Formulation study
16		DKB21005	Atopic dermatitis	Preclinical study

# Dongkook Pharmaceutical Co., Ltd.



<http://www.dkpharm.co.kr/en/>



## Category

- API
- Finished Pharmaceutical Products
- Others
- Medical Device
- Quasi Drug



## Company Profile

Dongkook Pharmaceutical was founded in 1968 and since its foundation, Dongkook has concentrated on R&D and technology innovation. Dongkook is well known for OTC products of high brand values in Korea. Additionally, Dongkook has developed and produced outstanding therapeutic products including anesthetics, contrast media and anti-cancer agents. Dongkook has been recognized by domestic and foreign authorities for its quality of APIs, finished products and medical devices. Currently, Dongkook exports the APIs, finished products and medical devices to over 50 countries around the world.

### CEO

Joon Ho, Song

### Established Date

1968.10.15

### Employee No.

1109

### Contact point

#### 1. Overseas Business

Overseas Business Department  
+82-2-2191-9806  
pdj1@dkpharm.co.kr

#### 2. Licensing In/Out

Overseas business development Team  
+82-2-2191-9896  
ljj12@dkpharm.co.kr

#### 3. Overseas Branch

N/A

## Strengths

1. Continuously develop and secure independent core technology
2. Develop first generic and improved new drug with source technology
3. Natural product-based product development capability

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Propofol	Pofol Injection	Induction and maintenance of general anaesthesia, Sedation of ventilated patients receiving intensive care, Sedation for diagnostic and surgical procedures	Armenia, Bolivia, Brazil, Cambodia, Chile, Dominica Rep., El Salvador, Egypt, Georgia, Iran, Iraq, Japan, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Myanmar, Nigeria, Panama, Pakistan, Peru, Philippines, Syria, Tajikistan, Thailand, United Arab Emirates, Uruguay, Ukraine, Vietnam	Approved from regulatory agencies of exporting countries	
2	Teicoplanin	Teicon Injection	Skin and soft tissue infections, urinary tract infections, lower respiratory tract infections, joint and bone infections, septicaemia, endocarditis and peritonitis related to continuous ambulatory peritoneal dialysis	Japan, Mongolia, Syria	Approved from regulatory agencies of exporting countries	
3	Leuprolide acetate	Lorelin Depot Injection	Prostatic cancer, Endometriosis, Premenopausal breast cancer	Iran, Mexico, Peru, Syria, Uruguay, Hong Kong, Kazakhstan, Kenya	Approved from regulatory agencies of exporting countries	
4	Octreotide acetate	Octrin LAR Injection	Acromegaly, Carcinoid tumors, Vasoactive Intestinal Peptide Tumors	Peru, Chile	Approved from regulatory agencies of exporting countries	
5	Sodium Hyaluronate	Haron Injection, Hyron First Injection	Degenerative osteoarthritis of the knees, Shoulder periarthritis	Mongolia, Myanmar, Uzbekistan	Approved from regulatory agencies of exporting countries	
6	Alprostadil	Alprostadil prefilled injection	Improvement of limb ulcers in chronic arterial occlusion and pain relief in stable condition of chronic arterial occlusion	Japan	Approved from regulatory agencies of exporting countries	
7	Amphotericin B	Lamphosome Injection	Systemic fungal infections sensitive to this drug	Dossier evaluation process	Registration in progress	Liposomal Product
8	Cross-linked hyaluronic acid	Bellast	Temporal correction of moderate to severe wrinkles(folds), or fine wrinkles/lines			* Bellast generated number of series but simply written as 'Bellast' here.

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Improved New Drug	DKF-310	Dementia	Preclinical study
2		DKM-413	Anesthetic	Preclinical study
3		DKM-412	Osteoarthritis	Clinical study
4		DKF-313	Benign Prostatic Hyperplasia	Clinical study
5		DKF-340	NSAID	Clinical study
6		DKF-361	Hypertension	Preclinical study
7		DKF-363	Respiratory Inflammation	Drug discovery
8		DKF-325	Anticoagulant	Preclinical study
9		DKF-334	Osteoporosis	Marketng authorization
10		DKF-335	Osteoporosis	Preclinical study
11		DKF-420	Osteoporosis	Preclinical study
12		DKM-415	Synovial Fluid Replacement	Clinical study



[www.dkpco.co.kr](http://www.dkpco.co.kr)



## Category

Finished Pharmaceutical Products

## Company Profile

Dongkwang has been contributing to advancement of pharmaceutical industry by developing pharmaceutical products for over the past 60 years since its establishment in 1952. We are always striving for 'Fulfillment of Human Health and Human Happiness' with 3 ideas of its philosophy.

One of the 3 ideas is, leading the pharmaceutical industry with a clear sense of duty. Dongkwang is committed to be the leading company based on the values of sincerity, passion and creativity.

The second is, making efforts to realize a welfare society for the public. We are constantly manufacturing high-quality medicines to make human life healthy and happy with a sense of duty.

Lastly, enabling the growth of individuals and the company with outstanding creativity. It means all members of the company maximize their abilities to contribute to not only growth of the company, but also national development.

Based on all these mentioned above, we will accomplish the vision of 'first or best' and pioneer the future.

## Strengths

1. Global operating contract manufacturing service
2. International Standards : PIC/S GMP and ISO13485
3. High technical expertise for injection : Pre-filled/Freeze-dried syringe



### CEO

Mr. Mansik Chang

### Established Date

Sep. 1952

### Employee No.

450

### Contact point

1. Overseas Business  
trade@dkpco.co.kr  
yeon-hee.woo@dkpco.co.kr
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Sodium hyaluronate 25mg/2.5mL	Aragan Injection	Osteoarthritis	4 countries	Pre-filled syringe
2	Sodium hyaluronate 20mg/3mL	Aragan Plus Injection	Osteoarthritis	10 countries	Pre-filled syringe
3	Betametasone dipropionate 0.64mg, Clotrimazole 10mg, Gentamycin sulfate 1mg	Silkron Cream	Corticoid reactive skin disease where infection is concerned, bacterial or fungal infection	7 countries	Ointment

## Others

The Pyeongtaek Plant of Dongkwang Pharm, which completed construction in 1992, produces outstanding medicine within facilities that conform to the standards of KGMP. Dongkwang has various product line-ups, in total approximately 170 kinds of products. Moreover, we are exporting good-quality medicines to over 20 countries and fulfilling the values of Dongkwang around the world.

# Dongwha



[www.dong-wha.co.kr/english](http://www.dong-wha.co.kr/english)



## Category

- API
- Finished Pharmaceutical Products
- Herbal Medicinal Product
- Others
  - Medical Device
  - Quasi Drug
  - Cosmetics

## Company Profile

Established as the first Korean pharmaceutical company in 1897, Dongwha has always remained committed to bringing happiness to customers and employees with its management focusing on happiness of people. What Myung Su, Korea's first western-style medicine, by integrating the advantages of Western medicine into the royal court's secret recipe in 1897. The key R&D outcomes include successful development of "Zabolante" in 2015, as a next-generation antibacterial agent, and currently distributing in Korea.

## Strengths

1. COVID-19 NCE
2. Astma/COVID-19 Natural Drug
3. Diabetes IMD

## Collaboration Opportunities

License in/out

### CEO

Junha Yoo

### Established Date

1897.09.25

### Employee No.

729

### Contact point

#### 1. Overseas Business

Overseas Sales Team/Manager  
82-2-2021-9345  
wena.cho@dong-wha.co.kr

#### 2. Licensing In/Out

Research Institute/Director  
82-31-270-0601  
yunha.hwang@dong-wha.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Ambroxol Hydrochloride		API	Japan, Indonesia, Mexico, Philippines
2	Pantoprazol Sodium Sesquihydrate		API	Portugal, Indonesia
3	Levosulpiride		API	Spain
4	Herbal extracts	What Myung Su	alimentary System	USA, Mongolia
5	Mecobalamin	M-Cobal	peripheral neuropathy	Vietnam
6	Acetaminophen, etc.	Pan Cold-S	The relief of common cold symptoms	Mongolia, Cambodia
7	Silver sulfadiazine	Silmazin1%Cream	burn, bed sore, skin ulcers	Mongolia

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	NCE	DW224	Antibiotics(AE COPD)	Launched in Korea.
2	Natural drug	DW2008	Antiviral drug(Astma, COVID-19)	phase II
3	NCE	DW1027	Antiviral drug(COVID-19, etc.)	preclinical
4	NCE	DW1026	Antiviral drug(COVID-19, etc.)	discovery
5	NCE	DW1023	Oncology	discovery
6	NCE	DW1024	Autoimmune Disease	discovery
7	NCE	DW1025	Asthma	discovery
8	IMD	DW6012	Diabetes	phase I
9	IMD	DW6013	Diabetes	phase I
10	IMD	DW6014	Diabetes	phase I

# Elyson Pharmaceuticals



[www.elyson.co.kr/index.php?lang=en](http://www.elyson.co.kr/index.php?lang=en)



## Category

Finished Pharmaceutical Products

## Company Profile

Elyson Pharmaceuticals has the goal to provide unique and meaningful advantages to patients with cardiovascular disease, and their healthcare providers. Since established in 2011, our products have been focused on the cardiovascular products having the indication of hypertension.

Our company that manufactures finished pharmaceutical product authorized by GMP in October 11, 2011 aiming at less variety bulk production.

We currently are manufacturing outstanding pharmaceutical product specialized in internal solid dosage form through strict GMP guidelines and up-to-date facilities

## Strengths

1. Focused on Cardiovascular system
2. Specialized R&D
3. Effective, safe and excellent pharmaceutical product

## Collaboration Opportunities

1. In- & Out-licensing
2. Co-development

### CEO

Yoonchan Jee

### Established Date

2011-01-01

### Employee No.

46

### Contact point

1. Overseas Business  
BD/+82 2 6342 7006  
pjkim@elyson.co.kr
2. Licensing In/Out  
BD/+82 2 6342 7006  
pjkim@elyson.co.kr
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use
1	Nebivolol, Rosuvastatin	Nebirosta Tablet	Hypertension/Heart failure and Hyperlipidemia
2	Molsidomine 2mg and 4mg	Molsiton Tablet	Angina pectoris, Hypertension
3	Bisoprolol fumarate 1.25mg, 2.5mg, 5mg, 10mg	Conbloc Tablet	Treatment of stable chronic heart failure
4	Nebivolol 1.25mg, 2.5mg, 5mg	Nebistol Tablet	Hypertension, treatment of chronic heart failure
5	Hydroxychloroquine 100mg, 150mg, 200mg, 300mg, 400mg	Oxiklorin Tablet	Treatment and prevention of malaria, Rheumatoid arthritis, juvenile rheumatoid arthritis, discoid and systemic lupus erythematosus, photosensitive skin disease

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	EL-1804	EL-1804	Chronic heart failure	Phase I

# Fresenius Kabi Korea Co., Ltd.



## CEO

Park Joo Ho

## Established Date

## Employee No.

## Contact point

1. Overseas Business  
82-2-3484-0900
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Company Profile

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.



## Main Products

No.	Main Ingredient	Product name	Use
1		SmofKabiven	Critical Illness, Geriatrics, Oncology, Surgery, Acute and Chronic Intestinal Failure, Liver Insufficiency, Renal Failure, Diabetes Mellitus, Maldigestion/Malabsorption
2		SMOFLipid	Critical Illness, Geriatrics, Oncology, Surgery, Acute and Chronic Intestinal Failure, Liver Insufficiency, Renal Failure, Diabetes Mellitus, Maldigestion/Malabsorption
3		Fresubin	Critical Illness, Geriatrics, Oncology, Surgery, Acute and Chronic Intestinal Failure, Liver Insufficiency, Renal Failure, Diabetes Mellitus, Maldigestion/Malabsorption
4		Fresofol MCT	General and local anesthesia
5		VOLULYTE	Blood volume substitutes to maintain blood volume, hemodynamic circulation and tissue oxygenation
6		Blood Bag	Hematology, Dermatology, Operating Rooms, Critical Care Units
7		Apheresis PLT Set	Hematology, Dermatology, Operating Rooms, Critical Care Units

# GC Biopharma



www.gcbiopharma.com



## Category

- API
- Finished Pharmaceutical Products
- Biopharmaceuticals
- Vaccine - Recombinant DNA - Cell/Gene Therapy - Biosimilar
- Platform Technology
- AI Drug Discovery

## CEO

Eun-Chul Huh

## Established Date

1967

## Employee No.

2,397

## Contact point

### 1. Overseas Business

Dong Min Lee  
Global Biz./General Manager  
T. +82-31-260-9084  
E. dmlee77@gccorp.com

### 2. Licensing In/Out

Sang Jin Park  
OI/General Manager  
T. +82-31-260-0877  
E. Sj.park@gccorp.com

### 3. Overseas Branch

Byung Lim Lee  
Global Biz./General manager  
T. +55-11-2597-5963  
E. blee@gccorp.com

## Company Profile

GC Biopharma has a history of taking an untrodden road with a pioneering spirit. Over the past half-century, GC BP has waded through a solitary path to strenuously develop 'Indispensable Medicines'.


GC Biopharma has persevered the passage to establish the society in which people do not suffer from diseases and live in prosperity. Consequently, GC BP earned the recognition as a 'Leading Pharmaceutical Company in Biotechnology'

## Strengths

1. Plasma derivatives
2. Vaccines
3. Recombinant Products

## Collaboration Opportunities

1. Sales Partnership
2. CDMO Partnership etc.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Purified Inactivated Influenza Virus Antigens	Split Virion Inactivated Influenza Vaccine	For prophylaxis against Influenza Virus	Asia, Middle-East, Central & South America	Vaccines
2	Live attenuated varicella virus (MAV/06 strain)	Varicella vaccine	For prophylaxis against Varicella (individuals aged 12 months or older)	Asia, Middle-East, Central & South America	Vaccines
3	Human immunoglobulin-G	IV-Globulin(IVIG- SN) (Immunoglobulin)	· A-Hypogammaglobulinemia · Combined therapy with antibiotics for severe bacterial or viral infections · Idiopathic thrombocytopenic purpura · Guillain-Barre syndrome · Kawasaki syndrome	Asia, Middle-East, Central & South America	Plasma Derivatives
4	Idursulfase-β	Hunterase	Mucopolysaccharidosis II (Hunter syndrome)	Asia, Middle-East, Central & South America	Recombinant Product
5	PEG-GCSF	Neulapeg (Pegteogastim)	For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma	Asia, Middle-East, Central & South America	Recombinant Product
6	Normal human serum albumin	Human Albumin Solution	For hypoalbuminemia and shock in acute hemorrhage from loss of albumin(burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	Asia, Middle-East, Central & South America	Plasma Derivatives
7	Antihemophilic factor VIII	Human Blood Coagulation Factor VIII	For the treatment of hemophilia A with supplies of blood coagulation factor VIII	Asia, Middle-East, Central & South America	Plasma Derivatives
8	Berococog alfa (Antihemophilic factor VIII, recombinant)	Recombinant Coagulation Factor VIII	For the prevention and control of bleeding episodes and preoperative management in hemophilia A	Asia, Middle-East, Central & South America	Recombinant Product
9	Hepatitis B immune globulin, human	Human Hepatitis B Immunoglobulin	· For prophylaxis of hepatitis B after exposure to HBsAg · For prophylaxis of hepatitis B in neonates · For prevention of recurrence of hepatitis B in patients with liver transplants	Asia, Middle-East, Central & South America	Plasma Derivatives
10	Tetanus immune globulin, human	Human Tetanus Immunoglobulin	For the prophylaxis of tetanus and the reduction of tetanus symptoms by providing passive immunization against infection caused by Clostridium tetani	Asia, Middle-East, Central & South America	Plasma Derivatives

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Recombinant	GC1126A	Acquired Thrombotic Thrombocytopenic Purpura	Pre-clinical
2	Recombinant	GC1130A	Sanfilippo syndrome	Pre-clinical
3	Recombinant	GC1133A	Mucopolysaccharidosis	Pre-clinical
4	Recombinant	GC1134A	Fabry	Pre-clinical
5	Recombinant	MG1113A	Hemophilia A/B treatment	Phase I
6	Vaccine	GC1109	Anthrax	Phase II
7	Vaccine	GC3111A	Tdap	Phase II
8	Vaccine	MG1120A	Varicella-zoster	Phase II
9	Recombinant	GC1118A	Colon cancer	Phase II
10	Plasma	GC5101B	Primary immune deficiency	Phase III
11	Plasma	GC5107B	Primary immune deficiency	Phase III
12	Vaccine	GC3107A	BCG	Phase III

# GC Cell Corp.



<https://gcell.com/eng/main>



## Category

Cell/Gene Therapy

## Company Profile

### BTS(Bio-Tech Solution Pioneer)

GC Cell's journey to another future has just begun. We promise to make the new GC Cell by making the next 10 years as the period of giant leap forward based on the efforts and successes we have been accumulating. All GC Cell executives and employees promise to fulfill roles and duties under the clear vision of realizing the better life for the humanity and goals of becoming the best cell therapy product company in the world. Furthermore, GC Cell will strengthen its global competitiveness in CDMO business by combining the differentiated process technologies of the cell center having the largest cell therapy product production facilities in Korea.

GC Cell promises to further expand its cell therapy product pipelines by actively investing on R&D for quickly responding to rapidly changing market environment and demands, carrying out process innovation, and establishing the extensive partnership.

### CEO

Dae-Woo Park

### Established Date

June, 2011

### Employee No.

815

### Contact point

#### 1. Overseas Business

Corporate Strategy Team  
+82 31 736 6734  
jeungrea.cho@gccorp.com

#### 2. Licensing In/Out

Research Planning Team  
+82 31 270 1307  
sebum.lee@gccorp.com

#### 3. Overseas Branch

N/A

## Strengths

### 1. Allogenic Cell Therapy Products(Allogenic-NK)

This is an anticancer immunocyte therapy product patented externally by our company and developed in order to allow for immediate provision to patients of hyperpure/highly potent NK cells in frozen storage that were mass-cultured through genetically manipulated sustentacular cells and automated bio-reactor culture process created using NK cell derived from peripheral blood or cord blood of a healthy adult. We have been conducting a clinical study that jointly uses antibodies and immune gateway antibodies characteristic of tumors toward increased effectiveness.

### 2. Next-Generation Cell/Gene Therapy Products(CAR-NK)

We are devoted to developing CAR-NK gene therapy products adopting CAR genes that induce the activation of NK cells and investigating cancer cells in NK cells derived from cord blood managed under strict regulations. We plan to conduct clinical studies in the US on not only hematologic malignancies but also solid cancer using next-generation CAR-NK with reinforced ability to track tumor antigens of long-lasting effectiveness in the body, through the application of a differentiated platform technology unique to GC Cell and partnerships with main antibody development companies both at home and abroad.

### 3. Cancer Immunotherapy

Immunotherapy(or cancer immunotherapy) consists of two major cell lines: cytokine-induced killer(CIK) cells and activated cytotoxic T lymphocytes(CTLs). Both cells differ in how to recognize cancer cells. CIK cells recognize cancer cells and destroy them without recognizing specific antigens, not like natural killer cells. However, CTLs recognize and destroy cancer cells through presented antigens on expressing cells. Both cells are active. They secrete substances that activate each other. Their complementary interaction induces effective treatment response.



### 4. Stem Cell Therapy Products(MSC)

We are spurring the development of next-generation isocellular stem cell therapy products with reinforced anti-inflammatory function through reinforced immunoregulation in mesenchymal stem cells, which have excellent immunoregulation function in its original state to begin with, derived from healthy donors' tonsils. Using the above, we are conducting pre-clinical studies targeting autoimmune diseases and lung inflammatory diseases such as psoriasis and Adult Respiratory Distress Syndrome (ARDS), which have huge medical demand that remains unmet. Furthermore, we are also steadily continuing our basic research under the objective of turning into reality regenerative medical treatment through the use of induced stem cells.

## Collaboration Opportunities

1. License In/Out
2. Partnering
3. Business Development

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Self-derived activated T-lymphocytes	Immuncell-LC	Adjuvant therapy for patients whose tumor has been removed after curative resection for Hepatocellular Carcinoma (Surgical resection, Radio Frequency Ablation, Percutaneous Ethanol Injection Therapy)	India	Publications of our clinical results in global top-tier oncology journals 1. Liver cancer Gastroenterology(May 2015) : Results of phase 3 clinical trial(SIT) • Recurrence Free Survival increased by 1.5 times(44m vs. 30m) • Risk of recurrence decreased by 37% • Risk of death decreased by 79% 2. Glioblastoma Immunotherapy(March 2017) : Results of phase 3 clinical trial(SIT) • Recurrence Free Survival increased by 1.5 times(22.5m vs. 16.9m) • Disease control rate increased by 30% 3. Pancreatic cancer Cancer Immunology, Immunotherapy(Jun, 2014) : Results of phase 2 clinical trial(IIT) • Disease control rate increased by 25% • Improvement of Quality of Life

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Allogenic CB-NK	AB-101	r/r Lymphoma	Phase I/II(US)	via ARTIVA
2	Allogenic CAR-NK	AB-201	Solid cancer	Pre-clinical	via ARTIVA
3	Allogenic CAR-NK	AB-202	B cell lymphoma	Pre-clinical	via ARTIVA
4	Allogenic CAR-NK	-	T cell lymphoma	Research	
5	Allogenic CAR-NK	Merck CAR-NK #1	Solid cancer	Pre-clinical	via ARTIVA&MSD
6	Allogenic CAR-NK	Merck CAR-NK #2	Solid cancer	Research	via ARTIVA&MSD
7	Allogenic Tonsil-derived MSC	CT-303A	Plaque Psoriasis	Phase I	
8	Allogenic Tonsil-derived MSC	CT-303B	ARDS	Phase I	
9	Autologous CIK(Immuncell-LC)	-	Pancreatic cancer	Phase III	
10	Autologous CAR-T	-	Pancreatic cancer	Pre-clinical	



# Genuine Sciences INC.



<http://genuonesciences.com/main/?lang=en>



## Category

- Finished Pharmaceutical Products
- Others
  - Medical Device
  - Quasi Drug

## Company Profile

Genuine Sciences (the integrated entity from the acquisition of Kolmar Korea's Pharmaceutical Division and Kolmar Pharma) is South Korea's top CMO pharmaceutical company, specializing in the full range of services from formulation development to manufacturing and clinical development of small molecule.

## Strengths

- NO.1 CMO as a leading pharmaceutical company in South Korea (+500 Generic)
- Full range of services for formulation development, manufacturing and clinical development capabilities
- Offer all dosage forms (Oral solids, Oral solution, Topical oint./gel/cream, Sterile products)

## Collaboration Opportunities

- CDMO/CMO Business
- OutLicense
- Sell finish product (FDF)



### CEO

Sam Soo Lee

### Established Date

2020-11-20

### Employee No.

727

### Contact point

#### 1. Overseas Business

Overseas group  
82-2-10-86005226  
suna.ryu@genuonesciences.com

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Entecavir 0.5mg	Hepavance	hepatitis b	Hong Kong etc.	Government tender purpose
2	Calcipotriol 50ug + Betamethasone dipropionate 0.643mg	Calcibeta Ointment 30g	Psoriasis vulgaris	Mongolia, HongKong, Philippines, Malaysia	
3	Calcipotriol 50ug + Betamethasone dipropionate 0.643mg	Calcibeta Gel 30g	Psoriasis vulgaris	HongKong, Etc	
4	Pregabalin 75mg	K-Barin Capsule	Fibromyalgia Agents, Anticonvulsants, Other	Philippines, Peru	
5	Amlodipine + Valsartan	Hiforge Tablet	Hypertension	HongKong, Philippines	
6	Esomeprazole 20mg, 40mg	Nexpesol Tablet	GERD	HongKong, Etc	
7	Neomycin Sulfate Polymyxin B sulfate, Nystatin	Neopole Vaginal soft capsule	Antifungal	Algeria, Vietnam, Cambodia, Azerbaijan, Uzbekistan	
8	Azithromycin 200mg/5mL	Azismile dry syrup	Antibiotic	Vietnam, Bolivia, Cambodia	
9	Mupirocin 20mg	Bacterocin ointment	Antibiotic	Peru, HongKong, Philippines, Mongolia, Vietnam	
10	Sodium Alginate 5g, Sodium Bicarbonate 2.13g, Calcium Carbonate 3.25g	Algina suspension	GERD	Philippines, Cambodia	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	IMD	KCSO	Dementia	Completed
2	1st Gx	KZTS	Onychomycosis	Completed
3	IMD	KKM-184-A	Diabetes	Completed
4	IMD	KKM-184-D	Diabetes	NDA
5	IMD	KKM-186-C	Hypertension	PHASE III
6	IMD	KKM-191-D	Diabetes	Phase I
7	IMD	KKM-201-D	Diabetes	R&D
8	IMD	KKM-201-A	Diabetes	R&D
9	IMD	GNS-212	Hyperosmotic preparations	R&D
10	IMD	KKM-203-D	Diabetes	R&D
11	IMD	KKM-202-C	Diabetes	R&D

# Green Pharmaceutical Co., Ltd.



## Category

Finished Pharmaceutical Products  
Others  
- Quasi Drug  
- Cosmetics

## Company Profile

Since its establishment in 1979, Green Pharmaceutical Co., Ltd. has been striving for a pleasant and clean environment, and to improve human health and quality of life. Our company is a professional producer of enemas, which are armbands, as well as skin disinfectants, which are essential medicines to prevent infection, which are essential in daily life, and high-level medical device disinfectants.

## Strengths

1. A company specializing in the manufacture of disinfectants for skin and medical devices to prevent infection.
2. Professional production of enema (Constipation, excretion of intestinal contents.)

## Collaboration Opportunities

It's a global company with all the essential medicines for infection control. Always welcome to product inquiries.



### CEO

Hong joon pyo

### Established Date

February 1979

### Employee No.

100

### Contact point

#### 1. Overseas Business

Ministry of Trade  
+82-2-842-1301  
kwon3419@greenpharma.co.kr

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Concentrated Glycerin 50g/100mL	Green ENEMA (FIT-APO)	Constipation, excretion of intestinal contents.	Mongolia	This product has the highest sales rate in Korea and our company
2	Povidone-Iodine 10g/100mL	Green Povidone-Iodine Topical Solution	<ul style="list-style-type: none"> <li>· Sterilization and disinfection of torn wounds, burns, and wounds</li> <li>· Sterilization and disinfection of ulcers and abscesses</li> <li>· Disinfection of infected skin surface</li> <li>· Sterilization and disinfection of the surgical site</li> <li>· Disinfection of injection and catheter site</li> </ul>	Mongolia	As a basic medicine for wound disinfection, It is an essential medicine used in all hospitals
3	Oxymatazoline Hydrochloride 50mg/100mL	Green Nasal Spray Moisture Solution	Relief of the following symptoms caused by nasal cold acute rhinitis, allergic rhinitis, nasal inflammation or sinusitis, stuffy nose, runny nose, sneezing, head heaviness.	USA	

## Others

As specializing in essential medicines (Enemas, Povidone iodine, chlorhexidine, stick swabs, etc), Green Pharmaceutical Co., Ltd. is a manufacture which specializes in producing disinfectants like OPA (O-Phthalaldehyde), GreenY-Na Solution (Glutaraldehyde), and Anafree Spray (anal disinfectant), Seracaine Spray (local anesthetic), which are high-level medical device disinfectants as well as skin disinfectants to prevent infection and so on.

# GUJU Pharm Co., Ltd.



<http://www.guju.co.kr>



## Category

Finished Pharmaceutical Products

## Company Profile

Since the foundation in 1974, GUJU has been a pharmaceutical company focusing on developing creative drugs and introducing superior technologies for the enhancement of national health and the quality of life.



## Strengths

1. Development of creative drugs
2. Introduction of advanced technologies

## CEO

Kim Woo Tae

## Established Date

23rd of Dec. 1974

## Employee No.

205 persons(2021.12)

## Contact point

### 1. Overseas Business

CMO/02-2672-1122, Ext 203  
dskim@guju.co.kr

### 2. Licensing In/Out

RA/02-2672-1122, Ext 400  
ra@guju.co.kr

### 3. Overseas Branch

CMO/02-2672-1122, Ext 203  
dskim@guju.co.kr

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Fentanyl citrate	Guju Fentanyl Citrate Inj. 10mL	Narcotic Analgesics	Peru	KGMP
2	Thymosin α 1	Avixin Alpha Inj.	Immunologic adjuvant	Indonesia	KGMP
3	Spironolactone	Guju Spirodacton Tab.	Antihypertensive	Japan	KGMP
4	Methylprednisolone sodium succinate	Disolrin Inj. 40mg	Adrenal gland hormone	Vitenam	KGMP
5	Ibandronated sodium monohydrate	Ibanel Inj.	Bisphosphonates	-	KGMP
7	Atorvastatin calcium	Atorix Tab.	Hyperlipidemia	-	KGMP
8	Choline Alfoscerate	Cereforin Soft Cap.	Nootropics & Neurotonics	-	KGMP
9	Loxoprofen	Lukpel Tab.	Anti-inflammatory	-	KGMP

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Incrementally Modified Drug	GJ2001	Antihistamine	Preclinical
2	Incrementally Modified Drug	GJ2002	Muscle relaxant	Preclinical
3	Incrementally Modified Drug	GJ2101	Stomach ulcer	Preclinical

## Others

From the beginning of our foundation, the importance of R&D has been appreciated. Thus we have been concentrating on technical innovations and developing new medicine continuously. We are preparing to proceed to the second take-off stage by securing competent researchers for strengthening oversea business in the period with intense technical competition.

GUJU pharmaceutical is the company that considers the health of the people and is based on creativity and challenge spirit. We can promise that all the members of GUJU pharm will cooperatively do our best to promote the best quality products in Korea and the world-class customer service.

# HAN KOOK SHIN YAK Corp.



[www.hsp.co.kr/eng/work/plan.html](http://www.hsp.co.kr/eng/work/plan.html)



## Category

Herbal Medicinal Product

## Company Profile

Han Kook Shin Yak Pharmaceutical Co., Ltd. was established in 1961 with the goal of globalizing oriental medicine. As a manufacturer that specializes in oriental medicine, we have developed and sold oriental medicines in liquid form. Currently, Han Kook Shin Yak Pharmaceutical Co., Ltd. is producing 400 oriental medicine products and 20 Western medicine-based products.

### CEO

Sang Wook, Han

### Established Date

1961. 02. 27

### Employee No.

179

### Contact point

#### 1. Overseas Business

Foreign Division/+82-41-740-8814

yjk1225@daum.net

#### 2. Licensing In/Out

Foreign Division/+82-41-740-8814

yjk1225@daum.net

#### 3. Overseas Branch

N/A

## Strengths

1. We have developed the anticancer immunity-booster(Mesima-Ex.) using cultured Phellinus igniarius mycelium since 1993.
2. We have manufactured 400 oriental medicine products and 20 Western medicine-based products.
3. We have a GMP plant in Yangchon Nonsan, Chungnam, South Korea.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Phellinus igniarius mycelium	Mesima	MESIMA is the medicine to enhance the immune function against cancer that contains protein polysaccharide PPLA that is obtained as extracting and purifying pure cultivation mycelium of Phellinus linteus.	Japan	None

# Han Wha Pharma Co., Ltd.

 Han Wha Pharma Co., Ltd.

[www.hwpharm.com/eng/main/main.php](http://www.hwpharm.com/eng/main/main.php)



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product  
Medical Device

## Company Profile

Han Wha Pharma(HWP) is a pharmaceutical company based in Seoul, Korea. HWP is well established in development, manufacture, distribution, marketing/sales and export of pharmaceutical and healthcare products. HWP is recognized to doctors and pharmacists as a specialized company that has ethical products in certain therapeutic areas such as alimentary, cardiovascular, obstetrics/gynecology, neuromuscular, and respiratory system. Aiming to become a global enterprise, HWP has introduced global marketing techniques through an organic partnership with several overseas companies. As a result, HWP has continued making record growth in sales by successfully launching new products in the domestic market to meet customer needs based on market research. In sales activities, HWP has grown into a most trusted company among customers by successfully supplying high-quality and superior medicines to hospitals and clinics. HWP has expanded its business area to dietary supplements. HWP family consists of NaturalLife focused on nutrition supplements for domestic market and NaturalLife Asia for exporting business to Asian territory.

## Strengths

1. Gastro-intestinal system
2. Respiratory system
3. Obstetrics/Gynecology

## Collaboration Opportunities

1. License in/out
2. CDMO
3. Co-development



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Lactobacillus acidophilus	Antibio Pro	Probiotics	Vietnam, Thailand, Indonesia	Marketed	-
2	Lactobacillus casei variety rhamnosus	Ramnos	Probiotics	Thailand	Marketed	-
3	Glimepiride+Metformin	Wingli-M	Anti-diabetics	Indonesia	Marketed	-
4	Amlodipine+Valsartan	Winex-G	Anti-hypertension	Indonesia	Marketed	-
5	Acetylcysteine	Muteran	Mucolytics	Myanmar, Peru	Marketed -	- Under registration
6	Echinacea purpurea herba tinc + Echinacea purpurea radix(root) tinc	Echinaforce Protect	Cough & Cold	Thailand	-	Under registration
7	Amlodipine+Telmisartan	Telmiam	Anti-hypertension	-	-	-

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Respiratory	YJF-009	Asthma & Allergic rhinitis	Phase 1	-
2	Antiviral	YJO-I01	Antiviral	Preclinical	-
3	Respiratory	YJF-008	Cough & Cold	Formulation	IR → SR
4	Analgesic & Antipyretic	YJF-015	Analgesic & Antipyretic	Formulation	-

# Hana Pharm. Co., Ltd.



[www.hanaph.co.kr/eng/index.do](http://www.hanaph.co.kr/eng/index.do)



## Category

API  
Finished Pharmaceutical Products

## Company Profile

Since founded in 1996, Hana Pharm. Co., Ltd. has been keeping steady product development and pharmaceutical synthesis, and now ready to advance to take-off stage. With our specialized products such as anesthetics (Propofol, sevoflurane, isoflurane) and narcotics (Oxycodone, fentanyl, morphine), we will continue our effort to become as a world-class global pharmaceutical company.

### CEO

Younha Lee, Ph.D.

### Established Date

1996

### Employee No.

+650

### Contact point

#### 1. Overseas Business

Overseas Business team  
+82-2-559-5778  
hana.business1996@gmail.com

#### 2. Licensing In/Out

GBD team  
+82-2-559-5778  
hana.business1996@gmail.com

#### 3. Overseas Branch


N/A

## Strengths

1. Specialized in Anesthetics, Narcotic Analgesics, and Antiemetics
2. Presence of Lyophilization in Injectable Production line
3. Engagement in various R&D projects

## Collaboration Opportunities

1. License In & Out
2. Partnering for export



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Propofol	Anepol Inj.	Anesthetics	Dominican Republic, Mexico, Myanmar, Philippines, Thailand, Vietnam, Yemen
2	Sevoflurane	Sevofran Liquid for Inhalation	Anesthetics	Brazil, Dominican Republic, Iran, Myanmar, Philippines, Yemen
3	Isoflurane	Ifran Solution	Anesthetics	Dominican Republic, Myanmar
4	Bupivacaine HCl/ Dextrose	Hana Bupivacaine HCl Heavy Inj 0.5%	Anesthetics	Yemen
5	Palonosetron HCl	Paloxi Inj.	Antiemetics	Philippines

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Anesthetics	Byfavo Inj. (Remimazolam besylate)	General Anesthesia, Procedural Sedation	Marketed	New Chemical Entity(NCE)
2	Contrast Medium	HNP-2006	MRI	Phase 2	
3	Anti-Cancer	BOLD-100	Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma, TNBC	Phase 1	
4	Gastrointestinal	P-CAB	GERD (Gastroesophageal reflux disease)	Preclinical	

## Others

Hana Pharm always does its best to realize our company's motto, "We are committed to better life with the Better medicine." With continuing research and development, we explore and prepare future medicines. We are also emerging as a global pharmaceutical company by expanding exports and strengthening cooperations with partnering companies.

Hana Pharm will be your preferred and reliable partner for Anesthetics, Narcotic Analgesics and other medicines with proven track records throughout 25 years of corporate history.

# HanAll Biopharma



www.Hanall.com



## Category

Finished Pharmaceutical Products  
Biopharmaceuticals

## Company Profile

HanAll Biopharma is a global biopharmaceutical company founded in 1973, with a mission of making meaningful contributions to patients' lives by introducing innovative, impactful therapies to address severe unmet medical needs. HanAll has been operating a portfolio of pharmaceutical products in areas ranging from endocrine, circulatory, and urologic diseases for more than 48 years. HanAll has also expanded its focus to ophthalmology, immunology, oncology and neurology to discover and develop innovative biological medicines for patients with diseases for which there are no effective treatments.

## Strengths

1. Unique Resistein™ Technology (Protein Engineering) to enhance affinity to targets and resistance to protease degradation
2. Over decades of know-how in antibody therapeutics from candidate screening to development

## Collaboration Opportunities

1. R&D investment
2. Biotherapeutics development

### CEO

Seungkook Park, Seon Jeong

### Established Date

1973

### Employee No.

307 persons

### Contact point

#### 1. Overseas Business

Business Development/02-2204-1753  
hanss@hanall.co.kr

#### 2. Licensing In/Out

Global OC/02-2204-1788  
dh.kim@hanall.co.kr

#### 3. Overseas Branch

Global OC/02-2204-1788  
dh.kim@hanall.co.kr

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Hydrocortisone	Cortisolu Injection	Corticosteroid	Philippines
2	Methylprednisolone 40mg	Medisolu Injection 40mg	Corticosteroid	Dominica
3	Methylprednisolone 125mg	Medisolu Injection	Corticosteroid	Dominica
4	triamcinolone	Tamceton Injection 40mg	Corticosteroid	Guatemala
5	Sildenafil	For Mr. tab. 100mg	Erectile dysfunction	Bolivia

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks		
1	Immunology	HL036 (INN: Tanfanercept)	Dry Eye Disease	Phase III	- (US) Co-developed with Daewoong Pharmaceutical		
2					- (China) Developed by Harbour BioMed		
3		HL161 (INN: Batoclimab)	Myasthenia gravis (MG)	Phase III	- (US) Developed by Immunovant		
4					- (China) Developed by Harbour BioMed		
5					Thyroid eye disease (TED)	Phase II	- (US) Developed by Immunovant
6							- (China) Developed by Harbour BioMed
7					Warm autoimmune hemolytic anemia (WAIHA)	Phase II	- (US) Developed by Immunovant
8					Neuromyelitis optica (NMO)	Phase II	- (China) Developed by Harbour BioMed
9					Immune thrombocytopenia (ITP)	Phase II	- (China) Developed by Harbour BioMed
10					Oncology	HL186/HL187	Cancer (TBD)



<https://www.handok.co.kr/eng>



## Category

Finished Pharmaceutical Products  
Cell/Gene Therapy  
Drug Delivery System  
Digital Therapeutics

## Company Profile

HANDOK, a leading innovation-driven pharmaceutical/healthcare company in Korea, develops and distributes healthcare solutions to improve health and quality life for all. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.

## Strengths

1. Optimized Market Access & Strong Medical Marketing
2. Excellence in Clinical Development & Internal Research Expertise
3. World-class Manufacturing Capabilities

## Collaboration Opportunities

1. Product Licensing
2. R&D Collaboration
3. Contract Manufacturing&QC

### CEO

Young Jin Kim, Jin ki Baik

### Established Date

1954.04.27

### Employee No.

961

### Contact point

#### 1. Overseas Business

BD/82-2-527-5435

Hyojin.lee@handok.com

#### 2. Licensing In/Out

BD/82-2-527-5435

Hyojin.lee@handok.com

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Thereacumin	Ready Q	Hang-over Drink/Chew	Asia Region	ISO/ Global License
2	Glimepiride/ Metformin Hydrochloride	Amaryl-M/ MeX	patients with type 2 diabetes	35 countries	ISO/ CMO Export
3	Furosemide	Lasix	diuretic	Asia Region	ISO/ CMO Export
4	Clobazam	Frisium	anxiolytic agent	Asia Region	ISO/ CMO Export
5	DISOPYRAMIDE PHOSPHATE	Rythmodan	antiarrhythmic agents	Japan	ISO/ CMO Export
6	Ketoprofen	Ketotop	pain relief plaster (arthritis deformans/periartthritis humeloscapularis/peritendinitis, tendinitis/muscular pain/pain, swelling resulted from trauma)	Asia Region	ISO/ Global License

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Biologics	HL2356 (GX-H9)	Adult/ Pediatric Growth Hormone Deficiency	Phase 2	Genexine Partnered
2	VEGF/DLL4	ABL001	Cancer	Phase 2	ABL Bio partnered
3	Chemical	HL5101	Cancer	Phase 1	CMG Pharma partnered Global L/O to AUM Bioscience
4	Diagnostics	RST Kit	CV/Infection	Clinical	NB Postec partnered
5	Diagnostics	RST Kit	COVID-19	Regulatory/Approval	CE mark (2020)

## Others

We are the best partner to bring your novel drugs to the Korean market

Innovation and partnership belong to Handok's core values, and we strive every day to bring innovativenew products to patients, wherever they may have been discovered. With a history as a jointventure, Handok knows how to value partnership as a way of growing business for both partiesinvolved. Handok offers its partners core competencies in areas that are critical for successfulldrug development and commercialization:



# HANLIM PHARM. CO., LTD.

 HANLIM PHARM.CO.,LTD.

[www.hanlim.com](http://www.hanlim.com)



## Category

Finished Pharmaceutical Products  
 Biopharmaceuticals  
 - Biosimilar  
 Herbal Medicinal Product  
 Platform Technology  
 - Drug Delivery System  
 Others  
 - Medical Device

## CEO

Mr. Jae-Yoon Kim, Mr. Jung-Jin Kim

## Established Date

September, 1974

## Employee No.

500

## Contact point

### 1. Overseas Business

Ms. Jeonghwa Jenny Yang  
 Director/Global Business Dept.  
 +82-2-3489-6214  
 yjh0717@hanlim.com

### 2. Licensing In/Out

Ms. Mijin Oh  
 Director/Development Dept.  
 +82-2-3489-6166  
 omijin@hanlim.com

### 3. Overseas Branch

N/A

## Company Profile

With the corporate mission of protecting the precious human life from various forms of diseases, we have constantly put our entire effort to develop and provide a wide range of pharmaceutical products with high quality. As part of our commitment to improve human health, we will strive to create significant and sustainable values in the future.

## Strengths

1. Various and innovative pharmaceutical products
2. Modern high-tech manufacturing facilities
3. Continuous great investment in R&D and advanced technologies

## Collaboration Opportunities

1. Export
2. R&D
3. CMO & CDMO

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Pepsin, Papain, Diastase, Cellulase, Pancreatin, Pancrelipase, UDCA	Dages Cap.	Dyspepsia, Anorexia, Overeating	China, Mongolia	Market Authorization
2	Sodium hyaluronate	Hyaluron Eye Drops	Dry Eyes	Vietnam, Malaysia	Market Authorization
3	Moxifloxacin	Moxiforce Eye Drops	Bacterial conjunctivitis	Vietnam, Nigeria, Myanmar	Market Authorization
4	Tobramycin, Dexamethasone	Oclex Eye Drops	Bacterial ocular infection	Cambodia, Hong Kong	Market Authorization
5	Ofloxacin	Quinovid Otic Solution	Inflammation in the ear	Vietnam, Mongolia	Market Authorization
6	Mometasone furoate, Azelastine HCl	Nasaflex Nasal Spray	Allergic rhinitis	Guatemala, Bolivia, Mongolia	Market Authorization
7	Budesonide	Desona Nasal Spray	Allergic rhinitis	Vietnam, Cambodia	Market Authorization
8	Heparin sodium	Heparin Sod. Inj.	Thrombosis, Pulmonary embolism	Singapore	Market Authorization
9	Carbetocin	Hanlim Carbetocin Inj.	Postpartum hemorrhage	Iran, Azerbaijan	Market Authorization
10	Pantoprazole	Peptazole Inj.	Gastric and Duodenal ulcer	Philippines, Mongolia	Market Authorization

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Mesenchymal stem cells	HL401	Lupus Nephritis	phase 1
2	Herbal Meicinal Product	HL301A	Radiation Pneumonia	phase 2
3	Herbal Meicinal Product	HL301B	COPD	phase 2
4	Herbal Meicinal Product	HL301C	Covid-19	phase 2
5	NCE	HL217	AMD	phase 2
6	NCE	HL237	Rheumatoid arthritis	phase 2
7	NCE	HL237A	Liver Transplantation	phase 2
8	NCE	HL237B	Sjogren's Syndrome	phase 2
9	IMD	HL188	Dyslipidemia + Hypertension	phase 3
10	IMD	Luminomark Inj.	Breast Lesion Surgery Marker	NDA
11	IMD	Jakfas XR Tab.	Rheumatoid Arthritis	Pre-clinical

# Hanmi Pharm. Co., Ltd.

**Hanmi** Hanmi Pharm.

[www.hanmipharm.com](http://www.hanmipharm.com)



## Category

- API
- Finished Pharmaceutical Products
- Biopharmaceuticals
- Platform Technology
- Others
  - Medical Device
  - Digital Therapeutics

## Company Profile

Hanmi Pharmaceutical is a Korean-based global pharmaceutical company, focused on the development and commercialization of new pharmaceutical products. The company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea, as well as in China.

### CEO

Jong-Soo Woo, Se-Chang Kwon

### Established Date

1973

### Employee No.

~2300

### Contact point

#### 1. Overseas Business

Global Business/82-2-410-0462  
haamincho@hanmi.co.kr

#### 2. Licensing In/Out

LI/82-2-410-0467  
innovation@hanmi.co.kr  
LO/82-2-410-9069  
kyunphyo.park@hanmi.co.kr

#### 3. Overseas Branch

N/A

## Strengths

1. Top average R&D expenditure as compared to the revenue for the last decade in Korean Pharmaceutical/Biotech industry
2. Strategic differentiation on R&D assets, leading to fulfilling medical unmet needs over the globe
3. From R&D to sales, Hanmi holds the entire SCM, leading to strong foundation within pharmaceutical business

## Collaboration Opportunities

1. L/I
2. Co-development
3. L/O
4. CDMO

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Amlodipine/Losartan	Amosartan	Treatment of Hypertension	SEA LATAM, CIS, etc (16 countries)	EUEA GMP
2	Amlodipine/Losartan/ Rosuvastatin	AmosartanQ	Hypertension and Dyslipidemia treatment	LATAM, CIS	PIC/S, COFEPRIS, EUEA GMP
3	Amlodipine/Losartan/ Chlorthalidone	Amosartan Plus	Treatment of hypertension, indicated in patients not adequately controlled on two agents	LATAM	PIC/S, COFEPRIS
4	Rosuvastatin/Ezetimibe	Rosuzet	Treatment of hypercholesterolemia	SEA, LATAM	PIC/S, COFEPRIS, ANVISA
5	Hyaluronate Sodium	Hyalrheuma Inj	Visco supplement for pain relief from osteoarthritis	USA	FDA(PMA)
6	Tadalafil	Gugu Tab	Treatment of ED	Japan	PMDA
7	Tamsulosin/Tadalafil	Gugutams	Treatment of ED and BPH	SEA, LATAM, CIS	PIC/S, COFEPRIS
8	Montelukast/ Levocetirizine	Monterizine	Relief allergic rhinitis and Asthma		
9	Esomeprazole Megnesium	Esomezol DR	Treatment of reflux esophagitis		
10	Amlodipine/Losartan/ Chlorthalidone/Rosuvastatin	Amosartan XQ	Controls Hypertension and Dyslipidemia at single treatment		

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	EZH1/2 dual inhibitor	HM97662	Oncology	Pre-clinical	2022 3Q IND filing
2	PD-L1/4-1BB BsAb	BH3120	Oncology	Pre-clinical	2022 2H IND filing
3	LAPS IL-2 Analog	HM16390	Oncology	Pre-clinical	
4	SOS1 inhibitor	HM99462	Oncology	Pre-clinical	
5	Recombinant	HM15450	Mucopolysaccharidosis	Pre-clinical	
6	Recombinant	HM15421	Fabry	Pre-clinical	
7	FLT3/SYK	HM43239	AML	Phase 1	Partnered with Aptose
8	PD-1/HER2 BsAb	BH2950/IBI315	Oncology	Phase 1	Partnered with Innovent
9	pan-RAF inhibitor	Belvarafenib	Oncology	Phase 1	Partnered with Genentech
10	LAPS Triple Agonist	HM15211	NASH	Phase 2	2023 1Q Phase 2b Interim available
11	LAPS GLP-2 Analog	HM15912	Short bowel syndrome	Phase 2	2023 1Q Phase 2 Data readout
12	LAPS Glucagon Analog	HM15136	Congenital Hyperinsulinism	Phase 2	2023 1Q Phase 2 Data readout
13	GLP-1/GCG dual agonist	Efinopegdutide	NASH	Phase 2	Partnered with Merck
14	CCR4 inhibitor	FLX475	Oncology	Phase 2	Partnered with RAPT
15	Integrin inhibitor	Luminate@(ALG-1001)	Ophthalmology	Phase 2b/3	Partnered with Allegro/AffaMed(CN)
16	LAPS GLP-1 Analog	Efpeglenatide	Diabetes	Phase 3	Indication expansion validation
17	Encequidar+Paclitaxel	Oraxol	Advanced breast cancer	Phase 3	Partnered with Athenex 2022 2H UK approval
18	pan-HER inhibitor	Poziotinib	HER2 Exon20 NSCLC	Registration	Partnered with Spectrum 2022 4Q US approval
19	Eflapegrastim	Rolontis	Chemotherapy-induced neutropenia	Registration	Partnered with Spectrum 2022 3Q US approval

# HapInScience



[www.hapInscience.com](http://www.hapInscience.com)



## Category

API  
 Finished Pharmaceutical Products  
 Biopharmaceuticals  
 - Recombinant Protein  
 Platform Technology  
 - Drug Delivery System

## Company Profile

HapInScience, a research based, preclinical stage Korean biotech company, was founded in late 2018, targeting to develop breakthrough therapies for aged related, tissue degenerative diseases such as COPD, OA, Dry Eye Disease, etc. It has successfully raised a total of around \$30M through series A & B rounds of funding by now and 30 employees including 23 in R&D are efficiently focusing on research and preclinical development of rhHAPLN1.

## Strengths

- I. Develop therapies for degenerated tissue diseases
  - including OA, COPD, Dry Eye Diseases with high medical unmet needs
- II. Global Leader in HAPLN1 based drug development
  - 1 Distinct Efficacy with tissue regeneration effect in animal PoC studies
    - Distinct tissue regeneration effect in animal PoC studies
    - New Concept of fundamental treatment in chronic, degenerative diseases
    - Rapid and distinct comparing to cell therapies expected
  2. Cost Efficiency
    - Strong and long-lasting efficacy with microgram level treatment
    - High sales price and low manufacturing cost
  3. Superior Safety as an Endogenous human protein
    - No toxicity shown at 140 times high effective dose

### CEO

CEO Hak Bae Choi  
 CSO Dae Kyong Kim

### Established Date

2018. 11. 22

### Employee No.

31

### Contact point

1. Overseas Business
  - Business Development Division
  - 82-31-724-2611
  - nayapark@hapInscience.com
2. Licensing In/Out
  - Same as above
3. Overseas Branch
  - N/A

## Collaboration Opportunities

1. License Out
2. Co-R&D
3. Strategic Investment

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	recombinant human protein	HS-101	OA	IND-enabling Preclinical
2	recombinant human protein	HS-401	COPD	IND-enabling Preclinical
3	recombinant human protein	HS-601	Dry Eye Disease	Animal PoC
4	recombinant human protein	HS-402	IPF	Animal PoC
5	recombinant human protein	HS-301	Hair-Loss	Animal PoC
6	recombinant human protein	HS-201	Skin Aging	Animal PoC

## Others

Global license-out or strategic investment partners with synergistic capabilities that can help create value for its strategic pipeline and accelerate its mission to address critical unmet needs in degenerative diseases worldwide.

# HITS Inc.



<https://hits.ai/>



## Category

Platform Technology  
AI Drug Discovery

## Company Profile

HITS is a pharmatech company which uses digital technologies to accelerate the drug development process and to introduce a new paradigm of drug discovery.

Since its foundation in 2020, HITS has developed an artificial intelligence(AI) platform that can discover active compounds with high patentability. It can be applied to various biological targets.

Our platform performance has been verified through multiple experiments in collaborations with major domestic drug discovery companies such as LG Chemistry, Ildong, HKInnoN, Chong Kun Dang, Boryung, and TheragenBio.

## Strengths

1. Efficiency achieved by fusion of AI and Physics
2. Performance is verified through experiments
3. Excellent researchers who are capable of integrating AI, computational chemistry, physics, and biology

## Collaboration Opportunities

1. Joint research
2. Platform service

### CEO

WOO YOUN KIM

### Established Date

May 18, 2020

### Employee No.

22

### Contact point

#### 1. Overseas Business

INSUNG NA/Drug Development Team  
82-10-5457-5676/insung.na@hits.ai

#### 2. Licensing In/Out

INSUNG NA/Drug Development Team  
82-10-5457-5676/insung.na@hits.ai

#### 3. Overseas Branch

INSUNG NA/Drug Development Team  
82-10-5457-5676/insung.na@hits.ai

## Others

Our solutions

### 1. Early drug discovery

: Our structure-based drug-target interaction model and state-of-the-art digital technology can select promising hit candidates from large chemical libraries.

### 2. Drug candidate design

: Our unique deep generative model produces drug candidates with novel molecular structures. The deep learning model can design synthesizable molecules using a molecule design algorithm based on a molecular fragment.

### 3. Drug property prediction

: Our deep learning technologies accurately predict various pharmacological properties related to PK/PD and ADME/T. The accurate prediction of PK/PD properties can significantly increase the pre-clinical trial success rate of each drug candidate.

# HK inno.N Corp.

inno.N

[www.inno-n.com/eng/](http://www.inno-n.com/eng/)



## Category

- API
- Finished Pharmaceutical Products
- Biopharmaceuticals
- Vaccine
- Recombinant DNA
- Cell/Gene Therapy
- Biosimilar
- Platform Technology
- Drug Delivery System
- AI Drug Discovery
- Others
- Cosmetics
- Health improvement

### CEO

Kwak Dal Won

### Established Date

April 1, 1984

### Employee No.

1,648(as of 31 March, 2022)

### Contact point

- Overseas Business**  
HKIN\_business@inno-n.com
- Licensing In/Out**  
HKIN\_business@inno-n.com
- Overseas Branch**  
HKIN\_business@inno-n.com

## Company Profile

HK inno.N started our business in 1984 as a division of CheilJedang Pharmaceuticals. Based on our 30-year history in pharmaceutical business, we have separated from Head Company and became independent in 2014. In 2019, we launched K-CAB Tab, Korea's 30th new drug and a new drug for gastrointestinal reflux disease. In 2020, We changed our name from CJHealthcare to HK inno.N. We secures technology-oriented business competitiveness in the fields of ETC, API and health & life care.

## Strengths

- GI (GERD, NASH, IBD, IBS)
- Auto immune (RA, Skin disease)
- Oncology (Targeted therapy Immuno-oncology)

## Collaboration Opportunities

- To export or out-license
- CMO business for FDF or API



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	amlodipine+valsartan+atrovastatin	EXONE-A Tab.	Hypertension with dyslipidemia	Asia(To be)
2	amlodipine+valsartan+rosuvastatin	EXONE-R Tab.	Hypertension with dyslipidemia	
3	amlodipine+Valsartan	EXONE Tab.	Hypertension	
4	atrovastatin+metformin	ATOMET XR Tab.	Type 2 Diabetes with Hyperlipidemia	Asia(To be)
5	candersartan+amlodipine	MACHKHAN Tab.	Hypertension	
6	clopidogrel+aspirin	CLOSONE Tab.	Atherosclerosis, thromboembolism	Asia
7	linezolid	CINEZOLID I.V. Solution bag	Vancormycin-resistant Enterococcus faecium infections	
8	ciprofloxacin	CITOPCIN I.V. Solution bag	Infections caused by microorganism	Asia
9	levofloxacin	LEVOTOPCIN I.V. Solution bag	Infections caused by microorganism	Asia
10	vancormycin	VANCORIN Inj.	Serious, life-threatening infections by gram-positive bacteria	Asia
11	irinotecan	CALMTOP RTU Inj.	Colorectal cancer	Asia, Africa
12	pemetrexed	PEMTA RTU Inj.	Pleural mesothelioma, non-small cell lung cancer	
13	lipid, amino acids, glucose	OMAPONE PERI Inj./ CENTRAL Inj.	Emulsion for intravenous nutrition	Asia, Africa
14	rh-EPO	EPOKINE vial/Inj.	Anemia of hemodialysis patients with end-stage renal disease	Asia, Africa, MENA
15	Tegoprazan	K-CAB Tab.	Gastroesophageal reflux disease	Vietnam, Lactam 17Countries, Indonesia, Thailand, Philippines, Mongolia, Singapore, Malaysia, India, Republic of South Africa, Russia, Ukraine, Kazakhstan, Uzbekistan, Belarus(To be)

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	
1	New chemical entity	IN-A001	Gastroesophageal reflux disease	NDA	
2		IN-A012	Antiemetics	NDA	
3		IN-A010	NASH, Glaucoma	P11	
4		IN-A002	Autoimmune disease	PI	
5		IN-A011	Nutrition	PI	
6		IN-A003	Cancer	PC	
7		IN-A008	Cancer	PC	
8		IN-A013	Cancer	PC	
9		IN-A004	NASH	DS	
10		IN-A006	Cancer	DS	
11		IN-A009	Cancer	DS	
12		IN-A014	Autoimmune disease	DS	
13		IN-A015	Cancer	DS	
14		IN-A016	Cancer	DS	
15		Biologicals	Hematopoietic agents	Anemia	NDA
16			IN-B001	Vaccine	PI
17	IN-B002		Vaccine	PC	
18	IN-B004		Autoimmune disease	PC	
19	IN-B008		Cancer	PC	
20	IN-B012		IBD, IBS	PC	
21	IN-B003		Vaccine	DS	
22	IN-B005		Cancer	DS	
23	IN-B010		Cancer	DS	
24	IN-B011		Cancer	DS	
25	IN-B013	IBD, IBS	DS		

# Humedix Co., Ltd.



<https://humedix.com/eng/home.php>



## Category

API  
Finished Pharmaceutical Products  
Medical Device



## Company Profile

We, Humedix, have platform technology for application of biocompatible polymers such as hyaluronic acid and polydeoxyribo nucleotide raw materials. By continuously innovating process, portfolio, we are expanding our business area into the aesthetic and biopharmaceutical field; aesthetic medical device, high-functional cosmetics, arthritis treatments, ophthalmic product and CMO business. In addition, we are focusing on developing new biomaterials and applied product to transformed into a total global healthcare company.

### CEO

Jin Hwan Kim

### Established Date

2003. 02.

### Employee No.

283 persons

### Contact point

#### 1. Overseas Business

Overseas Business team  
82-70-7492-5810  
hsoffice1206@humedix.com

#### 2. Licensing In/Out

Business Strategy Department  
82-70-7492-5170  
kevinkwag@humedix.com

#### 3. Overseas Branch

N/A

## Strengths

1. Prefilled Injection Production Facility of cGMP
2. Diversified portfolio of pharmaceuticals, medical devices and new functional synthetic materials
3. Core source technologies in various fields

## Collaboration Opportunities

1. Cooperation in Global Sales
2. Co-development
3. License In/Out



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Hyaluronic Acid Filler/ Lidocaine	Elravie Premier HA Filler	Wrinkle improvement	Worldwide	
2	Hyaluronic Acid Filler	Elravie HA Filler	Wrinkle improvement	Worldwide	CE
3	Sodium Hyaluronate/ Injection	High Hyal Plus Inj.	Remedies for Arthritis	Worldwide	
4	Sodium Hyaluronate/ Injection	HUMIA Inj.	Remedies for Arthritis	Worldwide	CE

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Bio	HMC3-039	Drug penetration aid	Apply for approval
2	synthetic drug	HMM1-021	Osteoarthritis	Clinical research
3	synthetic drug	HMM1-028	Hemostasis	Formulation research
4	synthetic drug	HMC3-012	Prostate cancer, Breast Cancer	Formulation research
5	synthetic drug	HMS1-007	Tissue restoration	Material research
6	synthetic drug	HMC3-045	Immunity improvement	Formulation research
7	synthetic drug	HMS1-049	Anticoagulation anticoagulant	Material research
8	synthetic drug	HMM1-050	bladder infection	Formulation research
9	synthetic drug	HMC3-051	Eye drop	Formulation research
10	synthetic drug	HMC3-052	Keratoconjunctivitis	Formulation research
11	synthetic drug	HMC3-059	Hyperparathyroidism	Formulation research

## Others

- CE marks on the Elravie HA Filler and HUMIA Injection for arthritis.
- High quality, Excellent duration, Safety.

# Huons Co., Ltd.



<https://huons.com/eng/home.php>



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product  
Others - Medical Device - Cosmetics

## Company Profile

Huons has manufactured the high quality finished products since 1965 and developed first local anesthetics and injections in Korea. Huons has been exporting our finished pharmaceutical products to about 30 countries including America, Europe, Japan, Asia, and Africa. We are waiting to be your good business partner for enjoying great coming future together. We focused on a specific aspect such as dental anesthetic and other injections.

### CEO

Sooyoung Song, Sangbae Yoon

### Established Date

1965.07

### Employee No.

873 persons

### Contact point

#### 1. Overseas Business

070-7492-5014  
birdie84@huons.com

#### 2. Licensing In/Out

070-7492-5287  
blueocean@huons.com

#### 3. Overseas Branch

070-7492-5728  
shlee19@huons.com

## Strengths

1. 1st place in the South Korean market share of anesthetics
2. Stable growth(both sales CAGR and CMO - Eye drops, Injections)
3. Diversified portfolio of pharmaceuticals, medical devices and health functional foods.

## Collaboration Opportunities

1. Cooperation in Global Sales
2. Co-development
3. License In/Out

## Others

Huons has existed for more than 50 years, and grown to a competent global company, producing original and effective essential medicine and medical products. Huons is putting a ceaseless effort for healthy life based on the advanced manufacturing technologies and production facilities. We are open for open innovation.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Lidocaine Hydrochloride	1% Lidocaine HCl	Local Anesthesia	3 countries	USA FDA ANDA approved	
2	Bupivacaine Hydrochloride	0.75% Bupivacaine with 8.25% Dextrose	Local Anesthesia	2 countries	USA FDA ANDA approved	
3	Articaine Hydrochloride	Articaine HCl 4% With Epinephrine(1:100,000)	Dental Anesthesia	over 20 countries	PMDA(JAPAN) approved	
4	Lidocaine Hydrochloride	Lidocaine HCl 2% With Epinephrine (1:80,000/1:100,000)	Dental Anesthesia	over 20 countries	PMDA(JAPAN) approved	
5	Sodium Chloride	0.9% Sodium Chloride	To flush intravascular catheters or as a sterile	2 countries	USA FDA ANDA approved	
6	Ketorolac Tromethamine	Ketorolac Inj.	To relieve moderately severe pain, usually pain	7 countries	MFDS approved	Nonsteroidal anti-inflammatory drugs (NSAIDs)
7	Heparin Sodium	Pine Inj.	Anticoagulant	5 countries	MFDS approved	
8	Norepinephrine Bitartrate	Norepine Inj.	To raise blood pressure in patients with severe, acute hypotension (short-term low blood pressure)	5 countries	MFDS approved	
	Hyaluronic Acid 0.15%	Noblian	Dry eyes	2 countries	MFDS approved	
9	Hyaluronic Acid 0.3%	Kynex 3	Dry eyes	2 countries	USA FDA inspected	
10	Cyclosporine	Clacier	Dry keratoconjunctivitis sicca	3 countries	KSA(Saudi Arabia)FDA inspected	
11	Carboxymethylcellulose sodium	High Eye Refresh	Xerophthalmia	1 country	MFDS approved	
12	Rocuronium Bromide	Curoni Inj.	Skeletal Muscle Relaxants	2 countries	MFDS approved	
13	Ginkgo Biloba	Ginkobal Inj.	To improve blood flow	4 countries	MFDS approved	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	NCE	HUC1-259	Liver disease	Discovery
2		HUC1-288	Heart failure	Preclinical
3		HUC1-394	Ocular disease	Preclinical
4	IMD	HUC2-007	Dry eye syndrome	Clinical Trial II
5		HUC2-344	Diabetes	Preclinical
6		HUC2-364	Gastroesophageal Reflux Disease(GERD)	Clinical Trial I
7		HUC2-396	Dyslipidemia	Clinical Trial I
8		HUC2-362	Peripheral Circulatory Disturbance	Discovery
9		HUC2-448	Dyslipidemia	Discovery
10	HFF	HUN2-388	Improving Sleep Quality	Clinical Trial
11		HUN2-434	Improving Muscular strength	Discovery
12		HUN2-435	Improving Muscular strength	Discovery
13		HUN2-483	Improving Cognitive intelligence	Discovery

# IKSU PHARMACEUTICAL CO., LTD.

**IKSU** PHARMA IKSU Pharmaceutical Co., Ltd.

[www.iksu.co.kr](http://www.iksu.co.kr)



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product

## Company Profile

With 50-year history Iksu Pharm. Co., Ltd. has made continuous growth on herb medicine in a half century history. Iksu Pharm. which has developed 'Gohowhan', a neuralgia, arthritis treatment medicine, Korean wonder drug 'Woohwangchungsimwon.', and 'Gongjindan' known as the best royal tonic medicine with its distinguished Korean herbal medication technology, is raising its public trust such as receiving license of Gongjindan, Banhasashintang and Cheers liquid released by its technology knowhow.

### CEO

Yong-jin Chung

### Established Date

1970.09

### Employee No.

121 persons

### Contact point

1. Overseas Business  
R&D Dept./82-2-416-1115  
a02580124@naver.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Strengths

1. Authorized plant as KGMP compliance
2. Manufacture FDFs (herbal medicines, prescription drugs)
3. Distribute FDFs in both retail and wholesale channels throughout Korea

## Collaboration Opportunities

1. Export of Chungsimwon
2. Import of Health functional food or materials



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Musk/Cervu parvum cornu Angelica gigas root/Cornus fruit Ginseng/Steamed rehmannia root	Iksu gongjindan pill/ liquid	valetudinarianism, asthenia, reduced stamina, dizziness by aggravated liver functions, headache, chronic fatigue, emmeniopathy	-	Achieved the first liquid production in the world
2	Musk(or L-Muscone)/Cattle gallstone Dioscorea rhizome/Licorice Ginseng/Typhae pollen Massa medicata fermentata/Glycine semen germinatum/Cinnamon Etc.	Yongpyo wonbang woohwang chungsimwon pill/liquid	Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility	-	-
3	Musk(or L-Muscone)/Cattle gallstone Dioscorea rhizome/Licorice Ginseng/Typhae pollen Massa medicata fermentata/Glycine semen germinatum/Cinnamon Etc.	Yongpyo woohwangchungsim won pill/liquid	Cerebral apoplexy (total paralysis, hemiplegia, speech defect, coma, lethargy condition, facial paralysis), hypertension, palpitation, anxiety neurosis, acute & chronic convulsion, autonomic imbalance, insensibility	Vietnam	-
4	Crowdipper/Skullcap Ginseng/Licorice Jujube/Zingiberis Rhizoma A barberry root	Iksu banhasashintang liquid	Following symptom of the person with stuffiness of epigastrium, nausea, anorexia, soft stools or diarrhea : acute&chronic gastric catarrh, fermental diarrhea, dyspepsia, gastric ptosis, gastroneuria, weak stomach, hangover, heartburn, stomatitis, nervousness	-	Achieved the first liquid production in the world
5	A root of an arrowroot/Citrus unshiu peel Atractylodes Rhizoma/Chinese quince Massa medicata fermentata Zingiberis Rhizoma/Mung been Pachyma hoelen/Crowdipper Taeksa/Black bean Vigna umbellata	Cheers liquid	Maldigestion, vomituration, thirst, headache caused by heavy drinking	-	-
6	A root of an arrowroot/Mahuang Cinnamon/Peony Licorice/Jujube Zingiberis Rhizoma	Iksu kalgeuntang liquid	Common cold, coryza, headache, pain of shoulder and hands	-	-
7	Rhemanniae Radix/Ginseng Scrophularia root/Salvia miltiorrhiza Polygala tenuifolia/Platycodon Pachyma hoelen/Schizandra Angelica gigas root/Asparagus Tuber Liriope tuber/Biota seed Seed of wild jujube/A barberry root	Yongpyo ansin pill/ liquid	Insomnia, unrest, anxiety, thirst, palpitation, neurasthenia, shortness of breath	-	-
8	Steamed rehmannia root Achyranthes/Angelica gigas root Phellodendron Bark/Atractylodes Rhizoma/ Peony Milk vetch root/Schizandra Ginseng Etc.	Iksu gohowhan pill	Neuralgia, arthralgia, myalgia	-	-
9	Ginseng/Perilla frutescens Anthriscus sylvestris/Crowdipper A root of an arrowroot/Pachyma hoelen Citrus unshiu peel/Platycodon Aurantii Fructus Immaturus/Licorice Jujube/Zingiberis Rhizoma	Iksu samsoeum liquid	Headache, fever, cough caused by cold	-	-
10	Mahuang/Peony Zingiberis Rhizoma/Licorice Cinnamon/Korean wildginger root Schizandra/Crowdipper	Iksu sochungryongtang liquid	Bronchitis, bronchial asthma, rhinorrhea, cough with sputum, rhinitis	-	-

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Antlers and 5 other ingredients	IK-101	Improve Liver Function	Under registration
2	Corni and 5 other ingredients	IK-102	Improve Liver Function	Under registration
3	Rehmannia glutinosa and 5 other ingredients	IK-103	Improve Liver Function	Under registration
4	Angelica root and 5 other ingredients	IK-104	Improve Liver Function	Under registration
5	Ginseng and 5 other ingredients	IK-105	Improve Liver Function	Preclinical
6	Peony and 1 other ingredients	IK-106	Pain relief	Formulation
7	Asparagus tuber and 15 other ingredients	IK-301	Atopic Dermatitis	Phase II
8	Antlers and 2 other ingredients	IK-401	Immunity Improvement	Immunity Improvement



# ILDONG Pharmaceutical Co., Ltd.

**ILDONG** 일동제약

<https://www.ildong.com/eng/main/main.id>



## Category

- API
- Finished Pharmaceutical Products
- Others
  - Medical Device
  - Cosmetics



## Company Profile

Ildong Pharmaceutical Co., Ltd. has been contributing to the health and happiness of humankind for 81 years by developing, manufacturing, and supplying pharmaceutical products from API to Finished Products, such as Anti-Cancer drugs, Fixed Dose Combination, Food supplement, Medical Devices, Cosmetics(Cosmeceutical) etc.

## Strengths

1. PIC/s GMP manufacturing facility from API to Finished Products
2. Growing R&D investment ('21 +14%)
3. Strong local and overseas sales network

## Collaboration Opportunities

1. L/O
2. IMD
3. CMO/CDMO

### CEO

Paul Woongsup Yun

### Established Date

March 1941

### Employee No.

1,403(Dec. 2021)

### Contact point

#### 1. Overseas Business

Overseas Business Team  
+82-2-526-3269  
export@ildong.com

#### 2. Licensing In/Out

BD Team/+82-2-526-3088  
!00052@ildong.com

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Pemetrexed	Algik inj.	Non-small Cell Lung Cancer	MENA, SEA, Western Asia	PIC/s	
2	Gefitinib	Specssa tab.	Non-small Cell Lung Cancer	SEA	PIC/s	
3	Entecavir	Vicure tab.	Hepatitis B	CIS, South America	PIC/s	
4	Rosuvastatin + Ezetimibe	Droptop tab.	Hypercholesterolemia	SEA	PIC/s	
5	Telmisartan + Amlodipine	Twotops tab.	Hypertension	SEA	PIC/s	
6	Memantine	Memanto tab.	Alzheimer's Disease	SEA	PIC/s	
7	Rivaroxaban	Xareliban tab.	Prevent blood clots	Under registration	PIC/s	
8	Fursultiamin HCl		Active Vitamin B1	JAPAN	PMDA	API

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	NCE	IDG16177	Type II diabetes	Phase I
2	NCE	ID119031166	NASH(Non-alcoholic steatohepatitis)	Preclinical
3	NCE	ID110521156	Type II diabetes	Preclinical
4	NCE	ID120040002	GERD(Gastroesophageal reflux disease)	Preclinical
5	NCE	ID110410395	DED(Dry eye diseases)	Preclinical
6	NCE	ID110910023	Respiratory diseases	Preclinical
7	NCE	ID119050134	Hepatic cirrhosis	Preclinical
8	NCE	ID11902	HCC(Hepatocellular carcinoma)	Discovery
9	NCE	ID11901GL	Glaucoma	Discovery

## Others

1. Strong L/O pipeline
2. IMD(Incrementally Modified Drug) lineup
3. ODEM business for food supplement

# IL-YANG PHARM. CO., LTD

A GLOBAL LEADER IN DRUG DEVELOPMENT  


[www.ilyang.co.kr](http://www.ilyang.co.kr)



## Category

API  
 Finished Pharmaceutical Products  
 Vaccine

## Company Profile

Under the corporate philosophy of 'Respect humanity', 'Promote human health' and 'Improve welfare', IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. With over 75 years of experience in pharmaceutical industry, we have developed 2 new chemical entities and influenza vaccine. Ilaprazole (Noltec®) is a 3rd generation Proton Pump Inhibitor (PPI) for the treatment of ulcerative symptoms and is considered as Korea's 14th new drug. Radotinib (Supect®) is a 2nd generation Bcr-Abl tyrosine kinase inhibitor (TKI) for the treatment of Philadelphia chromosome positive (Ph(+)) chronic myeloid leukemia and is considered as Korea's 18th new drug. We also established new vaccine plant in Korea on April, 2011, which can manufacture millions of doses of Influenza vaccine annually.

## Strengths

1. Innovative products
2. Long-term partnership
3. High quality products

## Collaboration Opportunities

1. Licensing in/out
2. Influenza vaccine export
3. Finished Product and/or API



## CEO

Dong Yeon Kim, Ph.D

## Established Date

July 1st, 1946

## Employee No.

650

## Contact point

### 1. Overseas Business

Young Hwi Ko/82-2-570-3804  
 yhko@ilyang.co.kr

### 2. Licensing In/Out

Young Hwi Ko/82-2-570-3804  
 yhko@ilyang.co.kr

### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Radotinib	SUPECT Cap	Chronic Myeloid Leukemia		New Drug
2	Ilaprazole	NOLTEC Tab	Gastric Ulcer, Duodenal Ulcer, Erosive Esophagitis, H.pylori Eradication	Mexico, Ecuador, Cambodia, Mongolia, Panama, Costa Rica, El Salvador	New Drug
3	Trivalent purified inactivated influenza virus antigen	IL-YANG Flu Vaccine Pre-filled Syringe INJ.	Prevention of influenza	Bhutan, Malaysia, Bangladesh	Generic
4	Quadrivalent purified inactivated influenza virus antigen	TERATECT Pre-filled Syringe INJ.	Prevention of influenza	Iran, Bangladesh, Pakistan	Generic
5	Almagate	Aldrin Suspension	Gastric Ulcer, Gastritis, Hyperacidity	Cambodia, Mongolia, Vietnam, etc	Generic
6	Colloidal Aluminum Phosphate, Magnesium Oxide	Alluphose Plus Suspension	Gastric Ulcer, Gastritis, Hyperacidity	Cambodia, Vietnam	Generic
7	Diocahedral Smectite	Shumecton Suspension	Chronic and Acute Diarrhea, Gastrointestinal Pain	Cambodia	Generic
8	Aluminum Magnesium Silicate	Noigel Suspension	Gastric Ulcer, Gastritis, Hyperacidity	Cambodia, Vietnam	Generic
9	Boehmite	Norumo Suspension	Gastric Ulcer, Gastritis, Hyperacidity	Cambodia	Generic
10	Azintamide, Cellulase, Pancreatin, Simethicone	Azintal Forte Tablet	Septic or Zymotic Digestion Disorder, Abdominal Fullness, Indigestion	Vietnam	Generic
11	Flubendazole	Allcom Tablet	Internal Parasite and Worm Infection	Mongolia	Generic
12	Ginseng Fluid Extract, and others	Wonbi-D	Health Drink	Malaysia, Mauritius	-
13	Korean Red Ginseng Extract, and others	Sol+(Ginseng Energy)	Energy Drink	Afghanistan, USA, Austria, etc	-
14	Magaldrate (API)		Antacid Raw Material	Bangladesh, Bolivia, Switzerland, Taiwan, Spain, Ecuador, Egypt, India, Chile, Pakistan, Mexico	
15	Dried Aluminum Hydroxide Gel (API)		Antacid Raw Material	Guatemala, Singapore, South Africa, Taiwan, Malaysia, USA, Bangladesh, Vietnam, Spain, Egypt, India, China, Cambodia, Costa Rica, Colombia, Thailand, Tunisia, Pakistan, Australia, Hong Kong	
16	Magnesium Hydroxide Gel (API)		Antacid Raw Material	Taiwan, Malaysia, US, Spain, Singapore, Indonesia, Thailand, Pakistan, Australia, Hong Kong, Bangladesh, Guatemala, New Zealand, Syria, Egypt	
17	Almagate (API)		Antacid Raw Material	China, Vietnam	
18	Magnesium Aluminum Metasilicate (API)		Antacid Raw Material	Taiwan, Malaysia, US, Spain, Singapore, Indonesia, Thailand, Pakistan, Australia, Hong Kong, Bangladesh, Guatemala, New Zealand, Syria, Egypt	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Radotinib		Parkinson's Disease	Phase I/II
2	Radotinib		Chronic Myeloid Leukemia	Phase III
3	Flu Vaccine		Pediatric Quadrivalent Flu Vaccine	Phase III


## Others

IL-YANG PHARM CO., LTD. is dedicated to realize the true value of the products which comply to IL-YANG's own vision and strategy. IL-YANG is also actively engaged in the In-Licensing business to introduce innovative products from all nations to Korea. ILYANG and Licensor will synergistically maximize the effect of registration, marketing, distribution and sales regarding the product.

# INIST ST Co., Ltd.



www.inistst.co.kr



## Category

API

## Company Profile

INIST ST strives to contribute to the society and community by delivering healthier living from ages 0 to 110 years. INIST ST develops non-cytotoxic anti-cancer, high quality generics & value-added APIs supply to domestic and overseas markets. INIST ST plays an intensive R&D function in the exploration of drug candidates and the process development of small molecules.

## Strengths

1. Own Synthetic Technowledge & R&D capability
2. High Quality Management & Stable Supplying
3. Years experience to export to Japan, US, EU, etc.

## Collaboration Opportunities

1. 1st generic APIs
2. CMO/CDMO Biz.
3. Co Development

### CEO

Ssangsoo, Han

### Established Date

June 1, 2003

### Employee No.

147

### Contact point

#### 1. Overseas Business

Michael Yoo in Overseas Sales Team  
+82 31-669-9531  
yooby@inistst.com

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A



## Main Products

No.	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Butenafine HCl	Antifungal	Japan, Taiwan, Turkey	JGMP, JDMF
2	Duloxetine HCl	Antidepressant	Japan	JGMP, JDMF
3	Famciclovir	Antiviral	Japan	JGMP, JDMF
4	Glimepride	Antidiabetic	Japan	JGMP, JDMF
5	Mosapride Citrate	Peristaltic Stimulant	Japan	JGMP, JDMF
6	Naftopidil	Prostatitis	Japan	JGMP, JDMF
7	Oseltamivir Phosphate	Antiviral	Japan, China	JGMP, JDMF
8	Temocapril HCl	Antihypertensive	Japan	JGMP, JDMF
9	Terbinafine HCl	Antifungal	Japan	JGMP, JDMF
10	Voglibose	Antidiabetic	Japan	JGMP, JDMF

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	USP	ST-MA0	Urinary incontinence treatment	Pilot/PV
2	IHS	ST-NA1	Anticoagulant	Pilot/PV
3	IHS	ST-BR2	Atypical antipsychotic	Under Development
4	IHS	ST-NI0	Antifibrotic	Under Development
5	IHS	ST-VO1	Antigastric ulcer	Under Development

## Others

1. US FDA Inspection: March, 2022 for anticancer drug substance, received EIR\* July, 2022.
2. Large scale new API plant is under construction, expected to complete in 4Q, 2022.
3. With international & Korean Pharmaceutical companies, CMO/CDMO businesses are ongoing.

\* EIR: Establishment Inspection Report

# ISUABXIS Co., Ltd.



www.abxis.com



## Category

API  
Finished Pharmaceutical Products  
Biopharmaceuticals - Biosimilar

## Company Profile

Since 2001, ISU Abxis has established its own platform technologies and product pipelines with a desire of being an axis of all therapeutic antibody industry as its name stands (ABXIS=AntiBody + aXIS). Beginning with the successful development and market-launch of Korean first therapeutic antibody in 2006. Consequently in 2013 and 2014, ISU Abxis launched two biotherapeutics for orphan diseases of Gaucher and Fabry disease. ISU's three products, supplied to over 30 countries including Turkey, Iran, Mexico and Algeria, are available as the only alternative against the reference drugs worldwide. Moreover, ISU ABXIS GMP which is for drug substance has been inspected under PIC/S guideline and successfully registered, and application of variation for DS manufacturing site addition were approved by MFDS (Ministry of Food and Drug Safety). ISU Abxis will grow its advanced technology based business for difficult-to-treat and orphan disease market both domestically and worldwide.

## Strengths

- 1st Antibody developer in Korea (Abciximab)
  - Skillful Antibody Discovery and Outstanding Antibody Optimization
- Specialized in Enzyme Replacement Therapy
  - Developed and commercialized Imiglucerase and Agalsidase Beta
- State of the Art GMP Facility
  - Certified by KFDA, PIC/s, etc.

## Collaboration Opportunities

1. Supplying Drug Product & Drug Substance of Abcertin and Fabagal
2. License Out of Abcertin and Fabagal
3. License Out of the projects in pipelines



## CEO

Yeob Hwang

## Established Date

2001.03.28

## Employee No.

140

## Contact point

### 1. Overseas Business

Pharmaceutical Business Team  
Seung Gun Yang  
031-696-4644

### 2. Licensing In/Out

Discovery & Innovation Team  
Junho Lim  
031-696-4671

### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Imiglucerase	Abcertin®	Enzyme Replacement Therapy (ERT) for Gaucher disease (GD)	Iran, Columbia, Ecuador, Peru, etc.	Drug Approval by country	The first drug for GD developed in Korea and the world's second Imiglucerase
		API		Germany	-	
2	Abciximab	Clotinab®	Adjunct to Percutaneous Coronary Intervention (PCI)	Turkey, Sri Lanka, Thailand, Paraguay, etc.	Drug Approval by country	The first therapeutic antibody developed in Korea and the world's second Abciximab
3	Agalsidase beta	Fabagal®	Enzyme Replacement Therapy (ERT) for Fabry disease (FD)	Russia (scheduled)	-	The first drug for FD developed in Korea and the world's second Agalsidase beta
		API		Germany	-	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Oncology	ISU104	Head and Neck Cancer	Phase 1	Novel human monoclonal anti-ErbB3 antibody
2		ISU104 CAR-NK	Solid Tumor	Discovery	Novel anti-cancer immune cell therapy that combines ISU104 with CAR-NK technology
3		ABX2001	Solid Tumor	Discovery	Novel cancer immunotherapy that uses Probody technology (pro-cytokines)
4	Rare Incurable Disease	ISU304	Hemophilia B	Phase 2	Modified recombinant Factor IX protein
5		ISU305	Paroxysmal Nocturnal Hemoglobinuria	Phase 1	Biosimilar of Soliris® developed by Alexion Pharmaceuticals
7		ISU203	Alzheimer's Disease	Pre-clinical	Novel monoclonal anti-ASM antibody for the treatment of Alzheimer's disease

## Others

Founded in 2001 with the goal of developing innovative antibody-based therapeutics to treat cancer, the name ABXIS is a reflection of our dedication to becoming an axis of antibody (Ab) therapeutics. Our pipeline also includes rare disease therapeutics, in addition to the anti-cancer therapeutics that we developed on our way to becoming a leading biotechnology company in Korea. By providing new ways of combatting cancer and rare diseases, ISU ABXIS will fulfill its vision of enhancing lives and easing the suffering of patients worldwide.

# Jeil Pharmaceutical Co., Ltd.

JEIL PHARMACEUTICAL CO.,LTD.

<https://www.jeilpharm.co.kr/english/>



## Category

Finished Pharmaceutical Products  
Cosmetics

## Company Profile

Founded in 1959, Jeil has developed and supplied superior pharmaceutical products to promote the happiness and health of mankind and has contributed to the growth and development of the pharmaceutical industry in Korea. Jeil has been listed on KOSPI since 1988, equipped with global-class research centers and production facilities, has been recognized for its outstanding value on the world market as well.

## Strengths

1. Global Major Strategic Alliances (License-in Partners)
2. R&D, manufacturing, Sales & marketing capability of prescription pharmaceutical products (generics, innovative drugs and API)



### CEO

SUK JE SUNG

### Established Date

March 7th, 1959

### Employee No.

1010

### Contact point

#### 1. Overseas Business

Global Business Team  
82-2-549-7451(Ext. 654)  
namkj@jeilpharm.co.kr

#### 2. Licensing In/Out

Global Business Development Team  
82-2-549-7451(Ext. 531)  
sedopark@jeilpharm.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Meropenem	Newropenem Inj. 500 mg	Antibiotic	Vietnam, Philippines, Mongol, Myanmar, Yemen, Bolivia	Vietnam, Philippines, Mongol, Myanmar, Yemen, Bolivia
2	Meropenem	Newropenem Inj. 1 g	Antibiotic	Vietnam, Philippines, Mongol, Myanmar, Yemen, Cambodia, Peru, Bolivia	Vietnam, Philippines, Mongol, Myanmar, Yemen, Cambodia, Peru, Bolivia
3	Cilastatin Sodium + Imipenem	Cilapenem Inj. 500 mg	Antibiotic	Philippines, Thailand, Mongol, Myanmar, Cambodia, Pakistan, Yemen, Azerbaijan	Philippines, Thailand, Mongol, Myanmar, Cambodia, Pakistan, Yemen, Azerbaijan
4	Entecavir	Encavir Tabs. 0.5 mg	Antiviral	Japan, Hongkong, Mongol, Myanmar, Yemen, Uzbekistan	Japan, Hongkong, Mongol, Myanmar, Yemen, Uzbekistan
5	Entecavir	Encavir Tabs. 1 mg	Antiviral	Hongkong, Mongol, Uzbekistan	Hongkong, Mongol, Uzbekistan
6	Valacyclovir HCl	Valtra Tabs. 500 mg	Antiviral	Japan, Mongol, Hongkong	Japan, Mongol, Hongkong
7	Rivaroxaban	Ribaxan Tabs. 20 mg, 15 mg, 10 mg	Anticoagulant	Azerbaijan	Azerbaijan
8	Amlodipine Besylate + Olmesartan Medoxomil	Seviduo Tabs. 10/40 mg, 5/40 mg, 5/20 mg	Cardiovascular	Georgia	Georgia
9	Glimepiride + Metformin HCl	Metmaryl Tabs. 2/500mg, 1/250 mg	Antidiabetic	Peru	Peru
10	Epinalstine HCl	Allerginon Tabs. 20 mg, 10 mg	Antiallergic	Yemen	Yemen
11	Cefpodoxime proxetil	API	Antibiotic	Mexico	EDQM
12	Flomoxef sodium	API	Antibiotic	Taiwan	Taiwan
13	Cefmetazole sodium	API	Antibiotic	Japan, Taiwan	Taiwan, Japan
14	Cefcapene pivoxil	API	Antibiotic	Japan	Japan
15	Cefotetan	API	Antibiotic	Egypt	Egypt
16	Cefditoren pivoxil	API	Antibiotic	Japan	Bangladesh, Japan
17	Imipenem & Cilastatin mixture	API	Antibiotic	Brazil	Brazil
18	Voglibose	API	Antidiabetic	Japan	Bangladesh, Japan
19	Entecavir hydrate	API	Antiviral	Japan	Bangladesh, Taiwan, Japan
20	Adefovir dipivoxil	API	Antiviral	Turkey	Turkey
21	Epinalstine hydrochloride	API	Antiallergic	Japan, Mexico	Japan
22	Sterile Meropenem	API	Antibiotic	Japan	Japan
23	Bosentan hydrate	API	Cardiovascular	Japan	Japan
24	Azelidipine	API	Cardiovascular	Japan	Japan
25	Cinacalcet	API	Antihypercalcemia	Japan	Japan
26	Tolvaptan	API	Cardiovascular	Japan	Japan

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	GERD / Gastric Ulcer	JP-1366		Clinical study 3
2	Acute Ischemic Stroke	JP-289		Clinical study 2
3	Cancer	JP-547		Clinical study 2
4	Diabetes Mellitus	JP-2266		Clinical study 1
5	Leukemia	PIM		Discovery
6	Rheumatoid Arthritis	RIP1		Discovery

# JINYANG PHARM. Co., Ltd.

**JIN YANG PHARM. CO., LTD.**  
www.jinyangpharm.com

www.jinyangpharm.com/



## Category

Chemicals and Synthetic drugs

## Company Profile

Since Jin Yang Pharm. Co., Ltd. was established in 1971, we have been trying to stay ahead of the pharmaceutical industry in Korea with our full automatic production system in the most modern and up to-date manufacturing facility.

In 2021, new manufacturing facility which is designed to export our products to advanced countries including U.S. & Europe(cGMP/EU-GMP standard) was completed and PIC/s GMP was approved.

It is capable of manufacturing oral formulations over 500 million Tablets(Capsules) per year by using state-of-the-art technologies & equipments.

We have also been leading the development of the pharmaceutical industry in Korea through cooperation with the global pharmaceutical companies.

For more than forty years, based on the principle of honesty and sincerity, all the staffs and employees of our company have been putting all their efforts into building a better world with the aim of developing good quality drugs for health and happy life of the people and with the faith of managing the company in a profound respect for humanity. We promise to be a company that keeps on doing research and development for the improvement of life quality of the people and clients can give their confidence to our company. We will contribute to healthy life of the people by bending over backwards to help you not to lose your healthy body and happy life.

### CEO

Jae-Joon, Choi

### Established Date

July 01, 1971

### Employee No.

209 Employee

### Contact point

#### 1. Overseas Business

82-2-3470-0372  
Chang Hwan, Lim  
82-2-3470-0361/chlim@jyp.co.kr

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Clopidogrel bisulfate	CLIVIX	Anti-coagulants	Vietnam, Mongolia
2	Esomeprazole	ESZOL	GERD	Vietnam
3	Atorvastatin	ATORAN	Hyperlipidemia	Vietnam
4	Acyclovir	JINACID	antiviral	HongKong
5	Atorvastatin Calcium Trihydrate/Ezetimibe	ZINTOZET	Hyperlipidemia	Vietnam, Philippines
6	Rosuvastatin Cap.	ROSUVATIN	Hyperlipidemia	Vietnam
7	Pregabalin	PREGABA	neuralgia	Vietnam, Mongolia
8	Entecavir Hydrate	Jinyang Entecavir	antiviral	Vietnam
9	Rebamipide	RAMISTA	Digestive system	Vietnam, Philippines
10	Celecoxib	Cebrex Cap.	NSAIDS	Vietnam
11	Indapamide	DAPID	Anti-hypertensives	Hongkong & Macau
12	Trimebutine maleate	TRIMA	GI-regulator	Vietnam
13	Sobrerol	SOBNAL	Antitussive & expectorants	Hongkong & Macau
14	Erdosteine	ELBUNAL	Respiratory system	Vietnam, Philippines
15	Itopride HCl.	MOGATON	GI-regulator	Vietnam, Philippines
16	Losartan potassium	KAZATAN	Anti-hypertensives	Vietnam

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	SGLT2 Inhibitors	JY302	Anti-diabetics	Clinical Study
2	DPP-4 Inhibitors	JY404	Anti-diabetics	BE Study
3	CCB + ARB	Amvaltan	Antihypertensives	BE Study
4	CCB + ARB	Temistar	Antihypertensives	BE Study
5	SGLT2 Inhibitors	JY301	Anti-diabetics	Formulation Study
6	DPP-4 Inhibitors	JY401	Anti-diabetics	Proof of concept
7	DPP-4 Inhibitors	JY402	Anti-diabetics	Proof of concept
8	DPP-4 Inhibitors	JY403	Anti-diabetics	Proof of concept
9	P-CAB	JY501	Digestive system	Proof of concept

## Financial Figures

Summary(1 Million Won)			
Fiscal Year	2019	2020	2021
Sales	45,000	49,500	62,800
R&D Expenditure	1,357	2,244	2,301
Capital	6,000	6,000	6,000

# KMS Pharm Co., Ltd.



www.kmspharm.com



## CEO

Seung Woo Lee

## Established Date

Jul. 1, 1997

## Employee No.

About 50

## Contact point

### 1. Overseas Business

Overseas business/82-31-2155456  
kjh2198159@naver.com

### 2. Licensing In/Out

Overseas business/82-31-2155456  
kjh2198159@naver.com

### 3. Overseas Branch

N/A

## Category

Finished Pharmaceutical Products

## Company Profile

KMS Pharm Co., Ltd. is a pharmaceutical manufacturer in Korea established in Jul. 1997 manufacturing and distributing mainly tablets and capsules to the domestic and overseas markets such as Vietnam, Mongolia, etc. Its manufacturing site follows the KGMP that covers the PIC/S and WHO regulations.

## Strengths

1. Bio Equivalence tested drugs
2. CMO business

## Collaboration Opportunities

1. Agent distributorship
2. Export business



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Ciprofloxacin HCl 582mg (as ciprofloxacin 500mg)	Cysfec 500mg Tablet	Quinolone antibacterial agent	Cambodia, Vietnam	Market Authorization	
2	Domperidone maleate 12.72mg (domperidone 10mg)	Domperiman Tablet	Gastrointestinal motility regulators	Cambodia	Market Authorization	
3	Levocetirizine dihydrochloride 5mg	Ketrazin Tablet	Antihistamins	Hong Kong, Mongolia, Myanmar	Market Authorization	
4	Levosulpiride 25mg	Lesulpiride Tablet	Gastrointestinal motility regulators	Cambodia, Myanmar, Vietnam	Market Authorization	Bio Equivalence tested
5	Losartan potassium 50mg	Locotan Tablet	Hypertention-Angiotensin II receptor antagonists	Hong Kong, Myanmar, Vietnam	Market Authorization	Bio Equivalence tested
6	Rebamipide 100mg	Levacos Tablet	Peptic Ulcer	Cambodia, Vietnam	Market Authorization	Bio Equivalence tested
7	Tramadol chloride 37.5mg/ Acetaminophen 325mg	Ultran Tablet	Non-narcotic central analgesics	Cambodia, Hong Kong, Vietnam	Market Authorization	
8	Trimebutine maleate 100mg	Manpotine Tablet	Gastrointestinal motility regulators	Cambodia	Market Authorization	

## Others

We have been looking for any overseas agents or/and distributors to perform the registration procedures, import, distribute and market our drugs on the behalf of our company in the overseas territory, particularly in the Asian, African and Central & South American nations. So we always welcome any business inquiry from the overseas companies.

# Kolon Life Science



www.kolonls.co.kr



## Category

API, Cell/Gene Therapy

## Company Profile

Kolon Life Science has two main businesses, which are Chemical and Bio. The Chemical business consists of the pharmaceutical business which supplies active pharmaceutical ingredients(API) and pharmaceutical intermediates to global markets, the Specialty Chemical (SC) business based on eco-friendly antimicrobials, and the Water Solution(W.S) business which produces and sells various water treatment products.

Kolon Life Science has a pharmaceutical business based on the entire process of researching, developing, manufacturing, and supplying APIs and intermediates with world-class facilities and strict quality control under the vision of "A Reliable Partner for General & CMO". We are selling Loxoprofen to Japanese companies since 1997 and supplying it to the original company. Currently, about 20 products including Argatroban, Pitavastatin and Rosuvastatin have been sold to 60 Japanese companies. Also, we are supplying two antibiotic intermediates to GSK since 2003. Recently, Kolon Life Science is focusing our internal capabilities on expanding to the new CDMO/CMO business. We have various partnerships with Korean companies to supply investigational new drug substances based on our experience in supplying new drug intermediates to Wyeth, Daiichi Sankyo, and GSK.

The Bio business has been committed to researching and developing various pipelines in the field of cell and gene therapy. Our representative pipelines include KLS-2031(on Phase1/2a clinical trial in the U.S.) which is an agent for treating neuropathic pain and KLS-3021(on the preclinical study) which is an anti-cancer agent.

Kolon Life Science will continue to promote its substantial growth through market expansion for its fields of business, alliances with global partners, and the development of new products.

## Strengths

1. Cutting-edge facilities and equipment : Highly customizable GMP-certified facilities with various equipment
2. Technological expertise with solid track record : Unique breadth of expertise developed through solid track record
3. Viral carrier platform technology/Continuous process technology

## Collaboration Opportunities

1. Cell and Gene Therapy - Licensing In/Out - Joint Development
2. Small molecule API CDMO/CMO
3. GE API supply

### CEO

Woosok Lee

### Established Date

April 21, 2000

### Employee No.

442

### Contact point

#### 1. Overseas Business

Pharmaceutical Business Team  
+82-2-3677-4814  
juhoon\_yoo@kolon.com

#### 2. Licensing In/Out

Business Development Team  
+82-2-3677-4235  
global\_care@kolon.com

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Argatroban Hydrate	-	Anticoagulant	Japan	JDMF
2	Donepezil HCl	-	Alzheimer's disease	Japan	JDMF
3	Famciclovir	-	Antiviral	Japan	JDMF
4	Felbinac	-	NSAIDs	Japan	JDMF
5	Fexofenadine HCl	-	Antiallergic	Japan	JDMF
6	Flurbiprofen	-	NSAIDs	Japan	JDMF
7	Gefitinib	-	Anticancer	Japan	JDMF
8	Losartan K	-	ARB	Japan	JDMF
9	Loxoprofen Na Hydrate	-	NSAIDs	Japan	JDMF
10	Mirtazapine	-	Antidepressant	Japan	JDMF
11	Nadifloxacin	-	Antibiotic	Japan	JDMF
12	Olopatadine HCl	-	Antiallergic	Japan	JDMF
13	Pitavastatin Ca	-	Antihyperlipidemic	Japan, Taiwan	USDMF, JDMF, EDMF, KDMF, TDMF, CDMF
14	Rosuvastatin Ca	-	Antihyperlipidemic	Japan	USDMF, JDMF
15	Voglibose	-	Antidiabetic	Japan	JDMF
16	Zaltoprofen	-	NSAIDs	Japan	JDMF

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Cell mediated gene therapy	TG-C	Osteoarthritis	Phase 3(US)	Have intellectual property rights for commercialization in Asia
2	AAV based gene therapy	KLS-2031	Neuropathic Pain	Phase 1/2a(US)	US FDA Fast track designation(Feb, 2020)
3	Oncolytic virus	KLS-3021	Solid Cancer	Preclinical	US FDA Pre-IND meeting(2019)
4	Small molecule API CDMO/CMO	-	Oncology	Completed	Supply intermediates to JP company('16)
5	Small molecule API CDMO/CMO	-	COPD	Completed	Supply intermediates to UK company('18)
6	Small molecule API CDMO/CMO	-	Radiation therapy	Completed	Supply API for Phase 2 to US company('19)
7	Small molecule API CDMO/CMO	-	Obesity	Completed	Supply API for Phase 2 to KR company('19, '20)
8	Small molecule API CDMO/CMO	-	Obesity	Completed	Supply API for Phase 1 to KR company('21)
9	Small molecule API CDMO/CMO	-	Malara	Ongoing	Supply API for Phase 1 to CH company('23F)
10	GE API	TNGT	Antidiabetic	Process Validated	-



# Korea Arlico Pharm Co., Ltd.



www.arlico.co.kr



## Category

Finished Pharmaceutical Products

Others

- Medical Device

- Cosmetics



## Company Profile

Korea Arlico Pharm is one of 50 major pharma company in Korea with 30 years of history. We mainly specialize CMO biz with the development and production of generic drugs at GMP facility.

Since our KOSDAQ listing in Feb 2018, we have actively moved on R&D for new drugs and recorded the consistent annual sales growth rate (CAGR) of 23.35% from 2013 to 2020. (Annual sales revenue USD 100 Million with 160 working people).

### CEO

LEE HANG GU

### Established Date

December, 1992

### Employee No.

160

### Contact point

#### 1. Overseas Business

Michelle Lee/Overseas biz team  
82-10-6308-5898  
michelle77@arlico.co.kr

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A

## Strengths

1. CMO specialized company (KOSDAQ listed)
2. Strong CSO marketing
3. KGMP facility

## Collaboration Opportunities

1. CMO service
2. CDMO service
3. License in biz

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Betamethasone Dipropionate 0.64mg Clotrimazole 10mg Gentamicin Sulfate 1mg	Acrason cream	Bacterial or fungal infections	Vietnam, Cambodia, Hongkong, Macao, Peru, Tanzania	ETC
2	Ginko biloba 80mg, 120mg, 240mg	Biloba Tab.	Strong blood circulation	Vietnam	OTC
3	Nystatin 10,000IU Neomycin sulfate 50.2mg Polymyxin B sulfate 35,000IU	Neopoline Soft Cap.	Vaginal candidiasis, nonspecific bacterial vaginosis, vulvovaginitis	Vietnam	ETC
4	Ursodeoxycholic Acid 200mg, 300mg	URSOMAXE Tab.	Liver function improvement	Vietnam	ETC
5	Lidocaine HCl 2%	Arlico Lidocaine Jelly	Anesthetic lubricant	Peru	ETC
6	Lidocaine 96mg	Emmao Plus Cream	Local anesthesia	Thailand (under registration)	OTC
7	Levodropropizine 60mg	Arlicough Tab	Acute, chronic bronchitis	Thailand (under registration)	ETC
8	Fimasartan 60mg, S-Amlodipine 5mg	Arduca Tab.	Primary hypertension	Vietnam (under registration)	ETC
9	Loxoprofen sodium 68.1mg	Loxafen Tab.	Rheumatoid arthritis	Iraq, Uzbekistan (under registration)	ETC
10	Hyaluronic acid, Lactic acid	Inner Su	Vaginal cleanser (single use)	Saudi Arabia, Uzbekistan (under registration)	Medical device

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	New drug		Parkinson's disease	Nonclinical/formulation development
2	IMD		Cardiovascular	Clinical phase
3	IMD		Diabetes	Clinical phase
4	IMD		Diabetes	Nonclinical/formulation development
5	IMD		Antitussive expectorants	Nonclinical/formulation development

## Others

The strength of Korea Arlico Pharm is the various efficacy of generic pharmaceuticals such as cardiovascular, antibiotics&steroid, antihistamines, NSAIDs & Analgesics, Antifungal, anti-patelet, skeletal muscle relaxants, local anesthetics, diabetes, digestive, allergy&respiratory etc. As well, we developed the new medical device, woman vaginal cleanser and anti-wrinkle botox multibalm so that we've been promoting aggressively to global customers. Focused on asean countries in the past, but now made some agreements with the customer in Middle East, South America.

# Korea Otsuka Pharmaceutical Co., Ltd.



[www.otsuka.co.kr/introduction\\_en](http://www.otsuka.co.kr/introduction_en)



## Category

- API
- Finished Pharmaceutical Products
- Others
  - Medical Device
  - Cosmetics
  - Dietary Supplement and Functional Foods



## Company Profile

Korea Otsuka Pharmaceutical supplies excellent and innovative pharmaceutical and healthcare products. At a multinational pharmaceutical company equipped with large-scale production facilities in Korea, we contribute to the growth of national economy through domestic production as well as export. With understanding of customers, markets and social responsibilities, we are fulfilling our role and mission to become a company contributing to the healthy life of Koreans.

### CEO

Moon, Sung-Ho

### Established Date

July 9, 1982

### Employee No.

375

### Contact point

#### 1. Overseas Business

Resource Management Team  
T. +82-2-3287-9060  
E. tank@otsuka.co.kr

#### 2. Licensing In/Out

Market Access Team  
T. +82-2-3287-9150  
E. hufs91@otsuka.co.kr

#### 3. Overseas Branch

N/A

## Strengths

1. Chemical drug of CNS category
2. Chemical drug of Oncology category
3. Orphan drugs & First in class products



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Aripiprazole	ABILIFY Tab.	Anti-psychotic agent	Hong-Kong, Philippines, Thailand, Indonesia	FDA Philippines, Thai FDA, TFDA
2	Aripiprazole	ABILIFY ODT	Anti-psychotic agent	Hong-Kong, Philippines, Thailand, Indonesia, Europe	MHRA, TFDA, FDA Philippines, ANSM, Thai FDA
3	Aripiprazole	ABILIFY Oral Sol.	Anti-psychotic agent	Europe, Indonesia, Thailand, China	MHRA, FDA Philippines, ANSM, Thai FDA, TFDA
4	Cilostazol	PLETAAL Tab.	Anti-platelet agent	Hong-Kong, Philippines, Thailand, Vietnam, Malaysia, Myanmar, Parkistan	FDA Philippines, NPCB
5	Cilostazol	PLETAAL SR Cap.	Anti-platelet agent	Philippines, Thailand, Indonesia	FDA Philippines, Thai FDA
6	Cilostazol	Cilostazol API	Anti-platelet agent	Japan, Indonesia, Taiwan, China	FDA, PMDA
7	Rebamipide	MUCOSTA Tab.	Anti-ulcer agent	Philippines, Thailand, Vietnam, Cambodia, Malaysia, Myanmar, Parkistan, Macao	DRAP, NPCB, FDA Philippines Thai FDA
8	Rebamipide	Rebamipide API	Anti-ulcer agent	Japan, Indonesia, China	PMDA
9	Tolvaptan	SAMSCA Tab.	Aquaretic agent	Philippines, Thailand, Vietnam, Indonesia	FDA Philippines, BPOM, Thai FDA
10	Brexpiprazole	REXULTI Tab.	Anti-psychotic agent	Indonesia	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Certain infectious or parasitic diseases	OPC-67683	Multidrug-resistant tuberculosis	Approved
2	Neoplasms	AP24534	Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia	Approved
3	Neoplasms	OPB-111077	Diffuse large B-cell lymphoma	Phase 1
4	Neoplasms	ASTX-727	Acute myeloid leukemia, Myelodysplastic syndromes	Phase 3
5	Diseases of the skin	OPA-15406	Atopic dermatitis	Phase 3
6	Neoplasms	SGI-110	Acute myeloid leukemia	Phase 3
7	Diseases of the nervous system	TEV-48125	Migraine	Phase 3
8	Mental, behavioural or neurodevelopmental disorders	OPC-34712	Schizophrenia	Phase 3
9	Mental, behavioural or neurodevelopmental disorders	OPC-14597	Schizophrenia	Approved
10	Mental, behavioural or neurodevelopmental disorders	OPC-14597	Bipolar depression	Phase 3
11	Endocrine, nutritional or metabolic diseases	OPC-41061	Hyponatremia, ADPKD	Approved
12	Diseases of the nervous system	OPC-13013	Cerebral infarction	Approved
13	Diseases of the digestive system	OPC-12579	Gastritis	Approved
14	Diseases of the circulatory system	PRDS-001	Resistant hypertension	Phase 3

# KOREA PHARMA Co., Ltd.

**KP** KOREA PHARMA CO.,LTD.

[www.koreaoharma.co.kr](http://www.koreaoharma.co.kr)



## Category

Finished Pharmaceutical Products

## Company Profile

Korea Pharma Co., Ltd. has been working unstintingly to perform a role of guard in protecting and improving the national health and welfare since its foundation in 1974. In order to advance to become a global pharmaceutical manufacturer in the 21st century, Korea Pharma has built the cGMP manufacturing facility and conducted validation process to assure efficacy, safety, and stability of all products.

Korea Pharma Co., Ltd. has also established an advanced pharmaceutical manufacturing management standard and a perfect quality control system.

## Strengths

3Cs to Beautiful Companions for Society and Company Together

1. COMMUNICATION
2. COMMUNITY
3. COMPLIANCE

### CEO

Ms. Park, Eun-Hee

### Established Date

Sep. 03, 1974

### Employee No.

290

### Contact point

#### 1. Overseas Business

yangho.chun@koreapharma.co.kr

#### 2. Licensing In/Out

heeseung.kim@koreapharma.co.kr

#### 3. Overseas Branch

jeahoon.cho@koreapharma.co.kr



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	L-Aspartic Acid L-Ornithine Hydrate 3g	PARAMEL Powder	Adjuvant treatment of severe liver disease detoxification with cirrhosis and chronic hepatitis	Vietnam Georgia Ecuador	Approved

## Others

Korea Pharma Co., Ltd. is putting efforts to open a healthier future in the 21st century by concentrating all capabilities in the constant R&D on various types of pharmaceuticals, especially on ETC drugs since the establishment of the central laboratory.

# Korean Drug Co., Ltd



www.nicepharma.com



## Category

Finished Pharmaceutical Products

## Company Profile

We manufacture, distribute, export and import more than 180 medicines, health functional foods and cosmetics. Also, we are manufacturer of specific dosage forms such as combined with solutions and powders or tablets.

We have always been eager to be the most reliable and trustworthy pharmaceutical company that can bring the highest value to the society, clients and employees since our establishment in 1980.



## Strengths

1. Precision Quality
2. Global Networks
3. Highly Dedicated Personnel
4. Financial Stability

## Collaboration Opportunities

1. License IN/OUT
2. API Import
3. R&D Collaborations

### CEO

Mr. Sang Hun, Park

### Established Date

1980.01.10

### Employee No.

264

### Contact point

#### 1. Overseas Business

Jisun oh/82-2-529-6100(EXT.315)  
jsoh78@nicepharma.com

#### 2. Licensing In/Out

Kipyung Lee/82-2-529-6100(EXT.300)  
kpl8284@nicepharma.com

#### 3. Overseas Branch

Kipyung Lee/82-2-529-6100(EXT.300)  
kpl8284@nicepharma.com

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Levetiracetam 500mg	Levirotin 500mg	ANTI-EPILEPTICS	Vietnam	MFDS/KDC	N/A
2	Clopidogrel 75mg	Midorel	ANTITHROMBOTIC AGENTS	Vietnam	MFDS/KDC	N/A
3	Isotretinoin 20mg	Pectomucil Soft Capsule	ANTI-ACNE PREPARATIONS	Vietnam	MFDS/KDC	N/A
4	Cetirizine 2HCl 10mg	Allertec	ANTI-HISTAMINES SYSTEMIC	Singapore	MFDS/KDC	N/A
5	Lysozyme Cl 30mg, Ascorbic acid 150mg, Tocopherol acetate 50% 10mg, Lysozyme 2mg	Dentaforce Capsules	ALIMENTARY T. & METABOLISM, STOMATOLOGICALS	Yemen	MFDS/KDC	N/A
6	Alfuzosin HCl 10mg	Alfuzosina Triple	G.U.SYSTEM & SEX HORMONES, UROLOGICALS	Guatemala	MFDS/KDC	N/A

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Natural Product Extracts	KDC-14-1	Osteoporosis	Research	N/A
2		KDC-14-1-1	Atopy treatment	Product launch(2019)	N/A
3		KDC-16-1	Inflammatory bowel disease	Research	N/A
4		KDC-16-2	Improvements of Bowel movement	Raw material launch(2020)	N/A
5		KDC-16-2-1	Bowel immunity	Research	N/A
6		KDC-17-2-1	Anti platelet	Research	N/A
7		KDC-18-1	Sarcopenia	Research	N/A
8		KDC-18-2	Improve exercise	Research	N/A
9		KDC-19-1	Memory improvement	Research	N/A
10		KDC-20-1	Arthritis	Research	N/A
11	Lactobacillus	KDC-19-2	Inhibition of harmful bacteria & Bowel movement	Product launch(2021)	N/A

## Others

We ensure that expertise and capabilities of our company meets the global standards. We always do all our outmost in the maintenance of our GMP manufacturing site and to be the holder of pharmaceutical manufacturing techniques, expanding our know-how in licensing pharmaceutical products and knowledge in training personnel and transfer of technology, research and development of new products.

# Koreavaccine Co., Ltd.



[www.koreavaccine.com](http://www.koreavaccine.com)



## Category

Finished Pharmaceutical Products  
Vaccine  
Medical Device

## Company Profile

Koreavaccine's business domains consist of manufacturing, biological products along with professional services.

Koreavaccine provides services based on our established outstanding infrastructure as an incubator of various Korea's bio company.

Koreavaccine provides CMO services for vaccine and other biological products.

Also Koreavaccine provides major global pharma's domestic logistics and sales support as an CSO.

### CEO

Sung-Bae, Ha

### Established Date

Jan, 1965

### Employee No.

185

### Contact point

1. Overseas Business  
RA/+82-2-443-2008
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Strengths

1. manufacturing Pharmaceuticals
2. manufacturing Medical device
3. CMO, CLO, CSO



# KUKJE PHARM Co., Ltd.



<https://www.kukjepharm.co.kr/index.php?lang=eng>



## Category

Finished Pharmaceutical Products  
Cosmetics

## Company Profile

Kukje Pharma was established in 1959 and is a manufacturer and sales company of Pharmaceuticals, dealing with ETC, OTC, and cosmetics. We have about 120 specialty medicines such as antibiotics, circulatory, digestive and diabetes treatments medicines. Recently, we have expanded production by installing facilities for eye drops(Mono dose) and plan to ensure a stable supply of the products.

## Strengths

1. Leading manufacturer in ophthalmic pharmaceutical industry.
2. PIC/s GMP approval factory in Ansan, Korea
3. Production line for Disposable Eye-drops

## Collaboration Opportunities

1. Exporting(Finished Products)
2. Licensing In/Out
3. Importing(APIs)

### CEO

T. H. Nam(Mr)

### Established Date

Oct. 1959

### Employee No.

420

### Contact point

#### 1. Overseas Business

Trading Dept./trading@kukjepharm.co.kr

#### 2. Licensing In/Out

Develo. Dept./ykkim@kukjepharm.co.kr

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Cefminox Sodium	Cefminox Sodium for Injection	Ceparosporin antibiotics used for sepsis, tonsillitis, bronchitis, pneumonia, pyelonephritis, bladder inflammation, gallbladder inflammation, etc	China	MMPA
2	Sodium hyaluronate	Cualone eye drops	keratoconjunctival epithelial damage(caused by sjogren syndrome, dry eye syndrome, trauma, hard contact lens, etc.)	Cambodia, Vietnam	Vietnam MOH
3	Cefuroxime	Zincef tab	otitis media, sinusitis, bronchitis, pneumonia, pyelonephritis, cystitis, urethritis, furunculosis, gonorrhea, etc.	Cambodia, Vietnam	Vietnam MOH
4	Ceftriaxone sodium	Kukje Ceftriaxone Na inj	espiratory infection, ENT infection, renal & urinary tract infection, septicemia, meningitis, peritonitis, cholecystitis, etc.	Cambodia, Vietnam	Vietnam MOH
5	Aminocaproic Acid	Camile Cool eye drops	Eyestrain, conjunctival hyperemia, eye discomfort after swimming or sweating or dust gets in your eyes, when due to the ultraviolet rays, and other eye irritation, fester eyelids, discomfort when wearing hard contact lenses, eye itching, blurry(when a lot of gum, etc.)	Cambodia, Vietnam	Vietnam MOH

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	NEW product of eye drops	not yet fixed	Eye drops	MA(Expected to 2022)

# Kwangdong Phama Co., Ltd.



eng.ekdp.com



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product  
Health functional food, Beverage

## Company Profile

As a top leading pharmaceutical company in Korea, Kwangdong Pharmaceutical Co., Ltd. has been building its brand power in pharmaceuticals and healthcare products. Under the vision of becoming a 'Human Healthcare Brand Company', Kwangdong has dedicated to the health and happiness of its customers by providing unique value.

### CEO

SungWon Choi

### Established Date

October. 16, 1963

### Employee No.

1078

### Contact point

1. Overseas Business  
82-2-6006-7217  
katebang21c@ekdp.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Strengths

1. R&D work on a wide range of natural substance ingredients and materials.
2. Leader in healthy functional drinks and RTD tea drinks.
3. Health functional products based on our own know-how of turning Oriental medicine into science.

## Collaboration Opportunities

1. Import & Sales(Distribution)
2. Market survey
3. RA(Registration)

## Others

We are engaged in development, production, and market launch of ETC, OTC medicines and Health functional food for such Oriental medicine, Anti-cancer agents, Antibiotics, GI, Anti-inflammatory, Cardiovascular and Others.



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Korean Ginseng, White Poria, Juice of Rehmannia Root, Honey	Kwang Dong Kyung Ok Go	Immunity enhancement/ During and after disease, Constitutional weakness, Physical fatigue, Malaise, Involutional disorder	Mongolia	Mongolia
2	Paeonia lactiflora, Cnidium officinale, Cinnamon, Astragalus membranaceus, Glycyrrhiza uralensis, Zingiber officinale Rosc, Angelica acutiloba, Rehmanniae Preparata Radix, Jujube, Scangwhatang Viscous Ex	SSANG HWA TANG	Cold systptoms (runny and stuffy nose, sneezing, sore throat, coughing, phlegm, chill, fever, headache, joint and muscular ache)	USA	
3	Civet, oriental bezoar, Ginseng	Woo Hwang Chung Sim Won (Civet, Wonbang)	Stroke, Hypertension, Palpitation, Mental anxiety, Acute, Chronic convulsion, Autonomic nervous ataxia, insensibility	Japan, Vietnam, Mongolia, USA	Japan, Vietnam, Mongolia
4	Civet, oriental bezoar, Ginseng, Dioscorea Rhizome, Glycyrrhiza Radix, Typhae Pollen, Massa Medicata Fermentata, Glycine Semen Germinatum, Cinnamon Bark, Peony Root, Liriope Tuber, Scutellaria Root, Angelica Gigas Root, Saposhnikovia Root, Atractylodes Rhizome White, Bupleurum Root, Platycodon Root, Apricot Kernel, Poria, Cnidium Rhizome, Cattle Gallstone, Asini Corii Colla, Gazellae seu Saigae Cornu, Borneolum, Ampelopsis Radix, Ginger	Woo Hwang Chung Sim Won (Civet, Bienbang)	Stroke, Hypertension, Palpitation, Mental anxiety, Acute, Chronic convulsion, Autonomic nervous ataxia, insensibility	Japan, Vietnam, Mongolia, USA	Japan, Vietnam, Mongolia
5	Civet, oriental bezoar, Ginseng, Dioscorea Rhizome, Glycyrrhiza Radix, Typhae Pollen, Massa Medicata Fermentata, Glycine Semen Germinatum, Cinnamon Bark, Peony Root, Liriope Tuber, Scutellaria Root, Angelica Gigas Root, Saposhnikovia Root, Atractylodes Rhizome White, Bupleurum Root, Platycodon Root, Apricot Kernel, Poria, Cnidium Rhizome, Cattle Gallstone, Asini Corii Colla, Gazellae seu Saigae Cornu, Borneolum, Ampelopsis Radix, Ginger	Woo Hwang Chung Sim Won 50ml Suspension (Civet, Wonbang)	Stroke, Hypertension, Palpitation, Mental anxiety, Acute, Chronic convulsion, Autonomic nervous ataxia, insensibility	USA	
6	Civet, oriental bezoar, Ginseng, Dioscorea Rhizome, Glycyrrhiza Radix, Typhae Pollen, Massa Medicata Fermentata, Glycine Semen Germinatum, Cinnamon Bark, Peony Root, Liriope Tuber, Scutellaria Root, Angelica Gigas Root, Saposhnikovia Root, Atractylodes Rhizome White, Bupleurum Root, Platycodon Root, Apricot Kernel, Poria, Cnidium Rhizome, Cattle Gallstone, Asini Corii Colla, Gazellae seu Saigae Cornu, Borneolum, Ampelopsis Radix, Ginger	Woo Hwang Chung Sim Won 50ml Suspension (Civet, Bienbang)	Stroke, Hypertension, Palpitation, Mental anxiety, Acute, Chronic convulsion, Autonomic nervous ataxia, insensibility	Vietnam, USA	Vietnam
7	Anastrozole 1mg	A-dex Tab.	Breast cancer	Philippines	Philippines
8	Letrozole 2.5mg	Lenara Tablet	Breast cancer	Philippines	Philippines
9	Bicalutamide 50mg	Bicalude Tablet	Advanced prostate cancer in combination with LHRH analogue therapy or surgical castration	Vietnam, Philippines	Vietnam, Philippines
10	Tamoxifen Citrate 10mg & 20mg	Tamoxifen tab. 10mg & 20mg	Breast cancer	Hong Kong, Vietnam	Hong Kong, Vietnam
11	Sildenafil citrate 50mg	IGNIS ODF	Treatment of erectile dysfunction	Mongolia, Russia, Macau, Indonesia, Ecuador	Mongolia, Russia, Macau, Indonesia, Ecuador
12	Tadalafil 20mg	Tadalong ODF	Treatment of erectile dysfunction	Indonesia, Guatemala, Costa Rica, El Salvador, Nicaragua	Indonesia, Guatemala, Costa Rica, El Salvador, Nicaragua
13	Pine needle distilled concentrate (3-Carene 12.5~16.5%, Limonene 5~10%, Terpinolene 18~26%)	KWANGDONG Pine Max	Blood Sugar Lowering Effect		
14	Genseng(6 years 70mg/g), Liquoride, Honey, Sweet Flag, Poria Cocos, Polygala Root	RED GINSENG Stick	When physical strength is reduced, to increase immunity, to busy office workers, to study examinees, to exercise, to fatigue conditions.	Philippines, Taiwan	Philippines, Taiwan
15	RED GINSENG & ANTLER, Liquoride, Jujube, Sweet Flag, Poria Cocos, Polygala Root	RED GINSENG & ANTLER Stick	When physical strength is reduced, to increase immunity to busy office workers, to study examinees, to exercise, to fatigue conditions.	Taiwan	Taiwan
16	Ssanghwa Concentrate, GINGER	GINGER' SSANG HWA JIN	Ssanghwa Concentrate (Steamed Rehmannia Root, Jujube, arrowroot, Cnidium officinale, Astragal Radix, Angelica Gigas Root, Licorice, Peony Root, Ginger, Cinnamon Cortex), plant extract (dried Rehmannia glutinosa, ginseng, Poria), Honey, Ginger Concentrate	Australia	
17	Ssanghwa Concentrate, JUJUBE	JUUJUBE' SSANG HWA JIN	Ssanghwa Concentrate (Peony Root, Jujube, arrowroot, Ginger, Steamed Rehmannia Root, Astragal Radix, Cnidium officinale, Licorice, Angelica Gigas Root, Cinnamon Cortex, Jujube concentrate, Pear concentrate, Platycodon grandiflorus root, plant extract (Jujube, Angelica Gigas Root, Astragal Radix, Cnidium officinale, Peony Root, Atractylodes Rhizoma alba, Poria, Ginger, ginseng, Steamed Rehmannia Root, Cinnamon Cortex, Licorice)	Australia	
18	Ssanghwa Concentrate, RED GINSENG	RED GINSENG' SSANG HWA JIN	Ssanghwa Concentrate (Peony Root, Jujube, arrowroot, Ginger, Steamed Rehmannia Root, Astragal Radix, Cnidium officinale, Licorice, Angelica Gigas Root, Cinnamon Cortex), Red ginseng concentrate, plant extract (Acorus gramineus Solander, Poria, Licorice), arrowroot concentrate	Australia	
19	Use of 'Vegetable Ingredients' Reed root, Ionicerajaponica, Chinese matrimony vine, mulberry, mulberry leaf, longan, gardenia fruit, cinnamon, cuscutasseed, angelica root, asparagus, raisin berry extract	ALVARIN	Hangover Reliever	Australia	
20	Raisin berry extract (15,000mg/100ml)	Hutkae POWER	Hangover Reliever	Australia	
21	Ascorbic Acid 97% Granule 1,031.0mg/ Tab.	KWANGDONG VITAMIN C Tab. 1000mg	1. The prevention and treatment of scurvy 2. an increase in the required amount of debilitating diseases, vitamin C	Mongolia, Philippines	Mongolia, Philippines
22	Vitamin C(500mg), Vitamin B1, Vitamin B2, Vitamin B6, Vitamin B12	VITA 500 Stick (Vitamin-C, Vitamin-B complex)	1. The prevention and treatment of scurvy 2. an increase in the required amount of debilitating diseases, vitamin C	Mongolia, Philippines	Mongolia, Philippines
23	Probiotics (Enterococcus faecium, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus lactis, strepto coccus thermophilus, Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus animalis ssp. lactis Lactobacillus bifidum, Lactobacillus brevis Lactobacillus longum)	Kwangdong Live Lactobacillus(Stick)	It is taken to treat and prevent diarrhea, including infectious types such as rotaviral diarrhea in children and traveler's diarrhea. It is also taken by mouth to prevent and treat diarrhea associated with using antibiotics	Taiwan	Taiwan
24	Vitamin C and collagen supplementation	TOK TOK(Powder) Low molecular Collagen peptides	low molecular weight collagen peptides 2,500 Da + Vitamin C 30mg + Probiotics		
25	Vitamin C and collagen supplementation	Pomegranate Collagen 'JELLY' Stick	low molecular weight collagen peptides 1,000mg/Stick + Pomegranate concentrate	Taiwan	Taiwan
26	Vitamin C and collagen supplementation	VITA 500 Collagen 'JELLY' Stick	low molecular weight collagen peptides 1,000mg + Vitamin C 100mg		

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Metabolic disease	KD101	obesity	Clinical Trial	Self developed
3	Central Nervous System	KD501	dementia	Clinical test Phase II	License in from Elcomscience (Kor) Self developed

# Kyung Dong Pharmaceutical Co., Ltd.



[www.kdpharma.co.kr](http://www.kdpharma.co.kr)



## Category

API  
Finished Pharmaceutical Products  
Cosmetics

## Company Profile

Since the establishment in 1975, Kyung Dong Pharm. Co., Ltd. continues to pursue advancing the company goal of improving the quality of human lives and health by upholding the core values of diligence in quality and manufacturing and innovative development of pharmaceutical products through R&D. With the completion of GMP grade factory in 1987 and designation as KGMP company in 1991, Kyung Dong Pharm. has manufactured safe and reliable pharmaceutical products(FDF and API) in various formulations(cephalosporin, freeze dry medication, tablets, capsules, injections, etc.) with greater emphasis on quality and ever increasing ICH regulatory guidelines. Kyung Dong has continuously reinforced the R&D capacity and developing wide range incrementally modified drugs and high quality APIs for domestic and global market.

## Strengths

1. Highly competitive and experienced R&D ability and personnel.
2. EU-GMP grade manufacturing facilities and infrastructure equipped with high-tech equipments.
3. Stable and resilient domestic sales allows for non-restricted advance and investment into export and expansion into new areas.

## Collaboration Opportunities

Overseas FDF & API sales

## Others

Apart from wide range of pharmaceutical productst of FDF and API, Kyung Dong Pharm. Co., Ltd. also carry variety of food supplementary products, masks and cosmetic products.

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Ceftriaxone Na 1g, 2g	Ceftisone Inj.	3rd Gen. Cephalosporin	Vietnam, Phillipines, Cambodia, Yemen	GMP	
2	Rebamipide	Rebamide Tab.	Antiulcerant	Vietnam, Phillipines, Cambodia	GMP	
3	Cetirizine HCl	Cozoltec Tab.	Antihistamine	Vietnam, Cambodia, Pakistan,	GMP	
4	Flunarizine HCl	Headache Cap.	Migraine	Vietnam, Cambodia,	GMP	
5	Tramadol, Acetaminophen	Megaspen Tab.	Analgesic & Antipyretics	Vietnam, Myanmar, Cambodia	GMP	
6	Tramadol HCl	Campex Cap./Inj.	Analgesic & Antipyretics	Pakistan	GMP	
7	Acyclovir	Aclova Tab./Inj.	Antiviral	Chile, Pakistan, Cambodia, Yemen	GMP	
8	Cefuroxime Na	Cefuroxime	2nd Gen. Cephalosporin	Phillipines	GMP	
9	Ketorolac Tromethamine	Ketolan Inj	NSAIDs	Pakistan, Dominican Republic	GMP	
11	Roxatidine acetate HCl (API)	-	H2 Receptor Blocker	Japan, China	PMDA	
12	Risperidone (API)	-	Antipsychotics	Japan	PMDA	
13	Clopidogrel bisulfate (API)	-	Antithrombotics, Antiplatelet	Japan	PMDA	Form I bead

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	IMD	KD4001	Diabetes	Registration	
2	IMD	KD4002	Diabetes	Phase I	
3	IMD	KD4003	Diabetes	Registration	
4	IMD	KD4004	Diabetes	Registration	
5	IMD	KDF2001	Diabetes	Phase I	
6	IMD	KDF1901	Hypertensive	Phase III	
7	IMD	KD1903	Hypertensive	Pre-clinical	
8	IMD	KDF1905	Urinary system	Phase III	
9	IMD	KD2003	Urinary system	Research	
10	Clopidogrel Bisulfate (API)	-	Anti-platelet	Plant scale	Form II bead
11	Azilsartan (API)	-	Hypertensive	Plant scale	
12	Sitagliptin Phosphate (API)	-	Diabetes	Pilot scale	
13	Vonoprazan fumarate (API)	-	Peptic Ulcer	R&D	
14	Bilastine (API)	-	Antihistamine	R&D	
15	Pemafibrate (API)	-	Atherogenic Dyslipidaemia	R&D	
16	Bempedoic Acid (API)	-	Hypercholesterolemia	R&D	
17	Daprodustat (API)	-	Renal Anemia	R&D	





## Category

Biopharmaceuticals  
Medical Device  
Cosmetics

## Company Profile

Medytox is the only company in the world that developed three different types of botulinum toxin (Neuronox®, INNOTOX®, Coretox®) and HA filler. Prefilled syringe of botulinum and injection lipolysis are also under development. With the goal of growing as a global biotechnology company, Medytox has been continuously working on research to raise competitiveness in new drug development.

### CEO

Hyunho Jung

### Established Date

May 2nd, 2000

### Employee No.

634

### Contact point

#### 1. Overseas Business

International Business Team  
02-6901-5426  
junchungmdt@medytox.com

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

MEDYTOX Thailand  
02-6901-5822  
chung.w@medytox.com  
MDT International  
+81-03-6452-9606  
jangys@medytox.com

## Strengths

1. The only company to develop 3 types of botulinum toxin in the world
2. Completed phase 3 clinical trials of new botulinum toxin 'MT10109L'
3. Continuous R&D for new drug development

## Collaboration Opportunities

1. Developing local new Market
2. Marketing activities
3. Sales grow up



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Clostridium botulinum toxin type A (Hall strain)	Neuronox®	<ol style="list-style-type: none"> <li>1. Benign essential blepharospasm in adults aged 18 or more</li> <li>2. To treat foot deformities due to spasticity in pediatric cerebral palsy patients aged 2 or older</li> <li>3. To temporarily improve moderate to severe glabellar lines related to eyebrow wrinkle muscle (corrugator muscle) and/or procerus muscle activity in adults aged from 20 to 65</li> <li>4. Muscle spasticity: upper limb local muscle spasticity related to stroke in adults aged 20 or more</li> <li>5. Treatment of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adult patients 20~65 years of age</li> <li>6. Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain</li> </ol>	31 countries (Brazil, Chile, Colombia, Ukraine, etc)	
2	Hyaluronic Acid	Neuramis®	Wrinkles and folds on the face	36 countries (Chile, Colombia, Thailand, Indonesia, Ukraine, etc)	CE mark

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Biopharmaceuticals	Neuronox®	Glabellar Line	BLA	China
2		Neuronox®	Blepharospasm	BLA	China
3		MT10109L	Glabellar Line	Phase 3	US, EU, Canada
4		MT10109L	Lateral Canthal Line	Phase 3	US, EU, Canada
5		MT912	Macular Degeneration	Preclinical	
6		MT925	Type 1 Diabetes	Discovery	
7		MT927	Myasthenia gravis	Discovery	
8		MT981	Cancers	Preclinical	
9		MT107	Cancers	Preclinical	
10	Chemical Drug	MT921	Lipolysis Injection	Phase 3	Korea
11		MT106	Anticancer therapy	Preclinical	
12	Medical Device	Neuramis® Volume Lidocaine	Mid Face Volume		China
13		Neuramis® Deep Lidocaine	Nasolabial Folds		China
14		MT941	Osteoarthritis	Preclinical	Korea
15		MTP50	Perioral lines	Preclinical	
16		MTP51	Fine lines	Preclinical	
17		MT945	Chin Augmentation	Preclinical	
18		Health Supplements	MT961	Obesity	Phase 1
19			NAFLD (non-alcoholic fatty liver disease)	Preclinical	Korea

# Mitsubishi Tanabe Pharma Korea Co., Ltd.



[www.mt-pharma-korea.com/](http://www.mt-pharma-korea.com/)



## Category

Finished Pharmaceutical Products

## Company Profile

Mitsubishi Tanabe Pharma Korea Co., Ltd was established in 1989 as the Korean subsidiary of Mitsubishi Chemical Holdings Corporation, manufacturing and sales company with development, sales and manufacture in Korea.

We actively introduce and develop products from Mitsubishi Tanabe Pharma Corporation and other companies from other countries such as America and Europe.

We are manufacture high-quality injections in Korea and exports them to Germany, Japan, and China.

### CEO

Taehwan Ryu

### Established Date

1989

### Employee No.

145

### Contact point

Overseas Business & Global BD(Licensing In/Out)

Corporate & Strategy Department  
Strategy & Planning Group  
82-510-2571,572,573

Head of Dept.:  
hanjoon.kim@mt-pharma-korea.com  
Group leader:

younga.kim@mt-pharma-korea.com  
Assistant Manager:  
hana.choi@mt-pharma-korea.com

## Strengths

1. Focused on CNS
  - We expect to increase the company's brand value by focusing on the development of CNS and orphan drugs.
2. KGMP
  - Our factory obtained the KGMP Certificate in 1991 in order to manufacture products with good quality.
3. Well-regulated Compliance Program
  - Since MTPK formed a dedicated CP organization in 2015, MTPK has operated a Well-regulated compliance program with no CP violations.

## Collaboration Opportunities

1. License in
2. License out
3. Co-promotion
4. Export



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Alprostadil	EGLANDIN	A vasodilator for blood flow maintenance after revascularization (including transplantation, etc.)	Mongolia, Myanmar (Expected 2023)	Mitsubishi Tanabe Pharma Corporation
2	Argatroban	NOVASTAN	A safe anticoagulant that directly works on thrombin	Manufactured in 2022	Mitsubishi Tanabe Pharma Corporation
3	Dexamethasone Palmitate	Limethason	A well-recognized rheumatoid arthritis treatment	Japan, Germany, China	Mitsubishi Tanabe Pharma Corporation
4	Edaravone	Radicut	ALS treatment approved by FDA	-	Mitsubishi Tanabe Pharma Corporation
5	Diltiazem Hydrochloride	Herben	Primary treatment for patients with angina	-	Mitsubishi Tanabe Pharma Corporation
6	Remifentanil Hydrochloride	Ultiva	Fast onset & offset anesthetic without accumulation in the body	-	Aspen PharmaCare Holdings Ltd
7	Diquafosol sodium	Diquas-S	Treatment for dry eye	-	Santen Pharmaceutical Co Ltd

## Others

Focus Area : CNS, Neurology, Cardiology

# Osstem Pharma Co., Ltd.



www.osstempharma.com



## Category

Finished Pharmaceutical Products

Others

- Medical Device

- Quasi Drug



## Company Profile

Founded in 2015, Osstem Pharma Co., Ltd. strives for the portfolio expansion of the dental medicine products with sustainable R&D performance. Based on accumulated experience and infrastructure, our R&D Center has developed various prescription drugs, over-the-counter drugs, quasi-drugs and medical devices used in the dental field.

## Strengths

1. Product portfolio including medicine, medical device, and quasi-drug for total oral care
2. Consistent R&D investment
3. Expert network


## CEO

## Established Date

## Employee No.

## Contact point

1. Overseas Business  
070-5118-0742  
paulkim@osstempharma.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Aminocaproic Acid, Hydrated Silica, Pyridoxine HCl, Tetrasodium Pyrophosphate Hydroxyapatite	Vussen H Brightening Toothpaste	Put appropriate amount of toothpaste on your toothbrush and brush your teeth.	Europe, USA, China, Russia etc.	CPNP(Europe), VCRP(USA)	Formula without aminocaproic acid is also available.
2	Hydrated Silica, Hydrogen peroxide	Vussen 7 Whitening Toothpaste	Put appropriate amount of toothpaste on your toothbrush and brush your teeth.	Europe, USA, China etc.	CPNP(Europe), VCRP(USA)	
3	Hydrated Silica, Hydrogen peroxide	Vussen 15 Tooth Whitening Paste	Brush your teeth for three minutes, three times a day by putting an appropriate amount of toothpaste on the toothbrush. Continue using for 4 weeks.	USA, China etc.	VCRP(USA)	
4	Hydrated Silica, Hydrogen peroxide	Vussen 28 Tooth Whitening Paste	Brush your teeth for three minutes, three times a day by putting an appropriate amount of toothpaste on the toothbrush. Continue using for 4 weeks.	USA, China etc.	VCRP(USA)	
5	Hydrated Silica, Tricalcium Phosphate	Vussen S Sensitive Care Toothpaste	Apply about 2cm of the product to the cervical/gingival margin(sensitive area), massage with the finger for 1 minute, then brush with a soft toothbrush.	Europe, USA, China, Russia etc.	CPNP(Europe)	
6	Hydrated Silica, Sodium Floride	Vussen C Caviti Care Toothpaste	Put appropriate amount of toothpaste on your toothbrush and brush your teeth.	Europe, Asia-Pacific	CPNP(Europe)	
7	-	Vussen Double-wide Toothbrush	-	Europe, USA, China, Russia etc.	CPNP(Europe), VCRP(USA)	

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Basic Oral Pharmaceuticals		Antiseptic analgesic tablets	Released
2	Dental Stomatic Pharmaceuticals		Antibiotics used in periodontal pockets/Spary for halitosis	Basic Research
3	Oral Disinfectant Products		Gingivitis treat, inflammation reduction	Basic Research
4	Oral Hygiene Products		Halitosis treat gargle, prevention of implantitis	Basic Research
5	Dental Helath Products		Tooth hypersensitivity treat	Released
6	Teeth Whitening Products		Whitening gel for the cosmetic dentistry procedure	Released

# Pharmicell Co., Ltd.



[www.pharmicell.com](http://www.pharmicell.com)



## Category

Cell/Gene Therapy  
Cosmetics

## Company Profile

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy(Hearticellgram-AMI) in 2011. The company's business area divided into two sectors.

In the bio business sector, stem cell therapy R&D and sales business for curing obstinate disease and improving human health.

The biochemical division develops and produces Raw Material Pharmaceutical Intermediates(Nucleoside and mPEGs) needed for the development of new pharmaceuticals by global pharmaceutical companies.

Pharmicell Co., Ltd. will do its best to grow into a respected company for curing obstinate disease and improving human health.

### CEO

Hyun-Soo Kim

### Established Date

1968. 8. 20

### Employee No.

131

### Contact point

#### 1. Overseas Business

Young-su Kim  
External Relations  
02-3496-0146  
passion2015@pharmicell.com

#### 2. Licensing In/Out

N/A

#### 3. Overseas Branch

N/A

## Strengths

1. Stem Cell Therapy Products
2. Next Generation Dendritic Cell Therapeutic Vaccines.
3. Raw Material Pharmaceutical Intermediates

## Collaboration Opportunities

1. License Out
2. Export Raw Material Pharmaceutical Intermediates



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Stem Cell	Hearticellgram-AMI	Acute myocardial infarction	-	World first stem cell therapy product

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Cellgram-LC		Liver Cirrhosis	Phase 3 Clinical Trial
2	Cellgram-ED		Erectile Dysfunction	Phase 2 Clinical Trial
3	Cellgram-CKD		Chronic Kidney Disease	Phase 1 Clinical Trial
4	Cellgram-DC		Prostate, Ovarian Cancer	Phase 1 Clinical Trial

# PHARVIS



## Category

Finished Pharmaceutical Products  
Medical Device

## Company Profile

We will continue our research and development, and continue to produce and supply excellent medicines through continuous technological innovation based on our experiences and know-how accumulated over the past 40 years to become a leading company that contributes to customer satisfaction and national health development.

## Strengths

1. License & Development Collaboration
2. Strong CSO marketing
3. Export of Finished Products

## Collaboration Opportunities

1. Exporting Finished Pharmaceutical Products
2. Introducing new drugs

### CEO

Yong Eun, Choi

### Established Date

November, 1976

### Employee No.

108

### Contact point

#### 1. Overseas Business

N/A

#### 2. Licensing In/Out

Licensing & Business Team

Junho Paek

hoyattack@gmail.com

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Albendazole	Alssac Tab.	Anthelmintic	Cambodia	Market Authorization
2	Cetirizine HCl	Pharvis Cetirizine Dihydrochloride Tab	Antihistamine	Cambodia	Market Authorization
3	esomeprazole	Yesome Tablet 20mg	Peptic ulcer	Vietnam	Market Authorization
4	esomeprazole	Yesome Tablet 40mg	Peptic ulcer	Vietnam	Market Authorization

## Others

We also have medical devices made with the best technology. If you are interested, please feel free to contact us.

HYAGEN : Collagen-based tissue supplement

HemostopTR : Absorbent body-containing hemostatic products

JUVENCOLL: wounddressings

# PMG PHARM Co., Ltd.



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product

## Company Profile

PMG Pharm has been a leading pharm in the market for treatments of rheumatoid arthritis, osteoarthritis, anti-osteoporosis and related diseases and its main business has been focused on the development of DMARDs, DMOADs and NSAIDs etc. At 13 Mar 2012, a Layla Tab has been registered as a new treatment for the osteoarthritis. Layla is consisted of 12 medicinal plants which has been recognised as traditional herbal medicines for arthrosis. PMG Pharm is ready to expand its business by licensing out Layla.

## Strengths

1. Laying the foundations of a global pharmaceutical company for rheumatoid arthritis diseases
2. 'Small Giant' pharmaceutical company developing natural product-based new drug for osteoarthritis
3. Korea's leading pharmaceutical company specializing in arthritis

### CEO

Mr. Young Chin Chun

### Established Date

Dec. 2001

### Employee No.

87

### Contact point

#### 1. Overseas Business

Management Team  
008231-439-5470  
kthan@pmgpharm.co.kr

#### 2. Licensing In/Out

R&D & Scientific Team  
008231-475-5470  
hymoon@pmgpharm.co.kr

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	12 Herbal extracts 405.4mg	Layla Tab.	Osteoarthritis	Ecuador
2	Diacerein 50mg	Rudia Cap.	Osteoarthritis	na
3	Hydroxychloroquine sulfate	Duroc Tab. 100, 200, 300, 400mg	Rheumatoid arthritis, Anti-malaria	na
4	Tacrolimus	Tarsin Cap. 0.5, 1mg	Rheumatoid arthritis	na
5	Leflunomide	Rheumakin Tab. 10, 20mg	Rheumatoid arthritis	na
6	Cholecalciferol(VitD 1,000IU)	Admin Forte Tab.	VitD deficiency	na
7	Indomethacin 25mg	Indometa Cap.	NSAID	na
8	Naproxen/Esomeprazole 500/20mg	SynflexSafe Tab.	NSAID	na
9	Meloxicam	Morix Cap. 7.5mg, 15mg	NSAID	na
10	Celecoxib	Laxib Cap. 100, 200mg/Laxib Tab. 100, 200mg	NSAID	na
11	Ibandronate 150mg	Droban Tab.	Anti-osteoporosis	na

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	PK101		Osteoarthritis	Termination of Phase III clinical trial

## Others

Duroc Tab., a malaria treatment and effective for rheumatoid arthritis, is also known to be helpful in treatment of COVID-19. In fact, Duroc Tab. was exported to many countries such as France, Luxembourg, Turkey, Australia, and Dominican Republic for the purpose of treating COVID-19 in 2020 and is planned to be exported to South Africa as a malaria treatment in 2022.

# PROTOX Inc.



[www.iprotox.co.kr/eng/](http://www.iprotox.co.kr/eng/)



## Category

Finished Pharmaceutical Products  
Biosimilar  
Cosmetics

## Company Profile

PROTOX Inc. is a company which specialises in technology with the aim of development manufacturing technology and product of the prescription drug to contribute to a healthy and beautiful life for human.

To attain this goal, Prottox is in the process of development of product for aesthetic and therapeutic based on 'Botulinum Toxin'.

In 2020, Prottox achieved the approval of GMP, Clinical trial Phase I / II and Authorization for Export by MFDS.

Now Prottox is focusing on Clinical trial Phase III after acquiring IND for Phase III and development of new product line for Botulinum Toxin and Cosmetic.

Prottox will reach the ultimate goal of becoming a company that produces the highest quality product of 'Botulinum Toxin' in the world.

## Strengths

1. Over 99%, High Purity
2. Improving and Simplifying the manufacture process
3. One stop automatic system under sterile condition for production process with highly qualified custom machine

## Collaboration Opportunities

1. Sales Partnership
2. Registration&Sales Partnership
3. Exclusive Partnership



### CEO

Dong Bum, Lee

### Established Date

Nov 01, 2015

### Employee No.

71

### Contact point

1. Overseas Business  
Global Sales Team  
+82-70-4018-8236  
alexlim@iprotox.com
2. Licensing In/Out  
Global Sales Team  
+82-70-4018-8236  
alexlim@iprotox.com
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Clostridium botulinum Toxin Type A	BTSA9	Against wrinkles, especially Glabellar Line	South East Asia, China, Brazil, Japan, Middle East, Europe, Australia, etc. (potential buyer)	Approved KGMP, IND for Clinical trial Phase III and Authorization for Export by MFDS

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Botulinum Toxin Type A	BTP001	Glabellar Line	Phase III

## Others

- About Botulinum toxin Product of PROTOX
  - Use of strains identified as Clostridium Botulinum ATCC 3502
  - Secure stable raw material production process technology by simplifying manufacturing process
  - Produces 99% or more high purity undiluted solution
    - ⇒ High purity product production is related to reducing the risk of resistance as the amount of active ingredient used per vial is reduced
- About R&D and Marketing Status
  - 2019 : Completion of pre-clinical study with rat and monkey
    - Cooperation with potential buyer from abroad since CPHI China 2019 attended as an exhibitor
  - 2020 : Approved GMP, IND for Clinical trial phase I / II and Authorization for Export by MFDS
  - 2021 : Completion of Clinical trial Phase I / II
  - 2022 : Approved IND for Clinical trial phase III by MFDS
    - Starting clinical trial phase III
    - Attending as an exhibitor in CPHI sea 2022

# QL Pharma Co., Ltd.



<http://www.ql-pharma.co.kr/eng/>



## Category

Finished Pharmaceutical Products

## Company Profile

QL PHARMA(Formerly Pharmatronic) was established in January 2005 with the corporate philosophy of "Service & Medicine". Since then, we have striven to make significant contributions on improving the health and happiness of mankind. We focus all our resources on our target markets of Urology and ENT to emerge as a leading specialist in the field. Apart from sales, distribution, and manufacturing, we also focus on in-licensing to provide better care for patients in Korea.

We will continue to do our very best to make improvements in all that we do, firm in the belief that corporate growth is predicated on 'Customer Satisfaction' and 'Customer Delight.'

## Strengths

1. Specialisation in Urology and ENT
2. Strength in marketing, sales, and distribution
3. kGMP certified manufacturing facility

## Collaboration Opportunities

In-licensing of Urology and ENT products

### CEO

Mr Seung Ha Lee

### Established Date

1st of January, 2005

### Employee No.

About 90

### Contact point

1. Overseas Business  
Business Development  
+82-2-3141-2720  
iluv1018@naver.com
2. Licensing In/Out  
Business Development  
+82-2-3141-2720  
iluv1018@naver.com
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Finasteride 1mg	Mosiamo Tab.	Male androgenetic alopecia	-	kGMP certified/ MAA in Korea
2	Finasteride 5mg	Qloid Tab. 5mg	Benign prostatic hyperplasia	-	kGMP certified/ MAA in Korea



# Richwood Pharmaceutical Co., Ltd.



www.richwood.net



## Category

API  
 Finished Pharmaceutical Products  
 Herbal Medicinal Product  
 Dietary Supplements

## Company Profile

Richwood has established an optimal process for all manufacturing stages- from product planning to rollout-as a contract development and manufacturing organization(CDMO) that meets the global pharmaceutical manufacturing standards. It supplies the best products catering to clients' needs through close communication with clients.

Focus Area : CDMO, Natural products, Finished products, Dietary Supplements

## Strengths

1. CDMO
2. Natural product-based medicines
3. GPCG series and 3-layer tablet machine

### CEO

Mr. JungSuk Lee

### Established Date

March, 1974

### Employee No.

204 persons

### Contact point

1. Overseas Business  
+82-2-2262-7550
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A




## Main Products

No.	Main Ingredient	Product name	Use	Remarks
1	Acetaminophen+Tramadol HCl	Acetracet Tab. Acetracet Semi Tab.	Acute, chronic pain reliever	325/37.5, 162.5/18.75mg
2	Amlodipine besilate	Novatension Tab.	Hypertension	5mg
3	Atorvastatin calcium trihydrate	Atolva Tab.	Hyperlipidemia	10, 20mg
4	Baclofen	Richwood Baclofen Tab.	Skeletal muscle relaxants	10mg
5	Bepotastine besilate	Betastine Tab.	Antihistamine	10mg
6	Diosmin	Diomax Tab.	Blood circulation enhancer	600mg
7	Ebastine+Pseudoephedrine HCl	Ebaco SR Cap.	Nasal decongestant, Antihistamine	10/120mg
8	Epinastine HCl	Alsnapin Tab.	Antihistamine, Antiallergy	10mg
9	Ethyl Icosapentate	Richwood Ethyl Icosapentate Soft Cap.	Antiatherosclerotic, Hyperlipidemia	300mg
10	Levodropropizine	Levorich Tab.	Antitussives & Expectorants	60mg
11	Artemisia asiatica 95% Ethanol Extract (20→1)	Patisren Tab. Patisren S Tab.	Anti-peptic ulcer	60mg, 90mg
12	Centella Titrated Extract	Womanzia Tab.	Blood circulation enhancer	30mg
13	Ginkgo Leaf Dried Extract	Ginkgopil Tab.	Blood circulation, Brain function	240mg
14	Levocetirizine HCl	Citirizine Tab.	Antihistamine, Antiallergy	5mg

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Finished product	RW5317	Anti-diabetics	Under development
2	Finished product	RW5417	Anti-diabetics	Under development
3	Finished product	RW5121	Fever reducer, Pain reliever	Under development
4	Finished product	RW5221	Fatigue recovery	Under development
5	Finished product	RW5321	Blood circulation, Brain function	Under development
6	Finished product	RW5222	Hypertension	Under development
7	API	RW0120	Fever reducer, Pain reliever	Under development
8	API	RW0221	Fever reducer, Pain reliever	Under development
9	API	RW0421	Fatigue recovery	Under development



### Category

Finished Pharmaceutical Products  
Herbal Medicinal Product

### Company Profile

RP Bio. is CMO by OEM/ODM specializing in Soft Gelatine Capsules for pharmaceutical and health functional food formulations since 1983. Initially founded as a J/V between R.P. Scherer USA and Daewoong Pharmaceutical Co., Ltd. Korea. RP Corp. boasts high quality production as a Korean company to pass international audits.

### Strengths

1. Korea's No.1 Pharmaceuticals & Dietary Supplement OEM/ODM Service Provider :  
Market share 70%(soft capsule)
2. 100% Pass Rate for facility audits

#### CEO

Nam-gi Kim, Jae-hoon Yoon

#### Established Date

Oct. 1983

#### Employee No.

521

#### Contact point

1. Overseas Business  
82-2-2002-9800  
[http://www.rpskorea.com/html/en/contactus\\_consulting.php](http://www.rpskorea.com/html/en/contactus_consulting.php)
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

### Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Ursodeoxycholic acid	Ursa	Hepatics	China, Vietnam, Myanmar	Soft gels
2	Korea Ginseng	Ginsatine	Koear Ginseng Multivitamin	Vietnam, Cambodia, Myanmar	Soft gels
3	Ibuprofen, pamabrom	Ezn6 EVE	Pain Reliever	-	Soft gels
4	Acetaminophen etc.	Whituben Q	Cold Medicine	-	Soft gels
5	Milk-thistle(silymarin)	Ener-Liver	Hepatics	Vietnam, Malaysia	Soft gels

# SAEHAN Pharm. Co., Ltd.

 SAEHAN PHARM. CO., LTD.

[www.shpharm.co.kr](http://www.shpharm.co.kr)



## Category

Finished Pharmaceutical Products  
Herbal Medicinal Product

## Company Profile

SAEHAN Pharm. Co., Ltd., a pharmaceuticals company in Korea, was founded in 1980 and has greatly contributed to supplying consumers with high-quality medicines.

In 2018, SAEHAN reconstructed their factory located in An Seong city, with state-of-the-art and high level of GMP compliance in accordance with PIC/S & EU GMP guideline as well as Korean cGMP.

This up-to-date GMP plant produces mainly oral solid dosage form of both Pharmaceuticals and healthy functional foods. SAEHAN is designing new production portfolio of their own and is also searching for an opportunity to enlarge their portfolio by contract manufacturing.

We welcome your contact.

### CEO

Sung-Suk Oh, Jang-Suk Oh

### Established Date

1980-10-01

### Employee No.

30~40

### Contact point

#### 1. Overseas Business

RA&BD Dept/82-2-553-7417  
development@shpharm.co.kr

#### 2. Licensing In/Out

RA&BD Dept/82-2-553-7417  
development@shpharm.co.kr

#### 3. Overseas Branch

RA&BD Dept/82-2-553-7417  
development@shpharm.co.kr

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Orphenadrine Citrate 50mg	Opheryl 50 SR Tab.	Muscle relaxants	-
2	Pregabalin 75mg, 150mg	Freeeca Cap.	Antiepileptics	-
3	Gabapentin 100mg, 300mg	Neurontic Cap.	Antiepileptics	-
4	Clopidogrel 75mg	Clodril Tab.	Platelet Aggregation Inhibitors	-
5	Sarpogrelate 300mg	Newplag SR Tab.	Platelet Aggregation Inhibitors	-
6	Donepezil 5mg, 10mg	Neocept Tab.	Anti-Alzheimer Agents	-
7	Zaltoprofen 80mg	Zaltozen Tab.	Anti-inflammatory agent	-

# Samil Pharm. Co., Ltd.



www.samil-pharm.com



## Category

Finished Pharmaceutical Products  
Medical Device  
Cosmetics

## Company Profile

Samil Pharm. is one of the oldest and well-known pharmaceutical companies in South Korea established in 1947. The company is mainly manufacturing eye drops, ointments, tablets, and granules and distributing the products worldwide. The major fields of interest are ophthalmology, hepatology, neurology, gastroenterology, and musculoskeletal disease. The company announced its new CI and slogan, "360 degree Human Care", in 2017 and expanding its global presence and operations.

## Strengths

1. The first and oldest Korean company specialized in ophthalmic therapy and care
2. Global Eye Drop CMO/CDMO with state-of-the-art technology
3. Long-term and strong partnership experiences with various multi-national companies all over the world

## Collaboration Opportunities

1. Ophthalmology products CMO/CDMO service
2. Licensing-in opportunity



### CEO

Seungbum Huh

### Established Date

1947.10.07

### Employee No.

467 (as of Dec 31, 2021)

### Contact point

#### 1. Overseas Business

Sophia Minji Song  
Global BD Specialist,  
Overseas Business Team  
Tel: +82 2 520 0395  
Email: minji.song@samil-pharm.com

#### 2. Licensing In/Out

Joonman Kim  
Director, BD Team  
Tel: +82 2 520 0385  
Email: jmkim@samil-pharm.com

#### 3. Overseas Branch

##### Vietnam

Hui Chang Kim  
General Manager  
Tel: +84 8 6255 6889  
Email: recon7781@samil-pharm.com

##### Canada

Sei H. Lee  
Deputy General Manager  
Overseas Business Team  
Tel: +1 778 372 8370  
Email: seihlee@samil-pharm.com

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Remarks
1	Ofloxacin 3mg/mL Ophthalmic Ointment	EyfloX	Topical treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, tarsadenitis, and keratitis and also as an aseptic measure in ophthalmic surgeries pre- and post-operatively	Vietnam, Cambodia, Yemen, others	Korean brand name: OcuFloX
2	Tobramycin 3mg/mL Ophthalmic Ointment	Eyrus	Topical treatment of ocular bacterial infections including blepharitis, dacryocystitis, hordeolum, conjunctivitis, keratitis, and corneal ulcer	Vietnam, Cambodia, Yemen, others	Korean brand name: OcuRacin
3	Acyclovir 30mg/g Ophthalmic Ointment	Herpacy	Treatment of keratitis caused by herpes simplex virus	Vietnam, Cambodia, Yemen, others	Korean brand name: Herpecid
4	Polymyxin B sulfate 6,000IU, Neomycin sulfate 3mg (potency), Dexamethasone 1mg / Ophthalmic Suspension & Ointment	Forus	Treatment of conjunctivitis, blepharitis, and keratitis caused by strains of the microorganisms susceptible to polymyxin B sulfate and neomycin sulfate	Vietnam, Cambodia, Yemen, others	Korean brand name: Forus

## R&D Pipeline

No.	Classification	Use	Stage of Development	Remarks
1	Aramchol Tab	NASH	Phase 3	License-in product
2	Lorecivivint	Knee osteoarthritis	Phase 3	License-in product
3	Zerviate Eye Drop	Conjunctivitis	NDA	License-in product
4	KSR-001 Eye Drop	Dry eye	Phase 3	R&D product

## Others

### CMO/CDMO Specialized in Ophthalmic Solutions

To expand global presence and operations, Samil Pharm will start to operate its new plant specialized in ophthalmic solutions from Q3 2022. The company's new plant is located in Ho Chi Minh City, Vietnam and its new manufacturing facilities strictly meet global GMP standards and requirements. The company will provide competitive and effective CMO/CDMO services, such as technology transfer, analytic testing, manufacturing, and others, to clients with 70 years of experiences in ophthalmology.

### Long-Term and Strong Partnership Experiences with Various Multi-National Companies

Begin with the technical alliance between Wellcome (UK, current GSK) and Samil Pharm. in 1970, Samil Pharm. has successfully engaged various partnerships with many multi-national companies. Now, the company has plentiful experiences in manufacturing, sales & marketing, and distribution of original and generic pharmaceutical products more than 50 years.

The company's notable Partnership experiences are strategic business partnerships with Allergan (USA) and Laboratory Thea (France). With these major Partnership, the company has strengthened its eye therapy and care business in S. Korea. Recently, the company has signed other licensing agreements with various multi-national companies for NASH, OA, and other treatments to strengthen its portfolios, and the company is continuously seeking potential business opportunities with other companies worldwide.

# SAMSUNG PHARM Co., Ltd.

**SAMSUNG PHARM**  
삼성제약주 Since 1929

[www.sspharm.co.kr](http://www.sspharm.co.kr)



## Category

Finished Pharmaceutical Products  
Quasi Drug

## Company Profile

Samsung Pharm was founded on August 15th, 1929 on the ideology of "Protection of People's Health". As human life is highly prized, there is no greater value and hope than life in the world. Having life act as the foundation of human life, Samsung Pharm have been making every effort to develop the most medicine in order to promote people's health and overcome various disease. Samsung Pharm will do our best to develop the outstanding medicine.

## Strengths

1. Specialized in Injections
2. Manufacturing of lyophilized drug products

### CEO

Kim, Ki-Ho

### Established Date

1929

### Employee No.

90

### Contact point

1. Overseas Business  
82-31-353-6681  
[human@sspharm.co.kr](mailto:human@sspharm.co.kr)
2. Licensing In/Out  
82-31-353-6681  
[human@sspharm.co.kr](mailto:human@sspharm.co.kr)
3. Overseas Branch  
82-31-353-6681  
[human@sspharm.co.kr](mailto:human@sspharm.co.kr)

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	piperacillin sodium 1g sulbactam sodium 0.5g	Combicin(injection)	Antibiotics	-
2	tramadol hydrochloride 50mg	Toranzin(injection)	Antipyretic analgesic & antiinflammatory	-
3	piroxicam 20mg	Rheoma(injection)	Antipyretic analgesic & antiinflammatory	-
4	hyaluronidase 1500IU	Hyloline(injection)	Remedies for Arthritis	-
5	acetaminophen 300mg, anhydrous caffeine 30mg	Panto-A(oral Solution)	Relief of common cold Symptoms	-
6	riboflavin 5mg thiamine nitrate 10mg ursodeoxycholic acid 50mg	Sulgidam 50mg(soft capsule)	Liver & Bile disease	

# SCM Lifescience, Inc.



<http://www.scmlifescience.com/en/>



## Category

Finished Pharmaceutical Products  
Cell/Gene Therapy

## Company Profile

SCM Life Sciences is a biotech company that provides cell therapy products that can treat incurable disease. SCM will provide hope for the lives of patients with incurable diseases through open innovation leading innovation by supplying high-purity, high-efficiency, high-quality cell therapy products through cell separation and manufacturing technology based on its proprietary Subfractionation Culturing Method.

## Strengths

1. Subfractionation Culturing Method
2. High-purity, high-efficiency, high-quality cell therapy product
3. Securing supply capacity through new cGMP construction

## Collaboration Opportunities

1. Research cooperation
2. Technology export
3. Investment in promising companies

### CEO

SONG SUN UK

### Established Date

July 2, 2014

### Employee No.

55

### Contact point

#### 1. Overseas Business

Financial & Business Management Dept.  
032-881-3600  
scmga@scmlifescience.com

#### 2. Licensing In/Out

Financial & Business Management Dept.  
032-881-3600  
scmga@scmlifescience.com

#### 3. Overseas Branch

Financial & Business Management Dept.  
032-881-3600  
scmga@scmlifescience.com

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Moderate to severe atopic dermatitis			Phase 2 clinical trial	The report is expected to be published next year.
2	Chronic graft-versus-host disease			Phase 2 clinical trial	Orphan drug designation in development stage
3	acute pancreatitis			Phase 2 clinical trial	Orphan drug designation in development stage, The report is expected to be published next year.

# Sinil Pharmaceutical Co., Ltd



<https://www.sinilpharm.com/eng/company/greeting.php>



## Category

Finished Pharmaceutical Products  
Medical Device  
Cosmetics



## Company Profile

Founded in 1971, we, Sinil Pharmaceutical Co., Ltd have made our fullest efforts to research and spread outstanding pharmaceutical products over the last 44 years. Since being listed in KOSDAQ in 1999, we have actively invested in manufacturing facilities and R&D activities to comply with the international standards

## Strengths

1. License & Development Collaboration
2. Export of Finished Products
3. Plaster/Patch Products

### CEO

Jaehyun Hong

### Established Date

1971.11

### Employee No.

363

### Contact point

1. Overseas Business  
markchoi@sinilpharm.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## New transdermal preparation by TDDS

Category	Preparation	Ingredient	Stage
Pharmaceuticals	Patch	Rivastigmine	Launched
		Tulobuterol	
		Lidocaine	
		Fentanyl	R&D Finished
		Nicotine	
		Buprenorphine	
		donepezil	R&D in progress
		oxybutynin	
		selegiline	
	Rotigotine		
	Granisetron		
	Ketoprofen		
	Plaster	Diclofenac Sodium	Launched
		Flurbiprofen	
		Diclofenac diethylammonium	
		Loxoprofen sodium	
		Indomethacin	
		Glycol salicylate, Menthol	
Methyl salicylate, Menthol			
Menthol			
		R&D finished	

## R&D Pipeline

No.	Reference Product (Originator)	APIs of Original Products	Indications
1	VIREAD Tab. (Gilead)	Tenofovir Disoproxil Fumarate 300mg	Hepatitis Bvirus(HBV) HIV/AIDS
2	TRAGENTA TAB. (Boehringer-Ingelheim)	Linagliptin 5mg, 2.5mg	Anti-diabetics
3	TRAGENTA DUO TAB. (Boehringer-Ingelheim)	Linagliptin 2.5mg Metformin HCl(1000, 850, 500mg)	Anti-diabetics
4	FARXIGA Tab. (AstraZeneca)	Dapagliflozin Propanediol (10mg, 5mg)	Anti-diabetics
5	XIGDUO XR (AstraZeneca)	Dapagliflozin + MTF(XR) (10/1000, 10/500.5/1000.5/500)	Anti-diabetics
6	ATOZET Tab. (MSD)	Atorvastatin+Ezetimibe (80/10, 40/10, 20/10, 10/10)	Anti-hyperlipidemia
7	LIXIANA Tab. (Daiichi Sankyo)	Edoxaban Tosilate (60, 30, 15)	Anti-coagulants
8	JANUMET Tab. (Merck)	Sitagliptin Phosphate (100, 50, 25mg)	Anti-diabetics
9	JANUMET XR Tab. (Merck)	Sitagliptin + Metformin (100/1000, 50/1000, 50/500)	Anti-diabetics
10	LYRICA 50, 25 (Pfizer)	Pregabalin 50, 25	Epilepsy, neuropathic pain, fibromyalgia, etc.

# SK bioscience, Ltd.



<https://www.skbioscience.co.kr/en/main>



## Category

Vaccine  
Recombinant DNA  
Cell/Gene Therapy

## Company Profile

SK bioscience is an innovative biopharmaceutical company, standing committed to global pandemic preparedness in vaccine development and manufacturing to create more equitable access to vaccines. In leveraging strengths on cutting-edge vaccine development technologies, SK bioscience has been dedicated to improving healthcare from prevention to cure across the globe. Under collaborations of domestic and international governments, regulatory agencies, healthcare providers, doctors and medical experts, SK bioscience has firmly established globally certified R&D and manufacturing technologies. All of SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

## Strengths

1. R&D
2. Vaccine Manufacturing
3. Global Partnership / Network

## Collaboration Opportunities

1. CMO/CDMO
2. Vaccine
3. CGT/Bio Platform



### CEO

Jaeyong Ahn

### Established Date

July 1st, 2018

### Employee No.

1111

### Contact point

1. Overseas Business  
SKBS.MAL.help@skdiscovery.com  
02-2008-2200
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Main Products

No.	Main Ingredient	Product name	Use	Global Quality Certification /Market Authorization
1	2 kinds of subtype A and 2 kinds of subtype B of purified inactivated influenza virus surface antigen	SKYCellflu Quadrivalent prefilled syringe	Prevention of influenza diseases caused by influenza A viruses and influenza B viruses contained in this vaccine for adults and children 6 months of age and older.	WHO PQ
2	2 kinds of subtype A and 2 kinds of subtype B of purified inactivated influenza virus surface antigen	SKYCellflu prefilled syringe	Prevention of influenza diseases caused by influenza A viruses and influenza B viruses contained in this vaccine for adults and children 6 months of age and older.	WHO PQ
3	Attenuated varicella live virus	SKYZoster Inj	Prevention of herpes zoster in adults 50 years of age or older	
4	Attenuated varicella live virus	SKYVaricella Inj.	Prevention of varicella infection in children aged 12 months to 12 years	WHO PQ
5	Typhoid composed of Vi polysaccharide conjugated to diphtheria toxoid	SKYTyphoid Multi Inj.	Prevention of typhoid infection in children aged 6 months to adult 45 years	WHO PQ(applied)

## R&D Pipeline

No.	Classification	Use	Stage of Development
1	SARS-CoV2 virus vaccine	COVID-19	Phase III Clinical Trial
2	Combo Vaccine (SARS-CoV2 + influenza virus)	COVID-19+Flu	Preclinical
3	Sarbecovirus Vaccine	Sarbecovirus	Preclinical
4	SARS-CoV2 virus vaccine (Nasal Spray)	COVID-19	Preclinical
5	Pneumococcal Vaccine	Pneumococcal Disease	Phase II Clinical Trial
6	Obesity Vaccine	Obesity	Preclinical
7	Respiratory Syncytial Virus (RSV) Vaccine	RSV	Preclinical
8	Non-Replicating Rota Virus (NRRV) Vaccine	Non-replicating rotavirus	Phase II Clinical Trial
9	Cervical Cancer Vaccine	Cervical Cancer	Phase I/II Clinical Trial
10	invasive Non-Typhoidal Salmonella (INTS) Vaccine	invasive Non-Typhoidal Salmonella	Preclinical
11	Hepatitis A Vaccine	Hepatitis A	Preclinical



# SK Chemicals Co., Ltd.



www.skchemicals.com



## Category

API  
Finished Pharmaceutical Products  
Herbal Medicinal Product

## Company Profile

SK chemicals is a leading pharmaceutical company promoting public health through innovations in new synthetic drugs, natural products, biotechnology, and more. Also, SK chemicals has been actively expanding its alliance with domestic and overseas partners to accelerate mid- to long-term growth.

## Strengths

1. R&D capability(developed 1st new chemical medicine and 1st new herbal medicine in Korea)
2. EU-GMP certified manufacturing facility(oral/transdermal)

## Collaboration Opportunities

1. In-licensing for domestic development and marketing
2. Out-licensing of R&D pipeline for development outside Korea



### CEO

James Jeon

### Established Date

1988 (for Pharma Biz)

### Employee No.

655 (for Pharma Biz, Dec 31, 2021)

### Contact point

#### 1. Overseas Business

N/A

#### 2. Licensing In/Out

Licensing & Business Development Team  
Jeonghyun Mun  
skchemicalsBD@partner.sk.com

#### 3. Overseas Branch

N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Rivastigmine	Rivastigmine patch	Alzheimer's disease	EU, Canada, Brazil, Colombia, Mexico, Saudi Arabia	EU-GMP certified facility
2	Omeprazole	Omeprazole tablet	Gastric ulcer	Germany, Switzerland	EU-GMP certified facility
3	Piroxicam	Trast patch	Arthritis	China, Saudi Arabia	
4	Ginkgo biloba extract	Ginexin tablet	Blood circulation enhancer	Saudi Arabia	


## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	IMD	SKP205	Migraine	pre-registration
2	IMD	SID1806	Arthritis	Phase 3
3	NCE	SKR206	Nonalcoholic steatohepatitis	Discovery
4	NCE	SKR207	Idiopathic Pulmonary Fibrosis	Discovery
5	NCE	NCE201	Nonalcoholic steatohepatitis	Preclinical
6	NCE	NCE202	Nonalcoholic steatohepatitis	Preclinical
7	NCE	NCE203	Idiopathic Pulmonary Fibrosis	Preclinical
8	NCE	NCE204	Nonalcoholic steatohepatitis	Discovery
9	NCE	NCE205	Idiopathic Pulmonary Fibrosis	Discovery

# Standigm Inc.

## Standigm®

[www.standigm.com](http://www.standigm.com)



### Category

AI Drug Discovery

### Company Profile

Standigm is a workflow AI-driven drug discovery company headquartered in Seoul, South Korea and Standigm has expanded its operations across the world, recently opening offices in the U.S. and UK. Standigm has proprietary AI platforms encompassing novel target identification to compound design, to generate commercially valuable drug pipelines. Founded in 2015, Standigm has established an early-stage drug discovery workflow AI to generate multiple First-in-Class compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow, and the automation effort has been expanding to the whole drug discovery process based on Standigm AI platforms, including Standigm ASK™ for novel target discovery, Standigm BEST™ for novel compound generation.

#### CEO

Jinhan Kim & Sojeong Yun

#### Established Date

2015.05.04

#### Employee No.

80

#### Contact point

##### 1. Overseas Business

BD team/+82.2.501.8118  
yeji.kim@standigm.com

##### 2. Licensing In/Out

BD team/+82.2.501.8118  
yeji.kim@standigm.com

##### 3. Overseas Branch

UK office/+44.1223.736110  
heejung.koo@standigm.com  
USA office/N/A/  
daehee.han@standigm.com

### Strengths

1. AI technologies encompassing novel target identification to compound design
2. Web lab for synthesis for accelerating drug discovery process
3. Multiple pipelines derived from own AI technologies

### Collaboration Opportunities

1. Pipeline licensing out
2. AI platform partnership



### Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	AI software	Standigm ASK	Target identification	USA	PCT
2	AI software	Standigm BEST	Compound design	USA	PCT

### R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Drug candidate	MP00103	TNIK inhibitor	Hit to lead
2	Drug candidate	SP010	WRN inhibitor	Hit to lead
3	Drug candidate	SP009	STK25 inhibitor	Hit to lead
4	Drug candidate	MP00307	P Kinase inhibitor	Hit identification
5	Drug candidate	EP002	DCLK1 inhibitor	Lead optimization

# Taejoon Pharmaceutical Co., Ltd.

**TAEJOON** 태준제약

<http://www.taejoon.co.kr/en/>



## Category

Finished Pharmaceutical Products

## Company Profile

Established in 1978, Taejoon Pharmaceutical Co., Ltd. ("Taejoon") is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI. With a vision to become the best global pharmaceutical company in the specialized area, Taejoon has been building up company's future growth by focusing its corporate resources; specialization, global marketing, and R&D innovation. In particular, Taejoon has acquired US and EU GMP certifications to secure global competitiveness and maintains state-of-the-art manufacturing facilities.

### CEO

Tae Young Lee

### Established Date

1978

### Employee No.

376

### Contact point

1. Overseas Business  
Business Development  
02-799-0072  
jhlee2@taejoon.co.kr
2. Licensing In/Out  
Business Development  
02-799-0072  
jhlee2@taejoon.co.kr
3. Overseas Branch  
Business Development  
02-799-0164  
grchoi@taejoon.co.kr

## Strengths

1. Ophthalmic IMD
2. Contrast media IMD
3. GI IMD



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Cyclosporine	Cyporin N Eye drop 0.05%	Dry eye			Launched
2	Latanoprost	Xalost-S Ophthalmic Solution	Glaucoma		Nigeria	Launched
3	Latanoprost	Xalost Ophthalmic Solution	Glaucoma	EU, China, Nigeria, Indonesia	EU, China, Nigeria, Indonesia	Launched
4	Latanoprost, Timolol maleate	Xalostplus Ophthalmic Solution	Glaucoma	EU, Hong Kong	EU, Hong Kong	Launched
5	Gadobutrol	Gadobirx Pre-filled Syringe Injection	Contrast enhancement of cranial and spinal MRI			Launched
6	Iohexol	Iobrix INJ 240/300/350		Thailand, Philippines	Thailand, Philippines	Launched
7	Polyethylene glycol 3350	CleanViewAL Powder	Bowel cleansing			Launched

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	IMD	Undecided	Eye disease	Phase II
2	IMD	Undecided	Eye disease	Phase III
3	IMD	Undecided	Eye disease	Preclinical
4	IMD	Undecided	Gastrointestinal disease	Preclinical
5	IMD	Undecided	Gastrointestinal disease	Phase I

# TAI GUK PHARM. Co., Ltd.



## Category

Finished Pharmaceutical Products  
Quasi Drug  
Cosmetics

## Company Profile

We, Tai Guk Pharm., are doing best to manufacture the world-class and high quality pharmaceutical products through stricter quality control and R&D Since 1957.

We have 3 factories(Buyeo, Hyangnam, Jangseong) and manage over 500 products such as pharmaceutical products, quasi drugs and health supplements in Korea. Plus, we have been exporting our high quality products to Vietnam, Cambodia, Singapore, Peru, etc.

## Strengths

1. Domina Cream(Hydroquinone) : Top selling freckles treatment in domestic(1996~2021 IQVIA)
2. Buyeo factory approved with EU-GMP and passed FDA audit

### CEO

Seungman Choi, Yeonhui Choi

### Established Date

1957

### Employee No.

349

### Contact point

1. Overseas Business  
82-2-3474-7761  
hnkang0806@taiguk.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Almagate	Partygel Suspension	Gastritis	Cambodia
2	Sucrafate Hydrate	Shumed Suspension	Gastritis	Vietnam
3	Oxethazaine, Dried aluminum hydroxide gel, Magnesium hydroxide	Barudon Suspension	Gastritis	Vietnam
4	Betamethasone Dipropionate, Clotrimazole, Gentamicine Sulfate	Neoderm Cream	Dermatitis	Singapore
5	Mupirocin	Bactrian Ointment	Antibiotic	Hongkong

# TDS Pharm Co., Ltd.



www.tdspharm.com



## Category

Finished Pharmaceutical Products

## Company Profile

TDS Pharm is a dedicated pharmaceutical developer of transdermal drug delivery system-adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream.

Transdermal drug delivery system offers an attractive alternative to the conventional drug delivery methods of oral administration and injection.

### CEO

### Established Date

### Employee No.

### Contact point


1. Overseas Business  
Global Business  
82-31-8018-7337  
hyejin.park@tdspharm.com
2. Licensing In/Out  
N/A
3. Overseas Branch  
N/A

## Strengths

1. Specialized in patch production and development for more than 20 years since establishment
2. Has been exporting to the USA and Canada for nearly 20 years
3. Customized product

## Collaboration Opportunities

1. Export(Finished product)
2. Import(Raw material)



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	L-menthol, Capsicum extract	Pain relief hot patch	Temporarily relieves minor pain	USA, Canada	OTC FDA Audit
2	L-menthol	Cold & Hot patch	Temporarily relieves minor pain	USA, Canada	OTC FDA Audit
3	Lidocaine	Lidocaine Cataplasma 4%	Temporarily relieves minor pain	USA, Canada	OTC FDA Audit

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	Rivastigmine	-	Dementia's disease	Development
2	Lotigotine	-	Parkinson's disease	Development
3	Donepezil	-	Alzheimer's disease	Development

# Tionlab Therapeutics



[www.tionlabrx.com](http://www.tionlabrx.com)



## Category

Platform Technology  
Drug Delivery System

## Company Profile

TionLab therapeutics is a R&D company dedicated to develop a novel, unprecedented drug delivery system platform. Our vision is to provide worthy option for patients by achieving goals of developing and launching new block-buster drugs by the drug-delivery approach. We will focus on developing the platform technology with wide range of applicability and commercial-scale manufacturing capability.

### CEO

Duck soo, Lim

### Established Date

2021. 02. 03

### Employee No.

6

### Contact point

R&D center  
070-8691-0499  
dslim@tionlabrx.com


## Strengths

Tionlab has developed two types of proprietary platform that can be applied to a wide range of drugs, such as chemical, peptide and biologics

- "Nano lipolock" is a lipid nano particle (LNP) formulated with our proprietary bio-fusion lipid. Our Nano-lipolock is a next generation LNP that replaced the conventional PEG with our proprietary bio-fusion lipid.
- "HiPAC platform" has double-coated layer to the innovative polymer depot microspheres. With this double layer, it significantly improved the initial burst-release of drug, which can also be applied to capture chemical and peptide-based drugs

## Collaboration Opportunities

1. Joint R&D
2. Tech Transfer
3. Partner



## R&D Pipeline

No.	Classification	Use	Stage of Development	Remarks
1	Once-a-month GLP-1 injection	Diabetes treatment	Pre-clinical studies on going	- No "burst-release" in the early phase - Steady concentration maintained up to 4 weeks
2	Depot antibiotics to prevent surgery site infection	to prevent bacterial biofilm formation	Feasibility study	- Local application of small amount of antibiotic powder/ cream
3	Kras silencing siRNA-LNP complex	KRAS-targeting	In-vivo study	- The KRAS-targeting siRNA showed dose-dependent reduction in tumor size in xenograft mouse models

## Others

TionLab's proprietary drug delivery system platform can be applied to various drug modalities, and we are willing to collaborate with drug developers who are looking for a better delivery option

# UKchemipharm Co., Ltd.

**UK Chemipharm Co., Kr.**

[www.ukchemipharm.com/eng](http://www.ukchemipharm.com/eng)



## Category

API  
Finished Pharmaceutical Products

## Company Profile

We developed a drug in which Antibiotics and Normal saline were integrated for the first time in Korea.

We have products that innovatively lower the risk of infection.  
We produce pharmaceuticals with excellent quality and safety.

### CEO

Gi-bum Oh

### Established Date

Jul. 1992

### Employee No.

100 persons

### Contact point

- Overseas Business  
82-31-8063-3085
- Licensing In/Out  
N/A
- Overseas Branch  
N/A

## Strengths

- Ready-To-Use (RTU)
- Antibiotics

## Collaboration Opportunities

Export (APIs, RTU Product)



## Main Products

No.	Main Ingredient	Product name	Use	Remarks
1	Iomeprol	-	CT Contrast Media	API
2	Ceftriaxone Sodium Hydrate 1g / 2g	Trisone Kit Inj	Antibiotics	Ready To Use Inj.
3	Cefmetazole Sodium 1g	Meta Kit Inj	Antibiotics	Ready To Use Inj.
4	Cefoperazone Sodium 0.5g + Sulbactam Sodium 0.5g	Perasul Kit Inj	Antibiotics	Ready To Use Inj.
5	Cefotiam HCL 1g	Tiam Kit Inj	Antibiotics	Ready To Use Inj.
6	Cefotetan Disodium 1g	Tetan Kit Inj	Antibiotics	Ready To Use Inj.
7	Vancomycin HCL 1g	Vanco Kit Inj	Antibiotics	Ready To Use Inj.
8	Imipenem Hydrate 0.5g + Cilastin sodium 0.5g	Imicl Kit Inj	Antibiotics	Ready To Use Inj.
9	Teicoplanin 0.2g	Tagonin Kit Inj	Antibiotics	Ready To Use Inj.

# Whan In Pharm. Co., Ltd.



[www.whanin.com/?lang=eng](http://www.whanin.com/?lang=eng)



## Category

Finished Pharmaceutical Products

## Company Profile

Ever since its foundation in 1978, We have exerted utmost efforts to fulfill its social role of contributing to making a healthier society by producing and supplying good medicine.

We currently produce various medicines including specialized Central Nervous System such as anti-psychotics, anti-depressants, anti-epileptics, and also drugs for cardiovascular diseases and gastrointestinal disorders.

## Strengths

1. The biggest CNS Player in Korean market
2. Enhanced manufacturing capacity with newly merged 2nd plant and stricter Quality Compliance
3. Optimization for foreign CMO & exportation Business

## Collaboration Opportunities

1. Exporting Whan In's Products
2. Foreign CMO Business
3. Licensing In/Out

### CEO

Wonbum Lee

### Established Date

1978.06.05

### Employee No.

About 470

### Contact point

#### 1. Overseas Business

Overseas Business Team  
Tel. +82-2-405-3067  
e-mail. : kwondojun@whanin.com

#### 2. Licensing In/Out

Business Development Department  
Tel. +82-2-405-3049  
e-mail. : suhsh@whanin.com

#### 3. Overseas Branch

N/A



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization
1	Carbamazepine	Epileptol CR Tab. 200mg	Anti-epileptics	Mongolia, Yemen	PIC/s GMP
2	Olanzapine	Zyrepin Tab. 2.5, 5, 10mg	Anti-psychotics	Mongolia, Yemen	PIC/s GMP
3	Quetiapine	Quetapin Tab. 25, 100, 300mg	Anti-psychotics	Mongolia, Yemen, Georgia	PIC/s GMP
4	Aripiprazole	Aripizol Tab. 5, 10, 15mg	Anti-psychotics	Mongolia, Philippines	PIC/s GMP
5	Levetiracetam	Kepreptol Tab. 250, 500, 1000mg	Anti-epileptics	Mongolia, Yemen, Philippines	PIC/s GMP
6	Risperidone	Riperidone Tab. 0.5, 1, 2mg, 3mg	Anti-psychotics	Mongolia, Yemen	PIC/s GMP
7	Mirtazapine	Mirzentac Tab. 7.5, 15, 30mg	Anti-depressants	Mongolia, Yemen, Georgia, Hong Kong	PIC/s GMP
8	Donepezil	WI Donepezil Tab. 5, 10mg	Nootropics & Anti-dementia	Yemen, Georgia, Philippines	PIC/s GMP

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development
1	First in Class Drugs	WID-2101	Parkinson's	Research
2	First in Class Drugs	WII-2002	Parkinson's	Research
3	First in Class Drugs	WID-2102	Dementia	Research
4	First in Class Drugs	WII-2001	Cancer	Research
5	First in Class Drugs	WII-2201	RA(Rheumatoid Arthritis)	Research
6	First in Class Drugs	WII-2104	Crohn's disease	Exploration
7	First in Class Drugs	WII-2105	Cancer	Research
8	IMD	WIL-1901	Dementia	Clinical Phase 1
9	IMD	WIP-DF17	depression	Drug Approval
10	1st Generic	WIG-2001	chronic arterial obstruction	Research
11	1st Generic	WIG-2002	depression	Research
12	1st Generic	WIG-1810	Epilepsy	Drug Approval
13	1st Generic	WIT-2001	Parkinson's	Clinical Phase 1



# YooYoung Pharmaceutical Co., Ltd.



www.yypharm.co.kr



## Category

Finished Pharmaceutical Products  
Medical Device

## Company Profile

YooYoung Pharmaceutical Co., Ltd. has founded in 1981 and we are dedicated to aim to be the highest level of pharmaceutical manufacturer. For the production of products, we reconstructed the factory with state-of-the-art in 2007, through which it is possible for the mass production of high standard of quality. In addition, we have always made persistent efforts on balanced development of society.

### CEO

WooPyong Yoo

### Established Date

Dec.23, 1981

### Employee No.

380

### Contact point

#### 1. Overseas Business

Overseas sales team  
sjzzz23@yypharm.co.kr/Ms. Ha

#### 2. Licensing In/Out

Development Planning Team  
khkim3@yypharm.co.kr/Ms. Kim

#### 3. Overseas Branch

N/A

## Strengths

1. OS products
2. Pre-filled syringe
3. CMO business

## Collaboration Opportunities

1. CMO business
2. Importer or Distributor



## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification /Market Authorization	Remarks
1	Sodium Hyaluronate 25mg/2.5ml	ATRI Injection	Arthritis scapular periarthritis (5 cycle inj.)	Bolivia, Dominican Republic, El Salvador, Ecuador, Russia, Turkey, Paraguay, Poland, Peru, Vietnam	CE	Intra-articular Injection
2	Sodium Hyaluronate 20mg/2.0ml	ATRI PLUS Injection	Arthritis scapular periarthritis (3 cycle inj.)	Vietnam, Singapore, Thailand, France, UK, Ukraine, Taiwan, Cambodia, Poland	CE	Intra-articular Injection
3	Cross-linked Sodium Hyaluronate Hydrogel	Resyno One Injection	Knee osteoarthritis (Single inj.)	* Under registration in some countries	Under process for CE	Cross-linked HA Monotherapy Inj.
4	Enoxaparin Sodium 20, 30, 40, 60, 80mg	Cnoxane Injection	LMWH : Anti-Coagulants	Georgia, Syria, Mongolia		Zone IV B Stability study
5	Palonosetron HCl 0.056/ mL, 1.5mL, 5mL	Yoosetron Injection	CINV (Chemotherapy Induced Nausea and Vomiting)	Georgia		Avoid patent infringement
6	Sodium Ibandronate Monohydrate 3.375mg/3mL	Yoodron Injection	Osteoporosis in postmenopausal women	Peru		
7	Sugammadex Sodium 108.8mg/ml (2ml, 5ml)	Yooridion Injection	Reversal of neuromuscular blockade	* Under registration in some countries		
8	Sulfasalazine 500mg, 250mg	Asasurfan Tab.	Ulcerative colitis, Rheumatoid arthritis	Japan, Peru		
9	Rabepazole sodium 10mg, 20mg	Rabetra Tab.	Proton Pump Inhibitor	Vietnam, Cambodia, Hong Kong		BE test
10	Baclofen 10mg	Baclan Tab.	Muscle relaxants	Philippines, Chile		Original (In Korea)

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	OSD forms	YYC301	Osteoarthritis	Phase 3	*FDC
2	OSD forms	YYC506	Hyperlipidemia	Phase 3	*FDC
3	OSD forms	YYC405	Diabetes	Phase 3	*FDC

\* FDC : Fixed Dose Combinations

## Others

We are finding a company who is specialized in a marketing of the OS products and a client for CMO business. Please contact us if you have any questions or interests in our products.

# Yuhan Corporation



<http://eng.yuhan.co.kr>



## Category

- Finished Pharmaceutical Products
- Platform Technology
- Drug Delivery System
- Others
- Medical Device
- Quasi Drug

## Company Profile

Since its foundation in year 1926 by Dr. Il-Han New, Yuhan Corporation thrived to provide high-quality pharmaceutical products and engage with various business sectors to grow and advance as a company. Currently, there are 30 innovative new drugs and 21 incrementally modified drugs under the Yuhan's R&D pipeline, which reflect portfolio built from strengthening internal research skills and through open innovation strategy. Yuhan also has offices abroad including in the USA, Australia and Hong Kong that help to effectively maximize opportunities by expanding and leveraging their worldwide networks.

## Strengths

1. Research and Development
  - Yuhan has achieved 5 out-licensing deals with a total value of 3.54 billion dollars
2. Manufacture
  - Equipped with state-of-the-art research capabilities and manufacturing facilities compliant with cGMP regulations
3. Overseas Business
  - Certified by FDA(US), TGA(AU), PMDA(Japan)
  - 133 Million Dollars Overseas Business sales in 2021

## Collaboration Opportunities

1. Custom Development & Manufacturing Services
2. Finished Products (ETC, OTC)
3. Supply Chain Management

### CEO

Wook Je Cho

### Established Date

1926

### Employee No.

1878

### Contact point

1. Overseas Business
  - T. +82-2-828-0191
  - E. dougpark@yuhan.co.kr
2. Licensing In/Out
  - T. +82-2-828-0093
  - E. josephine@yuhan.co.kr
3. Overseas Branch
  - N/A

## Main Products

No.	Main Ingredient	Product name	Use	Exporting Countries
1	Lazertinib mesylate monohydrate	LECLAZA	Non Small Cell Lung Cancer(NSCLC)	
2	Rebamipide	Rebamipide SR Tablet	Gastric ulcer, Improvement of Gastric mucosal lesion	
3	Esomeprazole, Precipitated Calcium Carbonate	Esomeprazole Combination Tablet	Gastroesophageal Reflux Disease, Antacid	
4	Pregabalin	Pregabalin SR Tablet	Neuropathic pain	
5	Telmisartan, Rosuvastatin	Duowell Tablet	Treatment for hypertension and hyperlipidemia	Uzbekistan
6	Telmisartan, Rosuvastatin, Ezetimibe	Duowell Plus Tablet	Treatment for hypertension and hyperlipidemia	
7	Amlodipine, Rosuvastatin	Rosuampine Tablet	Treatment for hypertension and hyperlipidemia	
8	Metformin SR, Rosuvastatin	Rosumet SR Tablet	Antidiabetic	
9	Bovine Lung Surfactant	Newfactan	Treatment for respiratory distress syndrome of newborns	Vietnam, Mongolia, Bolivia
10	Amoxicillin, Clavulanate Potassium	Yucla Tablet	Antibiotics	
11	Almagate	Almagate Suspension	Antiacidic functions	
12	Methyl Salicylate, L-menthol	Antiplamine S Lotion	Anti-inflammatory agent	Vietnam, Malaysia
13	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Willogel Double Action Suspensio	Alleviation of heartburn and indigestion	
14	Momethasone Furoate	Nazacare Nasal Spray Solution	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	

## R&D Pipeline

Discovery	Lead	Preclinical	Phase 1	Phase 2	Phase 3
YHC1107 (Liver cancer)	YHC1104 (NSCLC)	YH24931 (IO)	YH25724 (NASH)	YH14618 (DDD)	LECLAZA (NSCLC)
YHC2119 (IO)	YHC1103 (IO)	YH29143 (IO)	YH35324 (CSU)	YH12852 (FGID)	
YHC2122 (IO)	YH32364 (IO)	YH32367 (IO)			
YHC2124 (IO)	YH38560 (IO)	YH34160 (Obesity)			
YHC1128 (IO)	YHC1108 (NASH)	YH25487 (Asthma)			
YHC1125 (Brain tumor)	YH33619 (NASH)				
YHC2129 (Obesity)	YH36425 (Gaucher)				
YHC1131 (NASH)					
YHC2134 (Obesity)					
YHC2126 (CNS)					
YHC2127 (CNS)					
YHC2133 (CNS)					
YHC2135 (PNS/CNS)					

IO : Immuno-oncology  
 CNS : Central nervous system  
 PNS: Peripheral nervous system  
 NASH : Non-alcoholic steatohepatitis  
 NSCLC : Non-small cell lung cancer  
 CSU : Chronic spontaneous urticaria  
 DDD : Degenerative disk disease  
 FGID : Functional gastrointestinal disorder

## Others

1. Yuhan is a leading pharmaceutical company in Korea with generating more than KRW 1.6 trillion in sales.
2. Yuhan has come out on top at the Korea's Most Admired Companies Awards in its industry category for 19 consecutive years.
3. Yuhan is strictly abiding by Compliance Program.

# Yungjin Pharm. Co., Ltd.



<http://eng.yungjin.co.kr>



## Category

- API
- Finished Pharmaceutical Products
- Herbal Medicinal Product
- Quasi Drug



## Company Profile

Since its establishment in 1952, Yungjin Pharm. Co., Ltd. has been a pioneer in the Korean domestic pharmaceutical industry for national economic and improving public health with the lofty mission of saving humanity from disease and suffering through our medicines. As an affiliate of KT&G group, Yungjin plays a pivotal role in the bio pharmaceutical business within the group with outstanding drug product and R&D know-how and has grown into a global pharmaceutical company by developing new products and expanding exports.

### CEO

Lee, Kisu

### Established Date

June 29, 1952

### Employee No.

620

### Contact point

#### 1. Overseas Business

Kim, Yunhee  
Global Business Department  
+82-2-2041-8246  
yunhee.kim@yungjin.co.kr

#### 2. Licensing In/Out

Jung, Sunyoung  
BD&Licensing Division  
+82-2-2041-8222  
syjung@yungjin.co.kr

#### 3. Overseas Branch

N/A

## Strengths

- Manufacturing API and Finished product  
General(API, Tablets, Capsules, Syrups, Suspension, Lotion)  
Cephalosporin(API, Tablets, Capsules, Injections)
- CMO Business
- License In/Out

## Collaboration Opportunities

- Manufacturing API&FP
- CMO Business
- License In/Out

## Main Products


No.	Main Ingredient	Product name	Use	Exporting Countries	Global Quality Certification / Market Authorization	Remarks
1	Cefmetazole Sodium	Cefmetazole	Antibiotic	Worldwide	JP	API/Inj
2	Cefcapene Pivoxil HCl	Cefcapene	Antibiotic	Worldwide	JP	API/Tab/FineGranule
3	Cefditoren Pivoxil	Cefditoren	Antibiotic	Worldwide	JP	API/Tab/FineGranule
4	Flomoxef Sodium	Flomoxef	Antibiotic	Worldwide	JP	API/Inj
5	Cefdinir hydrate	Cefdinir	Antibiotic	Worldwide	JP	API/Tab/FineGranule
6	Ceftazidime Pentahydrate	Ceftazidime	Antibiotic	Worldwide	JP/USP	API/Inj
7	Cefpodoxime Proxetil	Cefpodoxime	Antibiotic	Worldwide	JP	API/Tab/DrySyrup
8	Cefotiam HCl	Cefotiam	Antibiotic	Worldwide	JP	API/Inj
9	Cefaclor Monohydrate	Cefaclor	Antibiotic	Worldwide	JP/EP	API/Cap/FineGranule/Syrup
10	Loxoprofen Sodium	Loxoprofen	NSAID	Worldwide	JP	
11	Febuxostat	Febuxostat	Treatment of hyperuricemia	Worldwide	In-house	API
12	Pirfenidone	Pirfenidone	Treatment of idiopathic pulmonary fibrosis(IPF)	Worldwide	In-house	API/Tab
13	Candesartan Cilexetil	Candesartan	Treatment of high blood pressure (hypertension)	Worldwide	JP	API/Tab
14	Limaprost Alfadex	Opast Tab.	Treatment of lumbar spinal canal stenosis	Worldwide	In-house	
15	Multi Vitamin	Alvityl Syrup	Multi vitamin syrup for kids	Worldwide	In-house	
16	Sodium Alginate+Calcium Carbonate+Sodium Bicarbonate	Baroscon Double Action Susp.	Treatment of gastroesophageal reflux disease(GERD)	Worldwide	In-house	
17	Ceftriaxone Sodium	Ceftriaxone Inj.	Antibiotic	Worldwide	JP/USP	0.5g/1.0g
18	Rivaroxaban	Xarex Tab.	Anticoagulant	Worldwide	In-house	2.5mg/10mg/15mg/20mg
19	Rabeprazole+Sodium bicarbonate	Rabenew Tab.	Treatment of gastroesophageal reflux disease(GERD)	New Product	In-house	10&500mg/20&500mg
20	Nicotinamide mononucleotide	NMN	Anti-aging	New Product		Food supplement

## R&D Pipeline

No.	Classification	Code	Use	Stage of Development	Remarks
1	Metabolic disorder	KL1333	Mitochondrial disease	Phase II / III	
2	Respiratory	YPL-001	COPD	Phase IIa	
3	Oncology	YPN-005	Cancer	pre-clinical	
4	Oncology	YPN-007	Cancer	research	
5	CNS	YPN-008	Parkinson's disease	research	
6	Autoimmune	YPN-011	PSC	research	
7	IMD	YPI-005	Lumbar spinal canal stenosis	Nonclinical	
8	IMD	YPI-010	Idiopathic pulmonary fibrosis	Phase I	
9	IMD	YPI-012	Gastro duodenal ulcers	Research	
10	Nintedanib		Idiopathic pulmonary fibrosis	under development	API
11	Azilsartan		Hypertension	under development	API
12	Ceftaroline Fosamil+L-Arginine		5th generation Cephalosporin	under development	API

# KPBMA Member Company List

2022 KPBMA MEMBERSHIP DIRECTORY



## Regular Members (May.2022)

NO	Company	Homepage	Phone
1	AHNGOOK Pharmaceutical Co., Ltd.	www.ahn-gook.com	82-2-3289-4200
2	AJU PHARM. CO., LTD.	www.ajupharm.co.kr	82-2-2630-0700
3	ALPHA PHARM. CO., LTD.	-	82-54-552-5381
4	Alvogen Korea	www.alvogenkorea.com	82-2-2047-7700
5	ANTROGEN. CO., LTD.	http://anterogen.com/	82-2-2104-0391
6	Aprogen Pharmaceutical	www.aprogen-pharm.com	82-2-561-4011
7	Astellas Pharma Korea Inc.	www.astellas.co.kr	82-2-3448-0504
8	B.Braun Korea	www.bbraun.co.kr	82-2-3459-7800
9	Baxter Incorporated.	www.baxter.co.kr	82-2-6262-7100
10	BCWORLD PHARM. CO., LTD.	www.bcwp.co.kr	82-2-2182-0400
11	BINEX Co., Ltd.	www.bi-nex.com	82-32-850-3000
12	Biosolution Co., Ltd.	www.biosolutions.co.kr	82-2-3446-8884
13	BMIKOREA	www.bmikr.co.kr	82-64-724-5101
14	Bolak Co., Ltd.	www.bolak.co.kr	82-31-352-6455
15	Boryung Co., Ltd.	www.boryung.co.kr	82-2-708-8000
16	Bukwang Pharm. Co., Ltd.	www.bukwang.co.kr	82-2-828-8114
17	CELLTRION PHARM INC.	www.celltrionph.com	82-43-717-7000
18	CHEMTROS CO., LTD	http://chemtros.com/	82-31-491-0653
19	CHO-A PHARM. CO., LTD.	www.choa.co.kr	82-2-6670-9200
20	CHODANG PHARM. CO., LTD.	www.chodang.com	82-2-2206-3800
21	Chong Kun Dang Pharmaceutical Corp.	www.ckdpharm.com	82-2-2194-0300
22	ChunHeDang Pharmaceutical Co., Ltd.	-	82-2-588-2333
23	CMG Pharmaceutical Co., Ltd.	www.cmgpharma.co.kr	82-2-3453-8816
24	CMIC CMO KOREA CO., LTD.	www.cmic-cmo.co.kr	82-32-678-5771
25	CORESTEM	www.corestem.com	82-2-497-3711
26	COSMAXPHARMA CO., LTD	www.cosmaxpharma.com	82-43-238-8477
27	CRYSTAL LIFE SCIENCES	www.crystallifescience.com	82-31-628-2900
28	CTCBIO INC.	www.ctcbio.com	82-70-4033-0200
29	DAE HWA PHARM. CO., LTD.	www.dhpharm.co.kr	82-2-586-6451
30	Daebongls Co., Ltd.	www.daebongls.co.kr	82-32-712-8818
31	Daewon Pharm. Co., Ltd.	www.daewonpharm.com	82-2-2204-7000
32	DAEWOO Pharmaceutical Co., Ltd.	www.dwpharm.co.kr	82-2-3477-1731
33	DAEWOONG BIO INC.	www.daewoongbio.co.kr	82-2-550-8289

NO	Company	Homepage	Phone
34	DAEWOONG PHARMACEUTICAL CO., LTD.	www.daewoong.co.kr	82-2-550-8534
35	Daihan Pharm. Co., Ltd.	www.daihan.co.kr	82-2-2678-3911
36	Daiichi Sankyo Korea Co., LTD.	www.daiichisankyo.co.kr	82-2-3453-3300
37	Dalim BioTech	www.dalimpharm.co.kr	82-2-335-1656
38	DHP KOREA Co., Ltd	www.dhpkorea.co.kr	82-2-2027-0078
39	DNBIO Pharm, Inc.	www.dnbio.kr	82-55-262-9470
40	Dong In Dang Pharmaceutical Co., Ltd.	www.dongin-dang.co.kr	82-31-319-1990
41	Dong-A Pharmaceutical Co., Ltd.	www.dapharm.com	82-2-920-8114
42	Dong-A ST Co., Ltd	www.donga-st.com	82-2-920-8111
43	Dongkoo Bio & Pharma Co., Ltd.	www.dongkoo.com	82-2-2684-5421
44	Dongkook pharmaceutical Co., Ltd.	www.dkpharm.co.kr	82-2-2191-9834
45	DONGKWANG Pharm. Co., Ltd.	www.dkpc.co.kr	82-2-776-7641
46	DONGSUNG BIO PHARM. CO., LTD.	www.dongsung-pharm.co.kr	82-2-6911-3600
47	DONGWHA PHARM	www.dong-wha.co.kr	82-2-2021-9300
48	Eisai Korea Inc.	Eisai Korea Inc.	82-2-3451-5500
49	Elyson pharmaceutical Co., Ltd.	www.elyson.co.kr	82-2-6342-7001
50	EstechPharma Co., Ltd.	www.estechpharma.com	82-31-831-4800
51	Firson	http://firson.co.kr/	82-1833-8200
52	Fresenius Kabi Korea Ltd.	www.fresenius-kabi.com	82-2-3484-0900
53	Fresenius Medical Care Korea Co., Ltd.	www.freseniusmedicalcare.kr	82-2-2146-8800
54	GALDERMA KOREA LTD.	www.galderma.co.kr	82-2-6717-2000
55	GC Biopharma Corp	www.gccorp.com	82-31-260-9300
56	GC Cell Corp.	www.gccell.com	82-31-736-6700
57	Genuone Sciences	http://genuonesciences.com	82-80-601-0090
58	GLpharma	www.glpharma.co.kr	82-31-443-3922
59	GREEN CROSS WellBeing	www.greencrosswb.com	82-1577-5560
60	Green Pharmaceutical Co., Ltd.	www.greenpharmaceutical.co.kr	82-2-842-1301
61	GUJU PHARM. CO., LTD.	www.guju.co.kr	82-2-2672-1122
62	Han Wha Pharma Co., Ltd.	www.hwpharm.com	82-2-959-3161
63	Hana Pharm. Co., Ltd.	www.hanaph.co.kr	02-577-7667
64	HANALL BIOPHARMA CO., LTD.	www.hanall.co.kr	82-1644-5515
65	HANDOK Inc.	www.handok.co.kr	82-2-527-5114
66	Hankook Korus Pharm. Co., Ltd.	www.koruspharm.co.kr	82-2-2632-4983

NO	Company	Homepage	Phone
67	Hankookshinyak Pharmaceutical Co. LTD	www.hsp.co.kr	82-41-740-8900
68	Hanlim Pharm. Co., Ltd.	www.hanlim.com	82-2-3489-6000
69	Hanmi Pharm Co., Ltd.	www.hanmi.co.kr	82-2-410-9114
70	Hanpoong Phamaceutical Co., Ltd.	www.hanpoong.co.kr	82-2-6909-5100
71	Hansol New Pharm. Co., Ltd	www.hansolpharm.com	82-43-881-6333
72	HAWON PHARMACEUTICAL CORPORATION	www.hawonpharm.co.kr	82-70-8260-6030
73	HK inno.N Corporation	www.inno-n.com	82-2-6477-0000
74	HLB PHARMACEUTICAL CO., LTD.	www.hlbpharma.co.kr	82-2-411-1530
75	HUGEL	www.hugel.co.kr	82-33-255-3882
76	Humedix Co., Ltd.	www.humedix.com	82-70-7492-5600
77	Huons Co., Ltd.	www.huons.com	82-2-854-4700
78	Huons Meditech Co., Ltd.	www.huonsmeditech.com	82-70-7469-8975
79	HuonsBiopharma	huonsbiopharma.com	82-2-854-4700
80	Hutechs Korea Pharmaceutical Co., Ltd.	www.hutechs.co.kr	82-31-377-7900
81	HYUNDAI PHARMACEUTICAL CO., LTD.	www.hyundaipharm.co.kr	82-1666-9979
82	ICURE Pharmaceuticals & Cosmetics	https://icure.co.kr/	82-2-6959-6909
83	IKSU PHARMACEUTICAL CO., LTD.	www.iksu.co.kr	82-2-416-1112
84	Ildong Pharmaceutical Co., Ltd	www.ildong.com	82-2-526-3114
85	ILHWA CO., LTD.	www.ilhwa.co.kr	82-31-550-0100
86	Ilsung Pharmaceuticals Co., Ltd.	www.ilsung-ph.co.kr	82-2-3271-8800
87	IL-YANG PHARM. CO., LTD.	www.ilyang.co.kr	82-2-570-3700
88	INIST ST. Co., Ltd.	www.inistst.co.kr	82-43-880-0600
89	ISU Abxis Co., Ltd.	www.abxis.com	82-31-696-4700
90	Janssen Korea Ltd.	www.janssen.com/korea	82-2-2094-4500
91	JEIL PHARMACEUTICAL CO., LTD.	www.jeilphar.co.kr	82-53-583-6226
92	JEIL PHARMACEUTICAL CO., LTD.	www.jeilpharm.co.kr	82-2-549-7451~65
93	JETEMA CO., LTD.	www.jetema.com	82-70-4814-6805
94	Jin Yang Pharmaceutical Co., Ltd.	www.jinyangpharm.com	82-2-3470-0300
95	JW Pharmaceutical Corporation.	www.jw-pharma.co.kr	82-2-840-6777
96	JW Shinyak	www.jw-shinyak.co.kr	82-2-2109-3300
97	KMS Pharm Co., Ltd.	www.kmspharm.com	82-31-215-5456
98	KOLON LIFE SCIENCE, INC.	www.kolonls.co.kr	82-2-3677-4150
99	KOLON PHARMACEUTICALS, INC.	www.kolonpharm.co.kr	82-2-2120-8300

NO	Company	Homepage	Phone
100	KOREA ARLICO PHARM. CO., LTD.	www.arlico.co.kr	82-2-585-0004
101	KOREA GLOBAL PHARM. CO., LTD.	www.globalpharm.co.kr	82-2-3394-5780
102	Korea Otsuka Pharmaceutical. Co., Ltd.	www.otsuka.co.kr	82-2-3287-9000
103	KOREA PHARMA	www.koreapharma.co.kr	82-2-558-1277
104	KOREA PRIME PHARM. CO., LTD.	www.koreaprime.co.kr	82-62-233-1110
105	Korea United Pharmaceutical Inc.	www.kup.co.kr	82-2-512-9981
106	KOREA VACCINE CO., LTD.	www.koreavaccine.com	82-2-443-1961
107	KOREAN DRUG CO., LTD	www.nicepharma.com	82-2-529-6100
108	Kowa Korea Company, Ltd.	www.kowakorea.com	82-2-6930-4800
109	KUHNIL PHARM. CO., LTD.	www.kuhnil.com	82-2-714-0091
110	Kukje Pharma. Co., Ltd.	www.kukjepharm.co.kr	82-31-781-9081
111	KWANG DONG PHARMACEUTICAL CO., LTD.	www.ekdp.com	82-2-6006-7880
112	KYONGBO PHARM. CO., LTD.	www.kbpharma.co.kr	82-41-420-0500
113	Kyowa Kirin Korea Co., Ltd.	www.kyowakirin.com/kr	82-2-3471-4321
114	Kyung Nam Pharm. Co., Ltd.	www.kyungnampharm.com	82-2-3490-5105
115	KyungDona Pharm. Co., Ltd.	www.kdpharma.co.kr	82-2-576-6121
116	LG Chem (Life Sciences)	ww.lgchem.com	82-2-6987-4001
117	McNulty Pharmaceutical Co., Ltd.	www.koreamcnulty.co.kr	82-31-378-1460
118	MEDICA KOREA Co., Ltd.	www.medicakorea.com	82-2-585-7799
119	Medytox Inc.	www.medytox.com	82-2-3471-8319
120	MG Co., Ltd.	www.medi-green.co.kr	82-43-535-5680
121	MIRAE PHARM KOREA CO., LTD.	www.miraepharmkorea.co.kr	82-2-583-9077
122	Mitsubishi Tanabe Pharma Korea Co., Ltd.	www.mt-pharma-korea.com	82-2-579-0121
123	MOTHER'S PHARMACEUTICAL CO., LTD.	www.mtspharm.co.kr	82-2-6958-8660
124	MYUNG IN PHARM. CO., LTD.	www.myunginph.co.kr	82-2-587-9060
125	MyungMoon Pharm. Co., Ltd.	www.mmpharm.co.kr	82-2-6711-2000
126	NelsonKorea Pharma Ind. Co., Ltd.	k-nelson.co.kr	82-2-588-0941
127	NEO BIO KOREA PHARM. CO., LTD.	www.nbkpharm.com	82-2-3478-1136
128	NEWGENPHARM INC.	www.newgenpharm.com	82-2-580-5900
129	Osstem Pharma Co.,Ltd.	www.osstempharma.com	82-70-4394-1477
130	PharmaResearch Co., Ltd	www.pharmaresearch.co.kr	82-33-645-7640
131	PHARMATRONIC CO.LTD.	www.ql-pharma.co.kr	82-2-2634-8002
132	Pharmbio Korea Co., Ltd	www.pharmbio.co.kr	82-2-857-2551

NO	Company	Homepage	Phone
133	Pharmcle	www.phramcle.com	82-2-470-3826
134	Pharvis Korea Pharm. Co., Ltd.	www.pharvis.co.kr	82-2-579-6262
135	PMG PHARM Co., Ltd.	www.pmgpharm.co.kr	82-31-439-5470
136	REYON PHARMACEUTICAL CO., LTD.	www.reyonpharm.co.kr	82-2-793-5557
137	Richwood Pharmaceutical Co., Ltd.	www.richwood.net	82-2-757-3071
138	RP Bio Inc.	ww.rpbio.co.kr	82-2-2002-9715
139	SAEHAN Pharm. Co., Ltd.	www.shpharm.co.kr	82-2-553-7417
140	Sam Chun Dang Pharm. Co., Ltd.	www.scd.co.kr	82-2-2046-1100
141	SAM NAM PHARM. CO., LTD.	www.samnam51.com	82-41-754-3771
142	SAMA PHARM. CO., LTD.	www.samapharm.co.kr	82-33-769-8400
143	Samik Pharmaceutial Co., Ltd	www.samik.co.kr	82-2-928-0661~4
144	Samil Pharm. Co., Ltd.	www.samil-pharm.com	82-2-520-0336
145	Samjinpharm	www.samjinpharm.co.kr	82-2-3140-0700
146	SAMSUNG PHARM. CO., LTD.	www.sspharm.co.kr	82-31-353-6681
147	SAMYANG Chemical Co., Ltd.	www.samyangchem.com	82-2-3488-5592
148	Samyang Holdings Corporation	www.samyangbiopharm.com	82-2-2157-9111
149	SANDOZ Korea Co., Ltd.	www.sandoz.com	82-2-768-9000
150	Santen Pharmaceutical Korea Co., Ltd.	www.santen.co.kr	82-2-754-1434
151	SCM Lifescience, Inc.	www.scm Lifescience.com	82-32-881-3600
152	Seoul Pharma Co., Ltd.	www.seoulpharma.com	82-2-3470-2300
153	SHIN POONG PHARM. CO., LTD.	www.shinpoong.co.kr	82-2-2189-3400
154	SINIL PHARM. CO., LTD.	www.sinilpharm.com	82-2-2211-6700
155	SINSIN PHARMACEUTICAL CO., LTD.	www.sinsin.com	82-2-2030-1700
156	SK bioscience co., ltd.	www.skbioscience.com	82-2-2008-2200
157	SK Chemicals Co., Ltd.	www.skchemicals.com	82-2-2008-2008
158	SS Pharm Co., Ltd.	www.susungpharm.co.kr	82-31-491-6311
159	Suheung Co., Ltd.	www.suheung.com	82-34-249-4100
160	Sungwonadcock Pharm Co., Ltd.	www.swpharm.com	82-2-3665-2872
161	TAEJOON PHARM CO., LTD.	www.taejoon.co.kr	82-2-798-6601
162	TAI GUK PHARM. CO., LTD	www.taiguk.co.kr	82-2-3474-7761
163	Takeda Pharmaceuticals Korea Co., Ltd.	www.takeda.com/ko-kr	82-2-3484-0800
164	TDSPHARM Co., Ltd.	www.tdspharm.com	82-31-8018-7337
165	Teva-Handok Pharma Co., Ltd.	www.teva-handok.co.kr	82-2-527-5506

NO	Company	Homepage	Phone
166	THERAGEN ETEX	www.theragenetex.com	82-2-3463 -7111
167	THEU pharmaceutical	www.theu.co.kr	82-2-2615-5724
168	UK Chemipharm Co., Ltd.	www.ukchemipharm.com	82-2-583-5494
169	UNIMED PHARM INC	www.unimed.co.kr	82-2-2240-5100
170	UNION KOREA PHARM CO.,LTD.	www.ukp.co.kr	82-2-489-3611
171	Whanin Pharm. Co., Ltd.	www.whanin.com	82-2-405-3000
172	WITHUS PHARMACEUTICAL. CO., LTD.	www.withuspharm.com	82-2-3486-7474
173	WonKwang Pharm. Co., Ltd.	www.wonpharm.co.kr	82-63-855-3333
174	WOOSHIN LABOTTACH CO.,LTD.	www.wooshinmed.com	82-2-786-9849
175	Yoo-Young Pharmaceutical Co., Ltd	www.yypharm.co.kr	82-2-6207-6114
176	youngpoong pharmaceutical Co.,Ltd	www.yppharm.co.kr	82-32-812-8356
177	YUHAN CORPORATION	www.yuhan.co.kr	82-2-828-0181
178	YUIL PHARM TECH CO., LTD	www.yuilpharm.co.kr	82-43-537-2161
179	Yungjin Pharm. Co., Ltd.	www.yungjin.co.kr	82-2-2041-8200
180	Yuyu Pharma, Inc.	www.yuyu.co.kr	82-2-2253-6600

## Associated Members (May.2022)

NO	Company	Homepage	Phone
1	ABNOBA KOREA	www.abnoba.co.kr	82-2-6121-8000
2	AbTis co., Ltd.	www.abtis.co.kr	82-31-294-0880
3	Addpharma Co. Ltd.	www.addpharma.co.kr	82-31-891-5000
4	AIMEDBIO	www.aimedbio.com	82-2-6285-0743
5	Amicogen, Inc.	www.amicogenpharma.com	82-2-859-4340
6	Amyloid Soutlion Inc.	www.amyloidsolution.com	82-31-8092-3800
7	ANYGEN CO., LTD.	www.anygen.com	82-62-714-1166
8	Arbormed Co., Ltd.	www.arbormedpharma.com	82-2-6953-1207
9	Aribio. Co., Ltd.	www.aribio.com	82-2-2637-0009
10	AULBIO	www.aulbio.com	82-31-895-5033
11	Bagel Labs	www.bagel-labs.com	82-31-8039-5050
12	Bionox. Inc.	www.bionox.com	82-31-719-9179
13	Biopharmer corp.	www.biopharmer.com	82-54-223-2420
14	BIXINK Therapeutics	www.bixink.com	82-2-572-2003
15	BL	www.bioleaders.com	82-31-280-9650
16	C&R Research Inc.	www.cnres.com	82-2-6251-1500
17	CellBion Co., Ltd	www.cellbion.co.kr	82-2-743-3311
18	CELLID	www.cellid.co.kr	82-2-3285-7860
19	CENYX BIOTECH Inc.	www.cenyxbiotech.com	82-2-741-6110
20	CHABiolab	www.chabiolab.com	82-31-881-7400
21	CMS Co., Ltd.	www.cmscorea.co.kr	82-2-3394-5161~3
22	Corepharm Bio Co., Ltd.	www.corepharmbio.com	82-31-698-4032
23	CtystalGenomics Inc.	www.crystalgenomics.com	82-31-628-2700
24	D&D Pharmatech Inc.	www.ddpharmatech.com	82-31-8019-7771
25	Daegu-Gyeong Medical Innovation Foundation	www.kmedihub.re.kr	82-53-790-5114
26	Deargen	https://deargen.me	82-70-4335-7236
27	DreamCIS Inc.	www.dreamcis.com	82-2-2010-4500
28	Ecell Co.,Ltd	www.ecellprocess.com	82-31-687-8266
29	FUGENBIO	www.fugenbio.com	82-2-3463-5410
30	GeneOne Life Science, Inc.	www.genels.com	82-2-3458-4030
31	Genexine, Inc.	www.genexine.com	82-2-6098-2600
32	Glpharmtech	www.glpt.co.kr	82-31-739-5220
33	HapInScience Inc.	www.hapInscience.com	82-31-724-2611

NO	Company	Homepage	Phone
34	HITS	http://hits.ai	82-2-6953-0317
35	Humanscape	https://humanscape.io	82-70-4900-1130
36	HysensBio	www.hysensbio.com	82-2-883-2155
37	HYUNDAIBIOLAND Co., Ltd.	www.hyundaibiland.co.kr	82-43-249-6720
38	ImmunoForge Co., Ltd	www.immunoforge.com	82-70-4946-8466
39	JBKLAB	www.jbklab.co.kr	82-70-5121-1319
40	Korea Institute of Toxicology	www.kitox.re.kr	82-42-610-8250
41	Medi Help Line	www.medihelpline.co.kr	82-2-6966-4100
42	NVP-Healthcare. Co., Ltd.	www.nvp-healthcare.com	82-31-895-5438
43	ORGANOIDSCIENCES	www.organoidrx.com	82-31-707-2024
44	PharmCADD CO., LTD	https://pharmacadd.com/	82-51-731-5688
45	PHARMICELL	www.pharmicell.com	82-2-3496-0114
46	Protox	www.iprotox.com/	82-70-4018-8200
47	Real Expert Pharm Tech	www.abc.or.kr	82-31-214-9660
48	REPURE HEALTH CARE	www.blmh.co.kr	82-2-3282-4753
49	SAMUNGBIOEPIS	www.samsungbioepis.com	82-32-455-6114
50	Sapiensbio Inc.	www.sapiensbio.com	82-70-4866-3231
51	Shaperon, Inc.	www.shaperon.com	82-2-6083-8302
52	Standigm Inc.	www.standigm.com	82-2-501-8118
53	TIONLAB THERAPEUTICS	http://tionlabrx.com/	82-70-8691-0499
54	Voronoi	www.voronoi.io	82-32-830-4855
55	VSPHarmTech Co., Ltd.	www.vsparmtech.com	82-70-4740-7117
56	WELT	www.weltcorp.com	82-2-6439-0707
57	WOOJUNGBIO, Inc.	www.woojungbio.kr	82-31-280-5200
58	ZTi Biosciences Co. , Ltd.	www.zti-bio.com	82-31-213-0566



